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HisTory of renal failUre
Although renal failure is a disease as old as humanity itself, our ability to understand kidney 
functioning, and the origin of this life threatening disease is much more recent. Around 
350 BC, the Greek philosopher and scientist Aristotle thought of the bladder as the main 
urine producing organ. Approximately four centuries later, Galen of Pergamos was the first to 
propose that urine is produced when blood is cleared by the kidneys [1].
The term uremia (Greek for urine poisoning, or “urine in the blood”) did not develop 
until the isolation of urea from urine in the 18th century. The two French physicians that led 
the discovery, Dr. Fourcroy and Dr. Vauquelin, predicted that if urea is not “separated” from 
the blood, an excess might lead to specific disorders [2]. At the time, this hypothesis was not 
easily accepted [3]. However, when in 1856 Picard developed a reproducible and sensitive 
method for the measurement of blood urea, the theory behind uremia gained popularity 
[4,5]. Since then, innovative research in the field of nephrology, has led to a dramatic im-
provement in the treatment of chronic kidney disease (CKD). Nowadays, the preferred treat-
ment of patients who suffer from end stage renal disease (ESRD) involves the transplantation 
of a donor kidney. However, due to the shortage of donor kidneys, most patients undergo 
renal replacement therapy such as dialysis. This procedure, based on physical processes like 
osmosis and diffusion, removes accumulating solutes such as urea from the circulation. Dr. 
Graham (1805–1869), considered a founding father of dialysis therapy, was one of the first to 
describe that crystalline urea could be dialyzed from urine through semi-permeable mem-
branes [6]. In 1945, Dr. Kolff introduced the first clinically functional hemodialysis machine 
for the treatment of uremia [7,8]. This device consisted of a rotating drum kidney in a static 
open bath, with 20 meters of cellophane dialysis tubing wound around it (Figure 1.1). Over 
the last 70 years, thorough optimization of the semi-permeable material used in these dialysis 
devices, and optimization of the design, have made the therapy much more efficient, compact 
and safe [9].
Current dialysis therapy has improved the prognosis of renal patients dramatically. In 
fact, in the field of long-term organ substitution, hemo- or peritoneal dialysis has been the 
most successful form of long term organ substitution therapy, prolonging life expectancy 
of patients suffering from ESRD with an average of 6.6 years [10]. However, since dialysis 
therapy is still mainly based on the processes filtration, osmosis and diffusion, the treatment 
cannot replace the secretory, reabsorptive, and metabolic functions of the kidney. Most kid-
ney disease patients keep experiencing serious medical problems, and their need for chronic 
intermittent treatment poses a large socio-economic burden. The scientific community is 
actively investigating possibilities to improve the quality of life for this group of patients. 
Increased understanding of kidney physiology, together with advances in the technical field of 
cell culture and tissue engineering, has created opportunities for further improvement of di-
alysis therapy. In the scope of this thesis, we examined the handling of cationic uremic toxins 
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(UTs) by renal tubular epithelial cells. By focusing on the epithelial transport pathways, and 
regulation involved in the renal removal of these cationic uremic retention solutes, we aim to 
elucidate the possibilities to utilize living renal epithelial cell membranes for the improvement 
of hemodialysis therapy.
General PHysioloGy of THe kidney
The kidney is an essential organ in the homeostatic regulation of the human body. It facilitates 
the removal of wastes or foreign substances, produces hormones (such as renin and Epo). 
The kidney activates Vitamin D, regulates systemic electrolyte balance, pH, and extracellular 
volume. Approximately 1 million functional units present in the kidney, called nephrons, 
perform these functions. Nephrons can be subdivided into five sections, made up by the 
glomerulus, the proximal tubule, the loop of Henle, the distal convoluted tubule and the col-
lecting duct. The three main processes that take place in the nephron are: filtration, reabsorp-
tion and secretion (Figure 1.2).
Upon entering the nephron, arterial blood flows through the glomerulus, where filtration 
occurs under influence of hydrodynamic forces. In a healthy kidney, only substances with a 
figure 1.1 The first clinically functional hemodialysis machine for the treatment of ckd.
This first clinically functional hemodialysis machine for the treatment of CKD was presented in the 
doctoral thesis of Dr. Kolff entitled ‘De Kunstmatige Nier’ [8]. In this picture nurse Maria ter Welle acts 
as model patient to show how the device should be installed.
11
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molecular weight up to 7,000 Dalton can freely pass the glomerular filtration barrier. For large 
molecules, molecular size as well as charge determine the rate of filtration [11]. The filtered 
fluid therefore consists mainly of water and unbound solutes. Once this fluid passes from the 
glomerulus into the tubular lumen, it becomes part of the body’s external environment. To 
prevent major loss of fluid, almost all of the filtered water is reabsorbed through channels 
present in the tubular segments of the nephron. Together with water, the proximal tubule 
cells reabsorb ions such as Na+ and Ca2+. Na+ is actively transported into the extracellular 
fluid by the Na+-K+-ATPase localized on the basolateral membrane. By means of facilitated 
Na+-coupled transport the proximal tubule is able to reabsorb a wide range of substances 
such as PO43−, amino acids, glucose and organic metabolites [12]. Furthermore, tubular trans-
cytosis, endocytosis and pinocytosis can mediate the reabsorption of proteins, hormones and 
enzymes that have passed through the glomerular filtration barrier.
Kidney
Nephron
Proximal tubule cells
Glomerulus
Proximal Tubule
Loop of Henle
Distal Convoluted Tubule
CollecƟng Duct
figure 1.2 kidney and nephron morphology.
The kidney consists of approximately 1 million nephrons that are localized mainly in the cortex of the 
kidney. The nephron can be subdivided in five sections, made up by the glomerulus, the proximal tu-
bule, the loop of Henle, the distal convoluted tubule and the collecting duct. We focused especially on 
the active solute transport taking place in proximal tubule epithelial cells, as proximal tubular secretion 
processes play an essential role in the removal of xenobiotics such as environmental chemicals, drugs, 
or endogenous waste products originating from metabolism.
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When the solute enters the loop of Henle, urinary concentration takes place [13]. A coun-
tercurrent exchange facilitates water reabsorption. In the (thick) ascending limb, active reup-
take of Na+, K+ and Cl- causes the fluid to become hyposmotic. The distal convoluted tubule 
then fine-tunes the electrolyte content by facilitating further sodium chloride reabsorption, 
potassium secretion, and adjusts Ca2+ and Mg2+ balance [14]. Subsequently, the collecting 
system; consisting of the connecting tubule and the collecting duct, makes the final adjust-
ments in urinary concentration [13].
To enhance urinary excretion of substances, the kidney is able to secrete specific molecules. 
Secretion is very important for the maintenance of body homeostasis, acid-base balance and 
the removal of xenobiotics or endogenous solutes. Proximal tubular secretion processes play 
an essential role in the removal of xenobiotics such as environmental chemicals, drugs, or 
endogenous waste products originating from metabolism.
renal solUTe clearance
Renal clearance is a measurement commonly used to analyze renal solute elimination and 
kidney function. The volume of the renal plasma flow, from which a specific compound is 
cleared within one minute, is based on the following calculation:
CLRenal =
Renal excretion rate
Cp
where CLRenal is the renal clearance rate of a solute (mL/min), which depends on the rate of 
renal solute excretion (g/min), and CP the plasma concentration of the solute (g/L) [15]. The 
rate of renal excretion is, in turn, dependent on glomerular filtration, tubular secretion and 
reabsorption processes, as described in the formula below.
Renal extretion = Filtation + Secretion − Reabsorption
Glomerular filtration
For some substances, elimination will directly reflect the glomerular filtration rate (GFR). 
One of these compounds is the polysaccharide inulin [16]. Inulin is inert, freely filtered by the 
glomerulus, and is neither reabsorbed nor secreted by the renal tubules, therefore, CLrenal 
= GFR, and can describe renal function accurately. However, in clinical settings, physicians 
prefer the use of the endogenous compound creatinine over inulin [16,17]. As a breakdown 
product of creatine phosphate, blood creatinine levels are generally stable; therefore this cat-
ionic compound does not need to be administered to the patient. While creatinine is filtered 
freely by the glomerulus, approximately 20% of the creatinine excreted is the result of active 
13
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secretion into the urine by organic cation transport proteins. Therefore, creatinine clearance 
measurements generally overestimate GFR.
Passive filtration by the glomerulus is restricted by two factors. First: the amount of 
filtered plasma represents approximately 20% of the glomerular blood flow. Meaning that 
during a single cycle a maximum of 20% of a substance can be excreted by filtration. The 
second restricting factor is plasma protein binding. Binding of solutes to plasma proteins like 
albumin facilitates the systemic transport of organic compounds that usually have greater 
biological activity (toxicity). Protein binding prevents these compounds from passing plasma 
membranes, thereby influencing their tissue distribution and bioavailability. However, the in-
creased size of protein bound solutes also makes glomerular filtration impossible. As a result, 
passive clearance by glomerular filtration depends on the free fraction of waste products in 
the circulation, and the GFR.
MRP2, MRP4
BCRP
OAT4
OCTN1,OCTN2
MATE1, MATE2
URAT 1
P-gP
K+
H+
Na+
DCs 
OAT1, OAT3
OCT2
(OCT1, OCT3)
OATP4C1
NaDC3 DCs 
Na+
OA-
ATP+
ATP+
ATP+
ATP+
OA-
OA-
OC+
OC+
Urate
OC+/H+
Urate/Cl-
OC+
NaK
ATPase
Blood Urine
figure 1.3 schematic model of the major organic anion (oa-)/ organic cation (oc+) transporters in 
human renal proximal tubular cells.
SLC transporters are depicted in blue and ABC transporters in red. Grey arrows depict the movement of 
driving ions. In bold transporters are labeled that are currently considered important for the clearance 
of organic cations. More details are given in the text.
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active proximal tubular organic solute clearance
For solutes that are unable to pass the glomerular filtration barrier due to size or charge, proxi-
mal tubular secretion is the primary route of elimination. Organic solutes make up a large part 
of these waste products. Organic solutes originate from direct ingestion, normal endogenous 
metabolism or are formed during putrefaction processes occurring in the intestine [18]. The 
presence of the many dedicated transport pathways in the proximal tubule ensures their rapid 
excretion (Figure 1.3). The clearance rates of many organic solutes often even exceed the renal 
plasma flow [19]. Tubular secretion occurs in three subsequent steps. First, the solute diffuses 
from the peritubular capillary into the interstitium. Then influx transporters carry the solute 
into the proximal tubule cell across the basolateral membrane. After passing through the cell, 
the solute is secreted at the apical plasma membrane into the lumen [20].
Proximal tubular organic anion transport
Influx of organic anions is mediated by members of the solute carrier (SLC) family known as 
organic anion transporter 1 and 3 (OAT1/3; SLC22A6 and -A8) and the bidirectional Organic 
Anion Transporting Peptide 4C1 (OATP4C1; SLCO4C1) [21-23]. As the uptake of negatively 
charged anions is an energy consuming process, the influx transport of OAT1 and 3 is driven 
by their exchange for intracellular anions, such as dicarboxylates [24]. The Na+-dicarboxylate 
cotransporter (NaDC3; SLC13A3), identified in human kidney tissue in 1996, is essential for 
the maintenance of a cellular dicarboxylate gradient [25]. The driving force for OATP4C1 has 
as of yet not been identified.
Cellular efflux of organic anions is facilitated by members of the ATP-binding cassette 
(ABC) transporter family, known as the Multidrug Resistance Proteins 2 and 4 (MRP2/4; 
ABCC2 and -C4), and Breast Cancer Resistance Protein (BCRP; ABCG2), through ATP de-
pendent transport [26,27]. Furthermore, the organic anion transporter 4 (OAT4; SLC22A11) 
and the urate reuptake transporter (URAT1; SLC22A12) mediate the transport of organic 
anions by their exchange for urate [28,29]. Figure 1.3 depicts a schematic model of the major 
organic anion and cation transporters in human renal proximal tubular cells
Proximal tubular organic cation transport
At the basolateral membrane of the proximal tubule, the SLC22 family of organic cation 
transporters (OCTs) mediate organic cation uptake. On the brush border membrane, the 
SLC47 multidrug and toxin extrusion proteins (MATEs) are expressed. OCTs and MATEs 
transport a wide variety of structurally unrelated organic cations [30-32]. In the human kid-
ney, OCT2 (SLC22A2) is considered one of the most important organic cation influx proteins. 
Though OCT1 (SLC22A1) and OCT3 (SLC22A3) are present as well, their renal expression 
levels are low. In contrast, their transport function in other tissues, such as liver, heart, skeletal 
muscle, small intestine and lung, is described well [33,34]. In the kidney, the OCT2-mediated 
basolateral transport of organic cations occurs through facilitated electrogenic diffusion. 
15
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OCT2 transport proteins make use of the internal negative membrane potential to allow 
organic cations to enter into the cell. For proper substrate influx, intracellular concentrations 
need to remain low, as transport direction is determined by the concentration gradient of 
the substrate. In order to retain those low intracellular levels of cationic substrates, apical 
secretion follows rapidly. The apical transporters MATE1 (SLC47A1), MATE2 (SLC47A2), 
OCTN1 (SLC22A4) and OCTN2 (SLC22A5), work in concert to mediate cation excretion on 
the apical brush border membrane [35,36]. Apical secretion is mostly driven by an H+/organic 
cation antiport process [37]. Also the ABC transporters P-glycoprotein (ABCB1; MDR1/P-
gp) and the BCRP (ABCG2) are involved in the transport of some uncharged and cationic 
substrates [38-40] (Figure 1.3).
Reabsorption in the proximal tubule
The proximal tubule reabsorbs approximately 67% of the filtered water, and a variety of ions 
and solutes. In addition, amino acids, glucose and albumin that pass the glomerular filter are 
reabsorbed. Many active reabsorption processes depend on the proper functioning of the Na+-
K+-ATPase pump. As this pump keeps the intracellular levels of Na+ low, the electrochemical 
gradient can provide Na+ linked transport of a wide range of substances such as glucose, 
amino acids, Cl-, Ca2+, HCO3−, and PO43-. The recovery of these solutes from the pre-urine to 
the interstitial space creates an osmotic gradient that promotes the subsequent reabsorption 
of water through the “leaky” tight junctions or water channels (aquaporins). Filtration of 
plasma at the glomerulus normally excludes most proteins, but some smaller proteins (i.e. 
albumin), hormones and enzymes can pass the filtration barrier. Proteins that are too large 
to be reabsorbed by carriers enter the proximal tubular epithelial cells by receptor-mediated 
endocytosis at the apical membrane. Both the megalin and cubulin receptors have been iden-
tified as key endocytotic receptors that enable selective transport of essential substances from 
the apical side of the proximal tubule to the basolateral compartment.
renal failUre, Uremia and TransPorT of caTionic 
reTenTion solUTes
Renal failure occurs when chronic or acute processes disturb the normal filtration, secretion, 
and reabsorptive processes of the kidney. CKD is defined by the “Kidney Disease Quality 
Outcome Initiative” as a reduction of the glomerular filtration rate from the normal rate of 
≥ 90 mL/min/1.73m2 to < 60 mL/min/1.73 m2 for 3 months or more [41]. In the early stages 
of kidney disease, the loss of nephron function can occur largely unnoticed. In experimental 
models of CKD, the remaining individual nephrons were found to experience glomerular 
hyperfiltration, a compensatory mechanism [42,43]. Thus, the adaptive response of the re-
sidual nephrons determines for how long normal homeostasis can be preserved. When over 
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time GFR starts to fall further, the tubular ability for renal urine concentration decreases. 
Phosphate and potassium excretion diminish, and filtered solutes such as creatinine and urea 
start to accumulate systemically [44]. When a GFR ≤ 15 mL/min/1.73 m2 is reached, the 
osmolarity of the excreted urine starts to resemble that of plasma. In addition, the secretion 
of organic retention solutes by the proximal tubule fails [45], which leads to severe systemic 
manifestations of uremia [46].
The uremic syndrome is characterized by symptoms resulting from the accumulation of 
various organic retention solutes. Symptoms of uremia can include anorexia, nausea, pru-
ritus, itching, anemia and sexual dysfunction. Furthermore, neurological, musculoskeletal, 
cardiovascular, and immunological problems arise [47]. The development of a chronic in-
flammatory state together with increased systemic cytokine accumulation is common in renal 
patients, and uremia is identified as an potential causative factor [48]. The European Uremic 
Toxin workgroup (EUtox) presently reports over 150 solutes that accumulate during renal 
failure [49]. Many of these solutes have the potential to act as UTs, because they exert biologi-
cal or biochemical activities. They are classified into three categories: 1. small, water-soluble, 
non-protein-bound compounds, 2. larger so-called middle molecules, and 3. protein-bound 
compounds [50]. Although many candidate toxins are known, it is very difficult to link spe-
cific symptoms to solutes. Treatment of end-stage renal disease (ESRD) therefore currently 
aims to remove as many uremic retention solutes as possible, thereby hoping to alleviate their 
destructive effects.
cationic uremic retention solutes
In order to improve the efficiency of the treatment of uremia, studies are executed to identify 
specific disease causing UTs. The systemic accumulation of several well-studied anionic com-
pounds, such as phenols and indoles, were found to correlate with the development of insulin 
resistance, epithelial to mesenchymal transition (EMT) and cardiovascular disease [51-54]. 
Mutsaers et al. recently evaluated the effects of accumulating uremic anions, including in-
doxyl sulphate, indole-3-acetic acid, p-cresyl sulfate, p-cresyl gluceronide, hippuric acid, and 
kynurenic acid, on renal tubular function [55-59]. The studies showed that these retention 
solutes can accumulate to high levels in ESRD patients, impede renal transport processes, and 
affect renal metabolic capacity.
Cationic organic solutes; on the other hand, received less attention. Among these, the gua-
nidino compounds and polyamines, were found to accumulate in plasma of uremic patients 
[60]. Increased plasma levels of the small water soluble guanidino compounds, such as gua-
nidine, methylguanidine and creatinine (the precursor of methylguanidine), were reported in 
uremic biologic fluids and tissues [61-63]. Guanidino compounds comprise a large group of 
solutes, formed during regular metabolism of arginine, originating from proteins and amino 
acids. The accumulation of these substances in ESRD patients can reach 2-106 times the levels 
found in healthy individuals (Table 1.1) [50]. The buildup of substances such as guanidine and 
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methylguanidine affects the immune response, hematopoietic cell functioning and can induce 
neuronal and cardiovascular adverse events [64-69]. These contributing effects of guanidino 
compounds to clinical symptoms observed in the uremic syndrome, warrants studying the 
renal transport processes underlying their clearance.
Other cationic retention solutes that are of interest as possible contributors to the uremic 
syndrome are the polyamines. This group of protein bound solutes includes cadaverine, 
putrescine, spermine and spermidine. Polyamines are formed after lysine, arginine and 
ornithine catabolism. In humans, systemic levels of free polyamines reported are generally 
below their detection limit, as the polyamines are predominantly localized intracellular [70]. 
However, under uremic conditions levels increased up to 100 µg/L, depending on the type of 
polyamine (Table 1.1). In healthy individuals, low levels of polyamines regulate cell growth 
and development [71,72]. These molecules also play essential roles in for example the regula-
tion of ion channels, free radical scavenging and maintenance of membrane and chromatin 
stability [73-76]. Though, increased plasma levels of spermine, spermidine, putrescine and 
cadaverine were found to inhibit erythropoiesis and erythroid colony formation [77,78]. 
Finally, elevated putrescine levels can inhibit cell growth in vitro, and negatively affect cyto-
plasmic, mitochondrial and nuclear membrane structures [79]. Furthermore, the enzymatic 
oxidation of polyamines can give rise to toxic metabolites. Sakata et al. identified acrolein as 
a major toxic compound produced from spermine and spermidine by the enzyme “serum 
amine oxidase” [80]. Acrolein is strongly protein bound. In the healthy situation the total 
concentration reported was approximately 1.7 ± 0.5 mg/L serum, which included the protein 
bound fraction. However during renal failure, this level can increase up to 5.8 times (Table 
1.1). Already at low doses, acrolein can inhibit cell proliferation and is thought to enhance 
apoptosis from secondary toxic assaults [81]. Furthermore, acrolein has a deleterious effect 
of protein function by the formation of adducts with lysine and histidine, gives rise to oxida-
tive stress, mitochondrial disruption, membrane damage, endoplasmic reticulum stress, and 
can lead to immune dysfunction. [82-84]. Besides the endogenous formation of acrolein 
during metabolism, exposure to this compound can occur through occupational exposure 
in the chemical industry, inhalation from (cigarette) smoke and by dietary ingestion [85]. 
Studies suggest that acrolein production increases during uremia, through accumulation of 
polyamines resulting from a decrease in their urinary excretion. Increased acrolein levels 
are found in patients suffering from diabetic nephropathy, chronic glomerulonephritis and 
nephrosclerosis. [86].
Knowledge on the clearance and effects of cationic uremic retention solutes during uremia 
is still largely elusive. The active organic cation transport system present within the proximal 
tubule is thought to be primarily responsible for their removal [87]. Various transporters, 
such as OCT2 and MATE1/2k, expressed at the basolateral and apical membranes of proximal 
tubule cells are believed to work in concert to enable the urinary efflux of cationic uremic 
retention solutes.
19
General introduction and outline of the thesis
ch
ap
te
r 1
cytokine production and regulatory transport effects of uremic solutes
Next to the intrinsic toxicity of uremic solutes, the development of a chronic inflammatory 
state is common in uremia. Clinical studies have demonstrated a correlation between increas-
ing IL-6, IL-8 and TNFα cytokine levels and reduced glomerular filtration [88,89]. Increased 
cytokine production in combination with inefficient clearance of the inflammatory mediators 
during uremia might cause these effects [48]. During renal failure, both elevated IL-6 and 
IL-8 levels correlated with increased mortality and poor disease outcome [90]. Furthermore, 
TNFα is known as an important factor in the development of renal fibrosis, and induces the 
production of additional inflammatory mediators such as endothelin-1 (ET-1) [91-93]. In 
healthy subjects, ET-1 functions as a potent peptide regulating the vascular tone, blood flow, 
and water and salt homeostasis. However, in patients suffering from renal disease, high levels 
of ET-1 are linked to a further decline in renal function [94-96], and exposure of the proximal 
tubule to nephrotoxicants has been shown to induce ET-1 release, leading to reduced ATP-
driven solute transport [97,98].
cHallenGes in THe bioarTificial remoVal of Uremic 
reTenTion solUTes
Due to the shortage of donor kidneys available for transplantation, ESRD is now treated 
predominantly with dialysis. Unfortunately, current renal replacement therapies cannot 
provide the active transport functions necessary for the removal of protein bound and highly 
compartmentalized uremic solutes such as polyamines and guanidino compounds. The in-
ability of current dialysis therapies to take over all of the highly specialized functions of the 
human kidney is clearly indicated by the survival benefit associated with renal transplantation 
over dialysis therapy [104]. Renal patients treated with dialysis still suffer from the complica-
tions and progression of CKD, associated, amongst others, with the systemic accumulation of 
retention solutes [105-108].
Utilizing renal proximal tubule epithelial cells in a bioartificial kidney
As a further improvement to existing synthetic dialysis procedures, the field of tissue engineer-
ing is exploring how cultured renal cells handle the clearance of UTs. Current research aims 
to examine the possibilities to utilize the functional properties of renal cells, in terms of their 
active role in the clearance of uremic retention solutes, in an add-on device to renal hemodi-
alysis therapy (Figure 1.4). A crucial step in the development of such a device is the selection 
of a suitable cell type. As recently reviewed by Masereeuw et al. studies towards proximal 
tubule specific elimination of (protein-bound) anionic and cationic organic retention solutes, 
have indicated proximal tubule cells as the preferred cell type for the development of such a 
bioartificial device [87]. Early studies used animal derived cell-lines to test the feasibility of 
Chapter 1
20
a bioartificial kidney. For example, porcine proximal tubular cells (LLC-PK1) were found to 
retain their reabsorption characteristics and secretion of the cationic compounds tetraethyl 
ammonium and creatinine by OCT2, under uremic conditions [109-112]. In 1999, Humes et 
al. reported the successful tissue engineering of a porcine cell based bioartificial renal assist 
device (RAD) [113]. Upscaling of this device even led to the successful treatment of uremic 
dogs, with regard to ammonia excretion, glutathione reabsorption, and the production of the 
active form of vitamin D (1,25-(OH)2D3) -[114].
For clinical development of a bioartificial device, the use of (endogenous) primary human 
renal proximal tubule cells (PTEC) would be ideal, since these cells still possess most of their 
proximal tubular characteristics. In-vitro experiments have shown functional OAT1/3 and 
MRP2/4 mediated PAH secretion, MDR1 and BCRP activity, and OCT2 mediated creatinine 
secretion by tight monolayers of primary hPTEC [115-118]. Promising in-vivo results in 
animal studies with a bioreactor cartridge containing primary human proximal tubule cells, 
paved the way for the first clinical tests of the bioartificial kidney, or RAD [119,120]. However, 
the limited number of primary cells that can be isolated from human kidney tissue poses a 
biological hurdle. To obtain sufficient cells for use in multiple bioartificial devices, in-vitro cel-
Renal Assist Device
Membrane
Proximal tubule cells
Hemodialysis machine 
figure 1.4 schematic set-up of an add-on device to renal hemodialysis therapy.
This bioartificial kidney, or also called renal assist device (RAD), consists of cultured PTEC monolay-
ers, grown on a semi-permeable hemodialysis membrane. Reprinted with permission from the Dutch 
Kidney Foundation (©Nierstichting)
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lular expansion is necessary. But when primary cells are brought into culture, loss of epithelial 
characteristics and cellular senescence rapidly sets in [121,122], thereby severely restricting 
the functionality of primary cells in-vitro.
The use of immortalized cell lines may be a promising tool for the development of a 
bioartificial device such as a RAD. In contrast to primary human PTEC, cell lines usually 
have unlimited growth potential, making large numbers of clonal cells readily available [123]. 
Some immortalized human renal epithelial cell lines, such as HK-2 or HEK293, are widely 
used for studying the physiology and pharmacology of the human kidney [124,125]. How-
ever, due to their low (endogenous) transporter expression levels, these cells are of limited 
use for tissue engineering purposes [126,127]. More recently, a conditionally immortalized 
PTEC line (ciPTEC) was developed from primary PTEC exfoliated in the urine of a healthy 
volunteer [128]. While exfoliated cells in urine might not be an ideal source for the establish-
ment of a PTEC cell line, its proximal tubular origin has been confirmed by the presence of 
a brush border membrane, as well as the expression of aminopeptidase N, zona occludens 
1 (ZO-1), aquaporin 1 and dipeptidyl peptidase IV [128]. Furthermore, next to mediating 
albumin and phosphate uptake, the developed ciPTEC cell line was found to functionally 
express the basolateral cation influx transporter OCT2 as well as the apical efflux transporters 
p-glycoprotein and MRP4. Additional characterization of this cell line and comparison with 
ciPTEC from fresh human renal tissue will provide insight into its functional capabilities with 
regard to the transport of uremic solutes.
Towards development of a living membrane
Next to the availability of functional and well-characterized human PTEC, an important 
aspect in the development of a bioartificial device is to establish a “living membrane”. Such 
a membrane would consist of tight cellular monolayers, and should be able to maintain the 
typical polarity and functionality on semi-permeable membranes. Various membrane ma-
terials and coatings have been evaluated for both the formation of epithelial tight junctions, 
whilst retaining biocompatibility [129]. Both Fay-Lamprecht et al. [130,131] and Sato et al. 
[132] evaluated monolayer growth of renal epithelial cells on a variety of dialysis membranes. 
These membranes were developed to favor hemocompatibility and prevent cellular adhesion. 
Therefore, the application of an extracellular matrix (ECM) based coating is essential to pro-
mote confluent monolayer formation. While ECM coatings have been reported to improve 
cell attachment, it appears challenging to maintain functional monolayer integrity [133-137]. 
Therefore, optimization of the coating process is necessary to prevent the obstruction of 
membrane pores and to increase the efficiency of the surface coating. Furthermore, a RAD 
would require cell monolayers to function within a dynamic system, i.e. in presence of fluid 
flow. Most in-vitro knowledge on monolayer formation and transporter functionality cur-
rently available has been obtained using static cell culture conditions. The application of flow 
in cellular systems might influence proximal tubular morphology and functionality. It is, as of 
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yet, not clear how flow would affect the monolayer and solute transport in ciPTEC. However, 
several studies reported flow-induced improvement of morphology and solute transport by 
the tubular epithelium [117,138,139].
aim and oUTline of THis THesis
The aim of this thesis is to functionally characterize uremic solute handling by ciPTEC. By 
evaluating the in vitro functional characteristics of cultured ciPTEC monolayers and measur-
ing their endogenous organic cation transport, we strive to gain more insight into crucial 
cellular aspects, and uremic toxin (UT) elimination pathways important for the development 
of a bioartificial kidney, or RAD.
chapter 2 evaluates the effect of cell origin on proximal tubule specific characteristics of 
two newly developed ciPTEC cell lines from human kidney in comparison to the existing 
ciPTEC cell line originating from exfoliated renal cells in urine. Next to the comparison of the 
functionality of key solute transporters, such as OCT2, Pg-P and BCRP, we examine phosphate 
uptake, ECM forming profiles and morphology of these cell lines. chapter 3 examines the 
OCT-mediated cation uptake in ciPTEC, by measuring cellular cation uptake and inhibition 
by known substrates. The inhibitory effect uremic guanidino compounds and polyamines on 
OCT-mediated cation uptake is demonstrated. Furthermore, this chapter shows the cytotoxic 
potential of these cationic UTs. chapter 4 describes the local cytokine and ET-1 production 
by human proximal tubule epithelial cells exposed to cationic UTs. Both polyamines and 
guanidino compounds are identified to stimulate the production of IL-6, IL-8, TNFα and 
ET-1. Furthermore, this chapter evaluates the short- and long-term effects of ET-1 on the 
regulation of organic cation influx transport in ciPTEC.
The application of cells in a clinical device requires the use of biocompatible materials. 
Therefore chapter 5 focuses on the optimization of ciPTEC monolayer culture on poly-
ethersulfone (PES) based dialysis membranes. We show functional transepithelial transport 
of creatinine, by ciPTEC monolayers cultured on differently coated PES and polyester cell 
culture surfaces. For ciPTEC characterization, static culture conditions were used. However, 
fluid flow plays an important role both in the in-vivo situation as well and in a bioartificial 
renal assist device. Therefore in chapter 6 the effect of fluid flow on ciPTEC cation transport 
is examined, together with the expression levels of various cation transporters, and trans-
epithelial cation transport processes.
The implications of the findings described in this thesis are discussed in chapter 7 and 
finally, both an English and Dutch summary are provided in chapter 8.
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absTracT
Promising renal replacement therapies include the development of a bioartificial kidney us-
ing functional human kidney cell models. In this study, human conditionally immortalized 
proximal tubular epithelial cell (ciPTEC) lines originating from kidney tissue (ciPTEC-T1 and 
ciPTEC-T2) were compared to ciPTEC previously isolated from urine (ciPTEC-U).
Subclones of all ciPTEC isolates formed tight cell layers on Transwell inserts as determined 
by transepithelial resistance, inulin diffusion, E-cadherin expression and immunocytochem-
istry. Extracellular matrix genes collagen I and -IV α1 were highly present in both kidney 
tissue derived matured cell lines (p<0.001) compared to matured ciPTEC-U, whereas ma-
tured ciPTEC-U showed a more pronounced fibronectin I and laminin 5 gene expression 
(p<0.01 and p<0.05, respectively). Expression of the influx carrier Organic Cation Trans-
porter 2 (OCT2), and the efflux pumps P-glycoprotein (P-gp), Multidrug Resistance Protein 
4 (MRP4) and Breast Cancer Resistance Protein (BCRP) were confirmed in the three cell lines 
using real-time PCR and Western blotting. The activities of OCT2 and P-gp were sensitive 
to specific inhibition in all models (p<0.001). The highest activity of MRP4 and BCRP was 
demonstrated in ciPTEC-U (p<0.05). Finally, active albumin reabsorption was highest in 
ciPTEC-T2 (p<0.001), while Na+-dependent phosphate reabsorption was most abundant in 
ciPTEC-U (p<0.01).
In conclusion, ciPTEC established from human urine or kidney tissue display comparable 
functional PTEC specific transporters and physiological characteristics, providing ideal hu-
man tools for bioartificial kidney development.
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inTrodUcTion
Worldwide, about 2 million people suffering from renal disorders are treated with hemo- or 
peritoneal dialysis and this number still increases. Main factors contributing to this increase 
are aging, an increased incidence of diabetes mellitus and hypertension [1-3]. Known 
limitations of the current dialysis methods as treatment modalities are related to the relatively 
poor clearance of protein-bound uremic retention solutes [4]. Up to now, a large number of 
compounds have been classified as uremic retention solutes [5] and their accumulation may 
have severe clinical implications, such as renal fibrosis, bone disorders, cardiovascular disease 
and mental disorders [6]. The preferred treatment of patients with end-stage renal disease 
(ESRD) is transplantation [7], which improves their quality of life and substantially reduces 
costs associated with extended dialysis [8]. However, tremendous shortages of donor organs 
as well as complications arising from immunosuppressive treatment and organ rejection after 
transplantation are profound problems worldwide [9-11].
To replace kidney function, tissue engineering is a promising avenue of research to over-
come the limitations of currently available renal replacement therapies [12]. The development 
of functional and stable human renal epithelial cell models, that are able to actively excrete 
uremic retention solutes, is a promising step towards a bioartificial kidney device. In the 
kidney, a heterogeneous cell system is present of which the proximal tubular epithelial cells 
(PTEC) play an important role in the excretion of endo- and xenobiotics, including uremic 
retention solutes. The excretory pathway is mediated via a complex interplay involving solute 
carriers, like OCT2 (SLC22A2), OAT1 (SLC22A6) and OAT3 (SLC22A8) [13], and ATP-
binding cassette efflux pumps, such as p-glycoprotein; P-gp (ABCB1), MRP4 (ABCC4) and 
BCRP (ABCG2) [14]. Besides waste product excretion, reabsorption of filtered solutes, such 
as phosphate, glucose, urate and albumin, occurs in PTEC [15-18].
In our group, a stable PTEC cell line isolated from human urine was developed (ciPTEC-U) 
[19]. This cell line demonstrated functional characteristics of important in- and efflux trans-
porters as well as active albumin and sodium-dependent phosphate transport [19], has proven 
to be valuable in elucidating renal pathological mechanisms [20-23] and in studying renal 
physiological transport pathways [24,25]. However, as this cell line originates from urine, 
it could be argued that ciPTEC-U might not reflect the physiological situation as close as 
cells directly derived from kidney tissue. Cells originating from urine are often thought to be 
exfoliated from tissue due to apoptosis-induced loss of function [26]. Recently it was shown 
that overcrowding of epithelial cells due to proliferation and migration, induces the extrusion 
of living cells to maintain homeostasis in epithelial cell numbers [27]. The aim of this study 
was to compare ciPTEC-U [19] with newly established human proximal tubular epithelial 
cell lines from human kidney tissue with respect to important functional properties. Human 
PTEC were isolated from nephrectomized kidneys followed by subcloning and immortaliza-
tion techniques. Characterizing the newly established human proximal tubular epithelial 
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cell lines will allow us to determine whether the sample source influences renal functional 
properties of cell lines in culture. Insights in these characteristics allows for the identification 
of the most suitable cell line for further development of a bioartificial kidney device.
maTerials and meTHods
chemicals and cell culture materials
All chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands) unless 
stated otherwise. Cell culture plates were purchased from Greiner Bio-One (Monroe, NC) 
and Transwell inserts were obtained from Corning Costar (cat. no 3460, New York, NY).
ethics statement
The kidney tissue used for cell line development in this study was obtained from non-
transplanted donors, after given informed consent. These organs could not be transplanted 
due to quality loss of the veins during surgery. No clinical history of renal disorders or any 
other chronic disease was identified.
isolation and culture of ciPTec from kidney tissue
Purification and isolation of renal epithelial cells from kidney tissue was performed as de-
scribed previously [28]. In short, epithelial cells were isolated by a gradient sieving procedure 
and subjected to collagenase digestion [29]. The collected primary fraction was transferred to 
supplemented PTEC culture media: phenol-red free DMEM-HAM’s F12 medium (catalogue 
number 11039, Lonza, Basel, Switzerland) containing 10% (v/v) FCS (Greiner Bio-One, Mon-
roe, NC), 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml selenium, 36 ng/ml hydrocortisone, 
10 ng/ml EGF and 40 pg/ml tri-iodothyronine. Primary cells were immortalized within the 
first two passages. Immortalization was performed using a combination of hTERT and SV40t 
as described previously [19,30]. To obtain a homogeneous culture, cells were subcloned using 
irradiated NIH 3T3 fibroblast as non-dividing feeder cells [30]. After culturing for 2 weeks at 
33°C, 5% (v/v) CO2, single cell clones were visible and picked using cloning discs drained in 
trypsin-EDTA (MP Biomedicals, Solon, OH). Single cell clones were transferred to a well plate 
and grown until confluent at 33°C, 5% (v/v) CO2. Optimal seeding conditions were determined 
for each obtained ciPTEC line in well plates and Transwell inserts (50 µg/ml collagen IV coating 
for ciPTEC-U (C6745-1ml)) by testing morphological characteristics and monolayer integrity 
properties using a cell density range (data not shown). According to the conditions described 
previously [19], ciPTEC were cultured for 24 h at 33°C 5% (v/v) CO2 to proliferate and subse-
quently transferred to 37°C, 5% (v/v) CO2 for 7 days to mature. Up to at least 40 cell passage 
numbers were used to investigate proliferation and functional properties following prolonged 
culturing. Phase contrast images were captured using a Leica DM IL phase contrast microscope.
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immunocytochemistry
To investigate morphology and polarization characteristics of the ciPTEC monolayers, 
immunocytochemistry was performed using cells cultured on polyester Transwell inserts. 
Matured ciPTEC were fixed using 2% (w/v) paraformaldehyde in HBSS supplemented with 
2% (w/v) sucrose for 5 min and permeabilized in 0.3% (v/v) triton X-100 in HBSS for 10 min. 
To prevent non-specific binding of antibodies, cells were exposed to block solution containing 
2% (w/v) bovine serum albumin fraction V (Roche, Woerden, The Netherlands) and 0.1% 
(v/v) tween-20 in HBSS for 30 min. Cells were incubated with antibodies diluted in block 
solution against the tight junction protein zonula occludens 1 (ZO-1, 1:50 dilution, Invitro-
gen, Carlsbad, CA) for 1 h, followed by incubation with goat-anti-rabbit-Alexa488 conjugate 
(1:200, Life Technologies Europe BV, Bleiswijk, The Netherlands) for 30 min. Finally, DAPI 
nuclei staining (300 nM, Life Technologies Europe BV) was performed for 5 min. Protein 
expression and localization were examined using the Olympus FV1000 Confocal Laser Scan-
ning Microscope (Olympus, Tokyo, Japan) and images were captured using the Olympus 
software FV10-ASW version 1.7. Next, cell size measurements were performed using Image 
J software (version 1.40g).
Transepithelial barrier functions
Transepithelial resistance of matured ciPTEC monolayers on Transwell inserts was measured 
using the Millicell electrical resistance volt-ohm system (Millipore, Billerca, MA). Mea-
surements were performed as described in the manufacturer’s protocol. To determine the 
tightness of the ciPTEC monolayers, inulin-FITC (Sigma-Aldrich) diffusion was measured 
of matured ciPTEC cultured on Transwell inserts. Both apical and basolateral compart-
ments were washed once with HBSS buffer (Life Technologies Europe BV), prior to 0.1 mg/
ml inulin-FITC in HBSS basolateral exposure for 1h at 37°C, 5% (v/v) CO2. Fluorescence 
was detected by measuring samples (200 µl) at excitation wavelength 485 nm and emission 
wavelength 535 nm, using a CytoFluor II Microplate reader (MTX Lab Systems, Vienna, VA).
To investigate monolayer development further, the presence of E-cadherin, a calcium-
dependent cell-cell adhesion protein abundantly expressed in PTEC cells [31], was investigated 
in proliferating and matured cells. After harvesting, cells were fixed and permeabilized using 4% 
(w/v) PFA and 0.1 % (v/v) saponin in HBSS on ice for 10 min. After centrifuging, cell pellets 
were resuspended in rat anti-E-cadherin antibody (1:100 in HBSS) and incubated at RT for 
30 min. Next, cells were centrifuged again, pellets resuspended in goat anti-rat Alexa 488 con-
jugate (1:200, Life Technologies Europe BV, Bleiswijk, The Netherlands) and incubated at RT for 
30 min. After a final centrifuge step, cells were resuspended in HBSS buffer and measured using 
a flowcytometer (FACSCalibur BD, software BD CellQuest Pro version 6.0, Becton Dickinson, 
Franklin Lakes, NJ) gating on live cells (a total of 15,000 cells counted). Separate cell fractions 
were incubated solely with goat anti-rat Alexa 488 conjugate and signal measured was set as 
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a negative control. Next to the extracted geometric mean data, representative flowcytometer 
histograms are shown to illustrate signal intensities (Alexa 488/FL1 signal).
Gene expression of relevant transporters and extracellular matrix proteins in 
ciPTec
Total RNA was isolated from proliferating and matured cells using TRIzol (Life Technologies 
Europe BV) and chloroform extraction according to the manufacturer’s protocol. The Om-
niscript RT kit (Qiagen, Venlo, The Netherlands) was used to synthesize cDNA. The mRNA 
expression levels of PTEC transporter genes were detected using gene specific primer-probe 
sets (Table S1, Applied Biosystems, CA, USA) and TaqMan Universal PCR Master Mix (Ap-
plied Biosystems). The quantitative PCR reactions were performed using the CFX96 Real 
Time PCR system (Bio-Rad Laboratories, Veenendaal, The Netherlands) and data were 
analyzed using the CFX Manager software (Bio-Rad Laboratories). The mRNA expression 
levels of extracellular matrix (ECM) genes were investigated using primer sets (Table S2) and 
SybrGreen PCR Master Mix (Qiagen). The quantitative PCR reactions were performed using 
the ABI 7900HT sequence detection system (Applied Biosystems, Nieuwekerk a/d IJssel, The 
Netherlands). Data of matured cells were normalized to expression levels of the reference 
gene GAPDH, and were expressed as fold increase compared to matured ciPTEC-U [19]. To 
compare expression levels from the proliferating towards matured stage per cell line, data of 
matured cells were expressed as fold increase compared to the corresponding proliferating 
cells (supplemental figures S1 and S2).
determination of proximal tubular specific transporter proteins
To detect proteins of interest in proliferating and matured cells, membrane fractions were 
obtained by ultracentrifugation. Confluent cell layers cultured in T175 flasks were harvested 
and homogenized in 30 ml buffer containing 18 mM Tris-HCL (pH 7.4), 6 mM EGTA, 0.3 M 
mannitol and protease inhibitors (100 mM phenylmethane sulphonylfluoride, 5 mg/ml apro-
tinin, 5 mg/ml leupeptin, and 5 mg/ml pepstatin). The suspension was homogenized using a 
tight fitting Dounce homogenizer (Kimble Chase LLC, Vineland, NJ) followed by ultracen-
trifugation (Sorval WX80, Thermo Fisher Scientific, Walhtam, MA) at 100,000 x g for 45 min 
at 4°C. Finally, the membrane pellets were resuspended in 100 µl RIPA buffer containing 1% 
(w/v) Igepal CA630, 0.5% (w/v) Na-deoxycholate, 0.1% (v/v) SDS (Amersham Biosciences, 
NJ, USA) and protease inhibitors (0.01% (v/v) phenylmethane sulphonylfluoride, 3% (v/v) 
aprotinin and 1 mM sodium orthovanadate). The amount of total protein was measured using 
the Bio-Rad protein detection reagent system (Bio-Rad Laboratories). Protein expression of 
Organic Cation Transporter 2 (OCT2), P-glycoprotein (P-gp), Multidrug Resistance Protein 
4 (MRP4) and Breast Cancer Resistance Protein (BCRP) was investigated by Western blotting 
using 12%, 6%, 6% and 10% (w/v) sodium dodecyl sulphate polyacrylamide gel electropho-
resis (SDS-PAGE), respectively. The iBlot Dry Blotting System (Life Technologies Europe BV) 
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was used for transferring proteins from the gels onto a nitrocellulose membrane. To prevent 
non-specific binding of antibodies, membranes were blocked in PBS supplemented with 0.1% 
(v/v) tween-20 (PBS-T) and 5% (w/v) milk powder (Campina, Woerden, The Netherlands) 
for 30 min. Subsequently, membranes were washed three times in PBS-T. Next, membranes 
were incubated for 1.5 h with rabbit anti-OCT2 antibody (1:500, Alpha Diagnostic Interna-
tional, San Antonio, TX), mouse anti-P-gp antibody (1:200, Abcam, Cambridge, UK), rabbit 
anti-MRP4 antibody (1:100, M49, [32]) or mouse anti-BCRP (1:200, Abcam®, Cambridge, 
UK). As a loading control mouse anti-β-actin (1:100,000) or rabbit anti-Na, K-ATPase anti-
body (α-subunit, 1:2,000, C356-M09 [33]) was used. Subsequently, after three washing steps 
in PBS-T, membranes were exposed to secondary antibodies Alexa fluor® 680 goat anti-rabbit 
IgG (1:10,000, Life Technologies Europe BV), IRDye 800 goat anti-mouse IgG (1:10,000, 
Rockland, PA) or IRDye 800 goat anti-rabbit IgG (1:10,000, Rockland, PA) for 1.5 h. Fluo-
rescence was quantified using the Odyssey Infrared Imaging System (version 2.1, LICOR® 
Biosciences, Lincoln, NE). Data of proliferating and matured cells were normalized to protein 
expression levels of the loading control and plotted in absolute pixel intensities.
Transport assays of renal in- and efflux proteins
The activity of the renal OCT influx proteins was measured as previously described by 
Schophuizen et al. [25]. In short, harvested matured cell suspensions were exposed to the 
fluorescent OCT substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) 
in the presence or absence of 5 mM OCT inhibitor tetrapentylammonium chloride (TPA). 
Data plotted were corrected for cell numbers.
The activity of the renal efflux protein P-gp in ciPTEC was examined by measuring the 
amount of calcein accumulation [34]. In short, matured cells were exposed to 1 µM calcein-
AM (Life Technologies Europe BV) in the presence or absence of 5 µM P-gp inhibitor 
PSC833 (Tocris Biosciences, Bristol, UK) for 1 h at 37°C, 5% (v/v) CO2. Fluorescence in lysed 
cells was measured and data plotted were corrected for protein concentrations.
To evaluate transport characteristics of the renal efflux transporters BCRP and 
MRP4 [32,35], ciPTEC were exposed to kynurenic acid, the end product of tryptophan me-
tabolism. Kynurenic acid is a known uremic retention solute and a substrate for both renal 
efflux transporters [24,36]. To investigate the transport properties of these proteins, cells were 
cultured in 24 well plates and matured monolayers were gently washed three times using 
krebs-henseleit buffer supplemented with 10 mM Hepes (pH 7.4, adjusted with Tris-HCl). 
Subsequently, cells were pre-incubated with supplemented krebs-henseleit buffer in the pres-
ence or absence of 5 µM KO143, a known BCRP inhibitor [37], and 5 µM MK 571 a known 
MRP inhibitor [38] (Alexis Biochemicals, Leiden, The Netherlands) at 37°C, 5% (v/v) CO2 for 
2 h. After pre-incubation, cells were exposed to 10 µM 3H-kynurenic acid (Scopus Research 
BV, Wageningen, The Netherlands) at 37°C for 2 h. The uptake was terminated by washing 
the cells 3 times with ice-cold supplemented krebs-henseleit buffer. Cells were lysed using 
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0.1% (v/v) triton X-100. To each sample 2 ml of scintillation liquid was added and radio-
activity was detected using liquid scintillation counting. Counts measured in supplemented 
krebs-henseleit buffer (blank) were subtracted and data plotted were corrected for protein 
concentrations.
albumin and phosphate uptake assays
To investigate albumin uptake mediated by endocytosis, matured ciPTEC were exposed to 
serum free medium for 4 h at 37°C, 5% (v/v) CO2. Subsequently, cells were exposed to 50 µg/
ml BSA-FITC and incubated at 37°C, 5% (v/v) CO2 for 30 min. In addition, experiments 
were performed at 4°C to inhibit endocytosis. After the incubation period, cells were har-
vested and centrifuged at 1,500 x g for 5 min. The cell pellet was resuspended in 4% (w/v) 
paraformaldehyde in PBS. Finally, intracellular albumin was measured using a flowcytometer 
(FACSCalibur BD, software BD CellQuest Pro version 6.0, Becton Dickinson, Franklin Lakes, 
NJ) gating on live cells (15,000 cells counted). Data was analyzed using FlowJo software (ver-
sion 9.2) and relative net uptake data was plotted next to the actual flowcytometer histograms.
Phosphate uptake was performed in confluent monolayers cultured at 33°C and 37°C, 5% 
(v/v) CO2 with 32PO4 (Perkin Elmer, Waltham, MA) as described earlier by Malmstrom et al. 
[19,39]. Cells were cultured in 24 well plates and gently washed three times using wash buffer 
(20 mM Hepes, 5.6 mM CaCl2, 10.8 mM KCl, 2.4 mM MgCl2, 274 mM NaCl) at 37°C. To 
determine the sodium- dependent uptake of phosphate, experiments were performed in the 
absence of sodium by replacing NaCl with 274 mM N-methyl-D-glucamine. The uptake buf-
fer was added for 5 min at 37°C consisting of wash buffer, supplemented with 0.22 mM phos-
phate with 1.0 µCi/mL 32PO4 added as tracer. The uptake was terminated by washing the cells 
five times with ice-cold wash buffer. Cells were lysed using 0.5 ml 0.05 M Na+-deoxycholate 
in 0.1 M NaOH. To each sample 2 ml of scintillation liquid was added and radioactivity was 
detected using liquid scintillation counting. Counts measured in wash buffer (blank) were 
subtracted and data plotted were corrected for protein concentrations.
data analysis
All data are expressed as mean ± SEM Statistical analysis was performed using one-way 
ANOVA analysis followed by Dunnett’s Multiple Comparison test or, where appropriate, an 
unpaired t test with GraphPad Prism version 5.02 (La Jolla, CA). A p-value of <0.05 was 
considered significant.
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resUlTs
successful development of ciPTec lines from human kidney tissue isolates
To appreciate the functional capacity of ciPTEC-U [19], new PTEC cell lines were generated 
from human kidney tissue and characterized to compare with ciPTEC-U. PTEC isolates were 
obtained from three different kidney donors and primary cells were grown successfully. All 
cell cultures that were immortalized using SV40t and hTERT, were found resistant to both 
hygromycin B and geneticin (G418) thereby confirming successful transduction. Next, cells 
were subcloned to obtain homogenous cell lines after which cell proliferation could be main-
tained for up to at least cell passage 42 without morphological changes. From the original 
three kidney isolates, different subclones were obtained. Based on mRNA expression levels of 
PTEC transporters, morphology and monolayer tightness, two out of twenty six kidney sub-
clones were selected (ciPTEC-T1 and -T2) for detailed characterization. The ciPTEC-T1 and 
-T2 originated from the same donor and were compared in great detail with ciPTEC-U [19]. 
Figure 2.1a represents a flow chart of the isolation and selection procedure performed in this 
study. Representative phase contrast images of the selected clones ciPTEC-T1 and -T2 are 
shown in Figure 2.1b. Transduction of kidney tissue derived cultures with hTERT solely did 
not result in suitable cell lines as determined by morphology and cell proliferation (data not 
shown).
figure 2.1a flow chart of clone selection.
Schematic overview of the cell isolation process from kidney tissue upon establishment of clonal cell 
lines. Cells were isolated from three donors and 26 subclones were selected in a first round. These sub-
clones were characterized morphologically, but also gene expression levels of PTEC specific transporters 
were investigated. Transduction of kidney tissue derived cultures with hTERT solely did not result in 
suitable cell lines as determined by morphology and cell proliferation. Finally, two clones from the same 
donor obtained after combined SV40 and hTERT transductions were chosen for detailed characteriza-
tion (ciPTEC-T1 and -T2), based on PTEC specific morphological characteristics and highest gene 
expression levels of PTEC transporters.
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morphological characteristics and extracellular matrix investigation
Optimal seeding conditions to obtain confluent layers of ciPTEC in well plates and Trans-
well inserts were determined as indicated in table 2.1. A collagen IV coating of 50 µg/ml 
stimulated the development of a homogeneous tight layer of ciPTEC-U on Transwell inserts. 
Interestingly, no coating was necessary for ciPTEC-T1 and -T2 to develop a homogeneous 
cell monolayer on the inserts (Figure 2.2a - c). In well plates, confluent ciPTEC monolayers 
were obtained without any additional coatings.
The tight junction protein zonula occludens-1 (ZO-1) in PTEC is a marker for the integrity 
and polarity of the cell layer. Furthermore, tight junctions contain interacting proteins that 
regulate differentiation, proliferation and gene expression, indicating an important role in 
figure 2.1b representative phase contrast images of ciPTec.
Proliferating (33°C, 5% (v/v) CO2) and fully matured (7 days at 37°C, 5% (v/v) CO2) ciPTEC-U passage 
40 (I), -T1 passage 38 (II), and -T2 passage 42 (III) are shown.
Table 2.1 optimal ciPTec seeding density in well plates and Transwell inserts
Cell line Well plates seeding density
 (cells. cm-2)
Transwell inserts seeding density
(cells. cm-2)
ciPTEC-U 4.8 x 104 1.3 x 105
ciPTEC-T1 1.9 x 104 0.60 x 105
ciPTEC-T2 1.9 x 104 0.60 x 105
ciPTEC cultured at indicated densities resulted in tight monolayer formation upon 7 days maturation.
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PTEC functionality [40]. Cells cultured on Transwell inserts, were stained against ZO-1 and 
the protein expression was examined using confocal microscopy. A clear ZO-1 expression 
was visible for all three cell lines (Figure 2.2a - c). A z-scan depicts the fluorescent signal of 
tight junction expression at the cell boundaries in each ciPTEC model, but most abundantly 
in ciPTEC-U, and confirms polarization of the cells. Next to this, we determined cell diameter 
and observed a larger span for matured ciPTEC-T1 (19.4 µm ± 0.8, p<0.001; Figure 2.2b) and 
-T2 (21.7 µm ± 0.6, p<0.001; Figure 2.2c) as compared to matured ciPTEC-U (10.9 µm ± 0.6; 
Figure 2.2a). Both ciPTEC cell lines isolated from kidney tissue showed a larger span com-
pared to ciPTEC-U when cultured in similar uncoated cell culture flasks, at both temperatures 
(Figure 2.1b). This indicates that cell size differences were not influenced by a collagen IV 
coating but may possibly source related.
Cell monolayer tightness was examined further by determination of the paracellular per-
meability of the cell monolayers using the diffusion marker inulin [41]. CiPTEC cultured on 
Transwell inserts were basolaterally exposed to FITC-inulin. No differences were observed in 
inulin flux between the ciPTEC-U versus kidney tissue derived cell lines, as shown in table 2.2. 
Furthermore, the epithelial barrier integrity was investigated by measuring the transepithelial 
electric resistance (TEER). Cell lines were cultured on Transwell inserts and the TEER was 
measured in matured cells (Table 2.2). CiPTEC-T1 demonstrated a higher resistance (140 ± 
figure 2.2 expression of Zo-1 protein in ciPTec.
Representative confocal images of ZO-1 (green) in x-y and y-z planes are shown (nuclei are stained 
with DAPI (blue)) in matured (37°C) ciPTEC cultured on Transwell inserts. (a-c) The expression of 
ZO-1 (green fluorescent) was determined at the cell boundaries and was most abundantly present in 
ciPTEC-U (a). Furthermore, the average cell diameter was measured, demonstrating a significantly 
larger cell size of ciPTEC-T1 and -T2 as compared to ciPTEC-U. Note: ciPTEC-U were cultured on col-
lagen IV coated surfaces, whereas ciPTEC-T1 and -T2 were cultured on uncoated Transwell inserts. *** 
= p<0.001, using one-way ANOVA analysis followed by Dunnett’s multiple comparison test.
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4 Ω.cm2, p<0.05) as compared to ciPTEC-U (124 ± 3 Ω.cm2), whereas no significant differ-
ences were observed between ciPTEC-T2 (126 ± 4 Ω.cm2) and ciPTEC-U
Table 2.2 Transepithelial barrier functions of ciPTec
Cell line Inulin diffusion (pmol. min-1. cm-2) TEER (Ω.cm2)
ciPTEC-U 9.3 ± 0.4 124 ± 3
ciPTEC-T1 8.0 ± 0.7 140 ± 4*
ciPTEC-T2 9.2 ± 0.5 126 ± 4
Monolayer integrity was measured using inulin flux and transepithelial electric resistance determina-
tion. * = p<0.05, using one-way ANOVA analysis followed by Dunnett’s multiple comparison test. Data 
presented are means of three independent experiments and expressed as mean ± SEM.
The cell-cell adhesion protein E-cadherin was clearly present in the models tested (Figure 
2.3) in proliferating (light gray histogram) as well as in matured (dark gray histogram) ciPTEC 
compared to the negative control (black histogram), emphasizing the abundant epithelial 
characteristics of these models. Interestingly, matured ciPTEC showed a more heterogeneous 
population compared to proliferating ciPTEC. Based on geometric mean data extracted 
from these histograms, matured ciPTEC-T1 only showed a more abundant prevalence of 
E-cadherin when compared to proliferating ciPTEC-T1.
To gain more insight in complexes involved in cell development [42,43], the presence of 
ECM genes was investigated. The mRNA expression levels of collagen I and –IV αI, fibronectin 
I and laminin 5 (LAMA5; alpha-5 subunit of laminin-10, -11 and -15) were detected in ma-
tured ciPTEC-U, -T1 and -T2. Interestingly, significant differences were observed between the 
cell lines. In matured ciPTEC-T1 and -T2 a higher expression of collagen I - and IV αI (Figure 
2.4a and b, p<0.001) was observed compared to matured ciPTEC-U. Whereas fibronectin I 
and laminin 5 expression was lower in matured kidney tissue derived cell lines (fibronectin 
I ciPTEC-T1 and -T2: p<0.01, laminin 5 ciPTEC-T2: p<0.05, ciPTEC-T1: not significant) 
compared to ciPTEC-U. In supplemental figure S1, mRNA expression levels of these genes 
in proliferating versus matured cells are shown. Matured tissue derived cell lines showed an 
increased collagen I αI (supplemental figure S1a; p<0.001), fibronectin I (supplemental figure 
S1c; p<0.001) and laminin 5 (supplemental figure S1d; p<0.05) gene expression, whereas 
matured ciPTEC-U showed a less pronounced genetic ECM profile. Interestingly, collagen IV 
αI (supplemental figure S1b) gene expression upon maturation was lower (p<0.001) in each 
cell line compared to proliferating cells.
Gene and protein expression levels of PTec specific transporters
The excretion of endo- and xenobiotics in the proximal tubular system is mediated via various 
important in- and efflux transporters like OCT2, P-gp, MRP4 and BCRP [13,14]. The presence 
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of these PTEC specific transporters was investigated on gene and protein level in matured 
ciPTEC-U, -T1 and -T2. The mRNA expression levels of most transporters (Figure 2.5) were 
comparable between the three matured cell lines, except for OCT2 in ciPTEC-T1 (p<0.05) 
and BCRP in ciPTEC-T2 (p<0.05) which showed a higher expression as compared to matured 
ciPTEC-U. In supplemental figure S2, mRNA expression levels of these genes in proliferating 
versus matured cells are shown. Each matured cell line showed an increased OCT2 gene ex-
pression (supplemental figure S2a; ciPTEC-U and -T1 p<0.05, ciPTEC-T2 p<0.001), whereas 
P-gp (supplemental figure S2b) and MRP4 (supplemental figure S2c) gene expressions were 
more abundantly only in matured tissue-derived cell lines (P-gp ciPTEC-T1 p<0.01, ciPTEC-
figure 2.4 expression of extracellular matrix genes in matured ciPTec models.
(a and b) Both cell lines derived from kidney tissue showed a higher gene expression of collagen I α1 (a) 
and –IV α1 (b) compared to ciPTEC-U. (c) In ciPTEC-T1 and -T2, a lower gene expression of fibronec-
tin I was observed compared to ciPTEC-U. (d) In ciPTEC-T2, a lower gene expression of laminin 5 was 
observed compared to ciPTEC-U. Expression levels were corrected for corresponding GAPDH mRNA 
levels and data are expressed as fold change and compared to ciPTEC-U. Data are presented as means of 
three independent experiments ± SEM * = p<0.05, ** = p<0.01, ***= p<0.001, using an ANOVA analysis 
followed by Dunnett’s multiple comparison test.
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T2 p<0.05; MRP4 ciPTEC-T2 p<0.01). Although not significant, the gene expression of BCRP 
(supplemental figure S2d) showed less expression upon maturation in each cell line.
In fully differentiated cells, a non-significant but recurrent trend in abundance of transport 
protein expression was observed, which points towards a somewhat higher expression of the 
investigated transporters as compared to the corresponding proliferating cells (Figure 2.6). 
The expression levels between the different cell lines in their proliferating or matured state 
was not significantly different.
figure 2.5 expression of proximal tubular specific transporters in matured ciPTec models. (a) In 
ciPTEC-T1 a higher OCT2 gene expression was observed compared to ciPTEC-U. (b and c) No signifi-
cant differences in P-gp (b) and MRP4 (c) gene expressions were observed between the three cell lines. 
(d) In ciPTEC-T2 a higher BCRP gene expression wasobserved compared to ciPTEC-U. Expression 
levels were corrected for corresponding GAPDH mRNA levels and data were expressed as fold change 
and compared to ciPTEC-U. Data are presented as means of three independent experiments ± SEM * = 
p<0.05, ** = p<0.01, using an ANOVA analysis followed by Dunnett’s multiple comparison test.
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functional transport in ciPTec
To functionally characterize OCTs, we used a recently established assay based on the up-
take of the fluorescent marker substrate ASP+ in ciPTEC suspensions [25] . All three cell 
lines showed a clear ASP+ uptake, which was sensitive to inhibition by TPA (p<0.001), in-
figure 2.6 Protein expression of ocT2, P-gp, mrP4 and bcrP in membrane fractions of ciPTec-
U, -T1 and -T2.
(a - d) Although not significant, all matured (black bars) ciPTEC showed a slight increased OCT2 (a), 
P-gp (b), MRP4 (c) and BCRP (d) expression compared to proliferating (white bars) ciPTEC. Signal 
intensities were corrected for the corresponding reference protein, which was used as a loading control 
and expression was analyzed semi-quantitative by measuring pixel intensity. Note that due to Western 
blot conditions Na,K-ATPase appears in multiple bands (b and c). Hence, for semi-quantification the 
intensity between 100 - 120 kDa was used as a reference. To semi-quantify the OCT2 expression, β-actin 
was used as a reference protein since the molecular mass of β-actin (42 kDa) is more within the mass 
range of OCT2 (60kDa) than Na, K-ATPase (112 kDa). The blots presented are representative for pro-
tein expression in the ciPTEC models. Data are presented as means of three independent experiments 
± SEM and statistical analysis was performed using an ANOVA analysis followed by Dunnett’s multiple 
comparison test.
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dicating active OCTs present in each ciPTEC model (Figure 2.7a). To compare the activity 
between the cell lines, the net ASP+ uptake was calculated, which was higher in ciPTEC-U 
(80 ± 8 RFU/1,000 cells) compared to ciPTEC-T1 (53 ± 2 RFU/1,000 cells; p<0.05), whereas 
no difference was observed between ciPTEC-U and -T2 (net transport 71 ± 5 RFU/1,000 cells).
The functional expression of P-gp was examined by measuring intracellular accumula-
tion of calcein in matured cells, as described earlier [34]. The inhibitor PSC833 was used 
to obtain accumulated intracellular fluorescent signals due to P-gp inhibition (Figure 2.7b). 
An increased accumulation was determined in all ciPTEC cell lines (p<0.001), indicating 
figure 2.7 functional in- and efflux proteins in 
matured ciPTec.
(a) OCT2 mediated ASP+ uptake was measured in 
matured ciPTEC in the presence (black bars) or ab-
sence (white bars) of an inhibitor, TPA (5 mM). All 
ciPTEC models showed ASP+ uptake which was sen-
sitive to inhibition by TPA, confirming specific OCT 
activity. In ciPTEC-T1 the net ASP+ uptake (values 
without inhibitor subtracted from values in presence 
of TPA) was lower compared to ciPTEC-U. (b) The 
P-gp activity in matured ciPTEC was measured in 
the presence (black bars) or absence (white bars) of 
a P-gp inhibitor, PSC833. An increased accumula-
tion of calcein was observed in all cell lines in the 
presence of the P-gp inhibitor. Moreover, in ciPTEC-
T1 and –T2 the net calcein accumulation (values 
without inhibitor subtracted from values in presence 
of PSC833) was higher as compared to ciPTEC-U. 
(c) The activity of MRP4 and BCRP in matured 
ciPTEC was detected in the presence (black bars) or 
absence (white bars) of the inhibitors, MK571 and 
KO143. A significant increased accumulation of 
kynurenic acid was observed in ciPTEC-U in the 
presence of the inhibitors. Although not significant, 
a slight increase in accumulation of kynurenic acid 
was detected in ciPTEC-T1 and -T2. The net kyn-
urenic acid accumulation (values without subtracted 
from values in presence of both inhibitors) showed 
no differences between the cell lines. Data are pre-
sented as means of three independent experiments ± 
SEM * = p<0.05, *** = p<0.001 compared to data in 
the absence of inhibitors per cell line, using an un-
paired t test. # = p<0.05, ## = p<0.01 compared to 
net activity in ciPTEC-U, using an ANOVA analysis 
followed by Dunnett’s multiple comparison test.
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figure 2.8 essential reabsorption of albumin and phosphate in PTec.
(a; upper panel) The albumin reabsorption was detected in matured cells incubated at 4°C (blue his-
togram) and 37°C (red histogram) during experimental processing (15,000 cells counted). The signal 
intensities obtained at 37°C clearly showed specific reabsorption in each model. (a; lower panel) The net 
albumin reabsorption was determined in matured ciPTEC and calculated by subtracting a-specific reab-
sorption data detected at 4°C from values determined at 37°C. Significantly increased albumin reabsorp-
tion was observed in ciPTEC-T2 as compared to ciPTEC-U. (b) The net sodium-dependent phosphate 
uptake was investigated in matured ciPTEC and calculated by subtracting sodium-independent uptake 
data from the uptake determined in presence of sodium. A significantly increased sodium-dependent 
phosphate uptake was detected in ciPTEC-U compared to ciPTEC-T1 and T2. Data are shown as mean 
± SEM of three independent experiments. ** = p < 0.01, *** = p < 0.001, using one-way ANOVA analysis 
followed by Dunnett’s multiple comparison test.
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functional P-gp present in each ciPTEC model. To compare the activity between the cell lines, 
the net calcein fluorescence was determined and a clearly higher calcein accumulation was 
observed in both cell lines established from kidney tissue (ciPTEC-T1 7.3 ± 0.6 RFU x 103.
mg protein-1.cm-2; p<0.01 and ciPTEC-T2 7.2 ± 0.4 RFU x 103.mg protein-1.cm-2; p<0.05) 
compared to ciPTEC-U (5.3 ± 0.4 RFU x 103.mg protein-1.cm-2).
The functional properties of BCRP and MRP4 were investigated by exposing matured 
ciPTEC models to kynurenic acid (Figure 2.7c). The compounds MK571 in combination with 
KO143 were used as MRP4 and BCRP inhibitors, respectively [37,38]. A higher accumulation 
was observed in ciPTEC-U in the presence of inhibitors (p<0.05). In both tissue derived cell 
lines, kynurenic acid accumulation was slightly increased in presence of the inhibitors but 
this effect was not significant. To investigate and compare the BCRP and MRP4 properties 
between matured ciPTEC models, the net accumulation of kynurenic acid was calculated and 
compared to ciPTEC-U (1.1 ± 0.4 pmol.mg protein-1.cm-2), but no differences were observed 
(ciPTEC-T1 0.7 ± 0.6 pmol.mg protein-1.cm-2, ciPTEC-T2 0.9 ± 0.3 pmol.mg protein-1.cm-2).
In addition to uremic toxin (UT) excretion, proximal tubule cells also play an important 
role in renal reabsorption processes. Wilmer et al. [44] and Gorvin et al. [12] previously 
reported on the presence of megalin in ciPTEC-U and specific megalin mediated albumin 
endocytosis was confirmed with the megalin-blocker recombinant receptor-associated pro-
tein (RAP). The temperature-sensitive reabsorption of albumin was investigated in the three 
cell lines (Figure 2.8a; upper panel). The reabsorption was similar in ciPTEC-T1 as compared 
to ciPTEC-U, whereas ciPTEC-T2 demonstrated a higher uptake of albumin (Figure 2.8a; 
lower panel; p<0.001).
Another PTEC feature concerns sodium-dependent phosphate re-absorption, mediated 
via NaPi-IIa and NaPi-IIc and driven by the free energy provided by the electrochemical 
gradient for Na+. The transporters are located at the luminal side of proximal tubular cells 
[16]. The mRNA expression of both phosphate transporters was confirmed in proliferat-
ing and matured cells (supplemental figure S3) and uptake in matured ciPTEC-U, -T1 and 
-T2 was studied (Figure 2.8b). Sodium-dependent phosphate uptake was found to be lower 
in ciPTEC-T1 and –T2 (p<0.01) as compared to ciPTEC-U. In proliferating cells sodium-
dependent phosphate uptake was determined as well (supplemental figure S4), however, the 
uptake was clearly higher in matured cells as compared to proliferating cells.
discUssion
In this study, human conditionally immortalized proximal tubular epithelial cell lines were 
successfully developed from kidney tissue. Characterization of the newly established human 
cell lines and comparison with a cell line isolated from urine revealed that cells from both 
sources comparably maintain renal physiological properties. A broad range of parameters was 
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endogenously present in the three cell lines, including the ability to form tight monolayers, 
ECM deposition and diverse transport activities. On a functional level, the cells isolated from 
kidney tissue were able to compete with the previously characterized cell line isolated from 
urine (ciPTEC-U), while collagen I and -IV α1 gene expression was more pronounced in cells 
derived from renal tissue samples.
To maintain homeostatic cell numbers in the epithelium, live cell extrusion can take place 
in epithelial cells into the tubular lumen [27]. Although viable cells can be exfoliated in urine, 
their release might be the result of reduced capability to excrete ECM proteins as demon-
strated in this study. The cell lines derived from kidney tissue showed a more pronounced 
endogenous expression of collagen I and -IV α1 as compared to ciPTEC-U, and monolayer 
formation of the urine derived cell line was clearly improved by collagen IV coating of culture 
material. These findings suggest that despite the more abundant gene expression of both 
fibronectin I and laminin 5 in matured ciPTEC-U, lower levels of essential collagen I and 
IV α1 expression prevents these cells from developing tight monolayers. In the kidney, the 
ECM proteins play an important role in intracellular signaling including cell proliferation, 
survival and migration as well in repair [42,43]. Therefore, it could be argued, that ciPTEC-U 
has limited properties with respect to ECM and related signaling functions. However, based 
on the functional data and E-cadherin expression obtained in this study, ciPTEC-U nicely 
competes with the cells originally derived from kidney tissue. Functionally active OCT2, 
P-gp, MRP4 and BCRP mediated transport was detected in all models tested, and no superior 
cell line with respect to the activity of the investigated transport proteins was identified. 
Furthermore, active albumin reabsorption and sodium-dependent phosphate uptake were 
measured in ciPTEC-U, ciPTEC-T1 and -T2, with only small variations between the cell lines.
Gene and protein expressions of OCT2, P-gp, MRP4 and BCRP transporters confirmed 
the endogenous presence of these proteins in ciPTEC-U, -T1 and -T2. The small differences 
between the three cell models most likely reflect the biovariability. Importantly, the ciPTEC 
models showed an extensive endogenous expression profile upon maturation, emphasizing 
the differentiation capacity of these human PTEC lines by immortalization using the tem-
perature sensitive SV40 tsA58 antigen. In the panel of transporters tested, only BCRP was less 
abundantly present in matured cells as compared to proliferating cells (supplemental figure 
S2d). This observation can be explained by the role of this efflux pump in kidney regeneration 
where it has a distinct function during cell development and a less prominent expression 
upon maturation [45].
Interestingly, although the gene expression levels of the four transporters investigated 
were lower in matured ciPTEC-U as compared to matured ciPTEC-T1 and -T2, their protein 
expressions and activities were almost equal in the three models. These observations might 
reflect differences in post-transcriptional or -translational regulation of the transport proteins. 
The first step from mRNA to protein can be influenced by epigenetic alterations in signaling 
molecules, such as Wnt proteins and DNA-binding factors which play a key role in proximal 
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tubular cell development [46]. The differences in the next step from inactive to a functional 
and active transport protein can possibly be influenced by an altered activity of kinases and/
or phosphatases responsible for phosphorylation and dephosphorylation, respectively [47]. 
Future research directed towards these pathways should reveal how the four transporters can 
be modulated in the cell lines.
Robust transport activity was undoubtedly proven for OCTs and P-gp, while the activity 
of MRP4 and BCRP was less pronounced with the assay used. For the latter transporters 
the combined substrate kynurenic acid [36] was used in combination with inhibitors for 
MRP4 and BCRP. A plausible explanation for the limited effect of both inhibitors on kyn-
urenic acid accumulation may be the absence of a specific uptake transporter for kynurenic 
acid. The uremic metabolite was proven to be an equally potent substrate for the basolaterally 
expressed organic anion transporters 1 (OAT1) and -3 (OAT3) [48]. OAT1 and OAT3 form 
important influx transporters in proximal tubular cells and determinants in the excretion of 
a variety of organic anions, including waste products from normal metabolism and drugs 
[49,50]. Unfortunately, these transporters are absent on gene, protein and functional levels 
in the immortalized cell lines isolated from both urine and kidney tissue (data not shown). 
Although the expression of OATs has been observed in primary proximal tubular cells [51], 
the levels decrease dramatically during the first days of culturing and are lost after cell passag-
ing (unpublished observations). This phenomenon has already been described in 1990 by J.H. 
Miller [52] and has, as of yet, not been solved. Stable expression of these OATs in renal cell 
lines may not only be of importance for studying regenerative nephrology, but may also be of 
great value for drug development in pharmaceutical industry. Next to the OAT transporters, 
OATP4C1 is another known anion uptake transporter expressed at the basal membrane of 
proximal tubule cells [53]. The gene expression was studied in these cell lines and the expres-
sion of OATP4C1 was confirmed in matured cells (an average C(t) value of 27.2 ± 0.1 was 
detected). Assays to demonstrate the functionality of this transporter are in progress. To study 
the role of transporters in disposition of new pharmaceutical entities and to identify potential 
drug-drug interactions, a need exists for human models predictive for renal drug handling 
[44,54,55]. Future research will be directed to further develop and optimize such models.
Next to the functional basolateral uptake and apical efflux transport, active albumin 
reabsorption and sodium-dependent phosphate uptake are essential processes occurring in 
human PTEC. Both mechanisms were detected in our ciPTEC models, although differences 
were observed between the cell lines. These findings underline the heterogeneity with respect 
to their endocytosis-mediated albumin uptake via megalin, and NaPi-IIa and -IIc mediated 
sodium-dependent phosphate uptake. As described before, post-transcriptional and -transla-
tional differences in these cell lines might explain the observed variability.
Isolating functional renal epithelial cells from human urine and applying conditional 
immortalization strategies could be a valuable tool in tissue engineering for personalized 
medicine in patients suffering from renal disorders, e.g. in development of a bioartificial 
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kidney, or so called renal assist device (RAD)[12]. Indications exist that residual renal func-
tion in CKD represents urine produced by tubular secretion rather than glomerular filtration 
[56]. Residual renal function is a predictor of survival in patients treated with dialysis [57]. 
Retaining or improving active tubular secretion processes may have profound effects on 
clinical outcome of CKD patients and the use bioartificial devices may be a good treatment 
alternative for this patient population [12]. However, the amount and the quality of functional 
cells in urine originating from these patients might be questionable. In this study, cells from 
healthy volunteers were transduced using hTERT in combination with the temperature sensi-
tive SV40t gene [19,30]. Although Wieser et al. [58] previously used a single transduction of 
hTERT only to immortalize primary renal cells, in our laboratory this method did not lead 
to successful immortalization and hTERT only transductions resulted in dysmorphic cells. 
A great advantage of using the combined immortalization strategy is that cells can remain 
in their proliferating state at 33°C, thereby providing an unlimited cell source. Matura-
tion can be initiated by transferring cells to 37°C, upon which the expression of SV40t in 
ciPTEC decreases [19] and expression levels of PTEC specific proteins adequately increases 
(supplemental figure S1 - S3). These findings support their suitability for studying regen-
erative nephrology. However, the oncogene transductions used require stringent biological 
safety regulation (e.g. filters absorbing eventually disrupted cells) before implementing in any 
clinical application, which is the focus of ongoing research and obviously a thorough risk 
assessment is needed. The use of serum-free culture conditions might be favorable to reduce 
a possible host immune response. However, culturing the ciPTEC models using serum-free 
medium for more than 24h induces epithelial-to-mesenchymal transition (EMT) and results 
in a loss of PTEC-specific characteristics (data not shown). Serum-replacement compounds 
might be an appropriate alternative, but to this end comprehensive research is required to 
study the possible effect in these PTEC models prior to implementation.
In conclusion, the human renal lines established from urine and kidney tissue display a 
comparable variety of functional PTEC specific transporters with maintained reabsorption 
mechanisms. Interestingly, a different ECM profile was observed in the cell lines isolated 
from kidney tissue as compared to the cell line isolated from cells exfoliated in urine. The 
cell models presented here could serve as valuable tools to study proximal tubule physiology 
and pharmacology. Furthermore, the availability of inexhaustible sources of functional hu-
man proximal tubule epithelial cells could allow for further development and up scaling of 
bioartificial kidney devices.
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absTracT
Several organic cations, such as guanidino compounds and polyamines, have been found to 
accumulate in plasma of patients with kidney failure due to inadequate renal clearance. Here, 
we studied the interaction of cationic uremic toxins (UTs) with renal organic cation transport 
in a conditionally immortalized human proximal tubule epithelial cell line (ciPTEC).
Transporter activity was measured and validated in cell suspensions by studying uptake of 
the fluorescent substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium-iodide (ASP+). 
Subsequently, the inhibitory potencies of the cationic UTs, cadaverine, putrescine, spermine 
and spermidine (polyamines), acrolein (polyamine breakdown product), guanidine and 
methylguanidine (guanidino compounds) were determined.
Concentration-dependent inhibition of ASP+ uptake by TPA, cimetidine, quinidine and 
metformin confirmed functional endogenous organic cation transporter 2 (OCT2) expres-
sion in ciPTEC. All UTs tested inhibited ASP+ uptake, of which acrolein required the lowest 
concentration to provoke a half-maximal inhibition (IC50 = 44 ± 2 µM). A Dixon plot was 
constructed for acrolein using three independent inhibition curves with 10, 20 or 30µM ASP+, 
which demonstrated competitive or mixed type of interaction (Ki = 93 ±16 µM). Exposing the 
cells to a mixture of cationic UTs resulted in a more potent and biphasic inhibitory response 
curve, indicating complex interactions between the toxins and ASP+ uptake.
In conclusion, ciPTEC proves a suitable model to study cationic xenobiotic interactions. 
Inhibition of cellular uptake transport was demonstrated for several UTs, which might indi-
cate a possible role in kidney disease progression during uremia.
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inTrodUcTion
In patients suffering from end-stage renal disease (ESRD), kidney function is severely im-
paired. As a consequence, waste products from normal metabolism are insufficiently cleared 
from the circulation, resulting in accumulation of uremic retention solutes in the patient 
[1,2]. Although in ESRD soluble xenobiotics can be cleared by dialysis, the clearance of small 
lipid soluble and/or protein bound toxins using currently available techniques is insufficient 
[3]. The accumulation of these UTs contribute to the development of the uremic syndrome, 
resulting in increased morbidity and mortality [4]. In addition, drug disposition is affected in 
ESRD patients due to altered pharmacokinetics. Renal failure has been found to affect both 
renal and non-renal toxin elimination routes [5]. Down regulation of various renal and he-
patic drug influx transporters, such as organic anion transporters, p-glycoprotein, multidrug 
resistance proteins and OCT2, has been observed in ERSD [6,7]. Insights in the mechanism 
of UT clearance in humans could aid us in the search for new therapeutic possibilities for 
patients on dialysis.
The human kidney expresses transporters involved in UT clearance. A system involved 
in renal tubular uptake are the OCT proteins, for which three isoforms (OCT1-3) have been 
identified [8].The OCT2 (SLC22A2) is abundantly expressed in the proximal tubule of human 
kidney, and is considered essential for the removal of potentially toxic cationic compounds 
from the circulation, including drugs such as cimetidine (H2 receptor antagonist), metformin 
(antidiabetic), and various antibiotics and antihistamines [9,10]. These compounds can 
cause toxicity via drug-drug interactions due to competitive inhibition caused by the limited 
transport capacity of OCT2 [11]. Furthermore, OCT2 is a determinant in cisplatin-induced 
nephrotoxicity due to its role in drug uptake into renal proximal tubular cells [12]. Next to 
OCT2, the OCT1 (SLC22A1) and 3 (SLC22A3) isoforms are also involved in cation uptake. 
While the expression of OCT1 and OCT2 is mainly restricted to the liver and kidney, OCT3 is 
more widely expressed in various tissues [8]. In normal functioning kidneys, the first step in 
the urinary excretion of cationic UTs might involve renal tubular cell uptake mediated by 
OCTs. Indeed, in renal failure several organic cations, such as guanidino compounds and 
polyamines that are derived from amino acids metabolism, have been found to accumulate in 
plasma of uremic patients [13].
The guanidino compounds guanidine and methylguanidine are part of a large group of 
structural metabolites of arginine. Guanidino compounds are small, water soluble cations 
and not bound to plasma proteins. Despite this, their dialytic removal is insufficient [14]. 
The accumulation of guanidine and methylguanidine is known to affect hematopoietic cell 
functioning and can induce neuronal and cardiovascular adverse events [15-18].
The polyamines, cadaverine, putrescine, spermine, spermidine and their breakdown 
product acrolein, are all protein bound solutes and therefore not freely filtered by the glom-
erulus. As a result, these solutes are insufficiently cleared through dialysis in ESRD [13]. These 
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polyamines are formed during cellular lysine, arginine and ornithine catabolism. In humans, 
serum levels of free polyamines are relatively low as the polyamines are predominantly lo-
calized intracellular [19]. Spermine, spermidine, putrescine and cadaverine are reported to 
inhibit erythropoiesis and erythroid colony formation in a dose-dependent manner [20,21]. 
High levels of putrescine were reported to inhibit cell growth in vitro and to alter cytoplasmic, 
mitochondrial and nuclear membrane structures [22].
In the present study, we examined the interaction of these classes of cationic uremic reten-
tion solutes with OCT-mediated transport in a human conditionally immortalized proximal 
tubule epithelial cell model (ciPTEC) [23]. To this end, we characterized the interaction of 
known substrates for OCT2 and studied the inhibitory potency of the guanidino compounds 
and polyamines on OCT-mediated transport. Furthermore, the cytotoxic potential of the 
cationic uremic retention solutes was evaluated, as well as the interaction of a cationic UT 
mixture, mimicking uremic conditions.
maTerials and meTHods
chemicals
4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) was purchased from Invit-
rogen (Eugene, Oregon, USA). Tetrapentylammoniumchloride (TPA), metformin, quinidine, 
cimetidine hydrochloride, spermine, spermidine, cadaverine, putrescine dihydrochloride, 
acrolein, guanidine hydrochloride, methylguanidine hydrochloride, insulin, transferrin, 
selenium, tri-iodothyronine, hydrocortisone and epidermal growth factor were purchased 
from Sigma-Aldrich Co. (Zwijndrecht, the Netherlands).
cell culture
The immortalized human proximal tubule epithelial cell line ciPTEC was developed as 
previously described [23]. ciPTEC were cultured in Dulbecco’s modified eagle medium 
DMEM-HAM’s F12 (Lonza; Basel, Switzerland) containing 10% v/v fetal calf serum (FCS) 
(Greiner Bio-One; Alphen a/d Rijn, the Netherlands), 5 µg/ml insulin, 5 µg/ml transferrin, 
5 ng/ml selenium, 36 ng/ml hydrocortisone, 10 ng/ml epidermal growth factor and 40 pg/ml 
tri-iodothyronine. Cells were cultured in the absence of phenol-red and antibiotics. Culture of 
ciPTEC was done for up to 40 passages, for which proximal tubular characteristics remained 
unaltered [23]. Cells were seeded at 30% density in tissue culture flasks and cultured for 24h 
at 33°C 5% v/v CO2, followed by maturation of the cells at 37°C 5% v/v CO2 for 7 days prior 
to experiments.
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rna expression of ocT1, 2 and 3 transporters in ciPTec
Total RNA was isolated from proliferating and matured cells of interest using TRIzol (Life 
Technologies Europe BV) and chloroform extraction according to the manufacturers’ 
protocol. The Omniscript RT kit (Qiagen, Venlo, The Netherlands) was used to synthesize 
cDNA. The mRNA expression levels were detected using gene specific primer-probe sets 
obtained from Applied biosystems® (OCT1 (SLC22A1) Hs00427552_m1, OCT2 (SLC22A2) 
hs01010723_m1, OCT3 (SLC22A3) Hs01009568_m1; Applied Biosystems, CA, USA) and 
TaqMan Universal PCR Master Mix (Applied Biosystems). The quantitative PCR reactions 
were performed using the CFX96 Real Time PCR system (Bio-Rad Laboratories, Veenendaal, 
The Netherlands) and data were analyzed using the CFX ManagerTM software (Bio-Rad Labo-
ratories). Data were normalized to mRNA expression levels of the reference gene GAPDH. 
Data were expressed as fold increase compared to proliferating ciPTEC.
Polyacrylamide gel electrophoresis and western blotting
Cellular homogenates of matured ciPTEC were obtained by scraping cells off a 75-cm2 tis-
sue culture flask by using a rubber policeman and lysis in 400 µl RIPA buffer containing 1% 
Igepal CA630, 0.5% Na-deoxycholate, 0.1% SDS, 0.01% phenylmethane sulphonylfluoride, 
3% aprotinin and 1 mM Na-orthovanadate. Western blotting was done using reduced 12% 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
onto a polyvinylidene difluoride membrane (Immobilon; Millipore, Bedford, Mass., USA). 
Expression of OCT2 in cell homogenates was analyzed using a rabbit anti-OCT2 (1:500; 
Alpha Diagnostics, San Antonio, Tex., USA), followed by a goat-anti-rabbit-HRP conjugate 
(DAKO). As a loading control the household gene rabbit anti-β-Actin was used (1:10000; 
Alpha Diagnostics, San Antonio, Tex., USA). Human kidney homogenate in RIPA buffer was 
used as a control.
ocT-mediated asP+ transport
OCT activity was measured in freshly harvested matured cell suspensions by addition of the 
fluorescent OCT substrate ASP+ in HEPES-TRIS (Hepes-Tris (10 mM), NaCl (132 mM), KCl 
(4.2 mM), CaCl2 (1 mM), MgCl2 (1 mM), D-glucose (5.5 mM), pH 7.4) buffer at 37°C, as 
described before [24]. The use of this suspension assay allows for high throughput compound 
screening. We compared the ASP+ uptake by ciPTEC using this suspension assay at 37°C 
and 4°C in order to investigate the feasibility of this method as cation influx screening assay 
(results are given in Online Resource 1). To validate the cation influx measurement further in 
ciPTEC, cells were pre-incubated for 30 min with compounds known for their OCT2 inhibi-
tory effects; tetrapentylammonium (TPA), cimetidine, metformin, quinidine or verapamil at 
a concentration range of 5-25,000 μM; prior to co-incubation with ASP+ (25 µM) for an 
additional 20 min. Exposure to various UTs; spermine, spermidine, cadaverine, putrescine, 
acrolein, guanidine and methylguanidine was performed accordingly within a concentration 
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range of 0.5-5000 μM. The fluorescence intensity was monitored on a Cytofluor 4000 Fluo-
rescence/Bioluminescence Reader (excitation 485 nm, emission 590 nm) for the complete 
incubation period. ASP+ uptake was calculated by subtracting the initial fluorescence at 
t=0 from the endpoint. Uptake was linear for at least up to 60 min (results are given in Online 
Resource 2). If significant maximal inhibition of ASP+ uptake was measured, the inhibition 
constant (Ki) was determined by performing the uptake with ASP+ at 10, 20 and 30 µM in 
addition to the respective inhibitor at the concentration ranges indicated.
Additionally, we tested the effect of a combination of UTs on ASP+ uptake, which represents 
more closely the situation in uremic patients. To mimic uremic conditions, a mixture of toxins 
was used comparable to 1000, 100, 10, 1, 0.1 and 0.01 times the uremic plasma concentrations 
reported in literature (Table 3.2: spermidine 0.67 µM, spermine 0.09 µM, cadaverine 0.21 µM, 
putrescine 0.88 µM, acrolein 1.42 µM, guanidine 2.18 µM, and methylguanidine 7.66 µM) 
with which cells were pre-incubated for 30 min followed by ASP+ uptake measurements as 
described.
mTT assay
An (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation 
assay was performed to measure cellular toxicity of the compounds tested on the ciPTEC 
[23,25]. In short, cells were seeded onto a 96 wells plate at 30% confluence. After maturation 
at 37°C for 7 days, the culture medium was removed and the cells were exposed for 30 min to 
UTs dissolved in culture medium at the concentration range used in the uptake assays. The 
medium was changed to 5 mg/ml MTT in PBS and the plate was incubated for four hours at 
37°C. The intracellular accumulated precipitate was solubilized in 200 µL dimethylsulfoxide. 
The absorbance was read using a Dynatech MR 580 plate reader using a wavelength of 570 nm 
from which background was subtracted.
data analysis
Nonlinear regression analysis was performed using GraphPad Prism version 5.00 for Win-
dows. A sigmoidal or biphasic dose–response model was applied, depending on best fit 
(determined using the extra sum-of-squares F-test). For the UTs a constraint was applied 
limiting the top of the curve to a maximum of 100%. To enable detection of partial inhibition, 
no constraint was applied to the bottom of the curve. The Ki values were calculated by deter-
mining the intersections from three separate experiments. Lines of best fit were determined 
by least square linear regression analysis. Transport inhibition studies were performed in 
triplicate and repeated at least three times. From the MTT assay, viability was expressed as a 
percentage of the values obtained from untreated control cells within the same experiment. 
MTT assays were performed in triplicate and repeated at least three times.
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Statistics were performed using GraphPad Prism 5.00 via an unpaired student’s t-test or 
one-way analysis of variance followed by Dunnett’s multiple comparison test where appropri-
ate. Differences between groups were considered to be statistically significant when p<0.05.
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figure 3.1 concentration dependent asP+ uptake, and ocT expression levels in proliferating and 
matured ciPTec.
a: Concentration dependent uptake of the fluorescent OCT substrate ASP+ during 20 min by ciPTEC 
suspensions prepared from proliferating ○ and matured ▲ cells. Data are shown as mean ± SEM of 
three independent experiments. b: Fold changes in mRNA expression levels of OCT1, 2 and 3 corrected 
for corresponding GAPDH mRNA levels, expressed as fold increase in matured cells compared to pro-
liferating ciPTEC (proliferating ciPTEC ΔC(t) values OCT1: 13.9 ± 1.1, OCT2: 19.9 ± 0.7, OCT3: 8.4 ± 
0.6, and matured ciPTEC ΔC(t) values OCT1: 15.2 ± 0.7, OCT2: 17.7 ± 0.5, OCT3: 7.8 ± 0.5) Data are 
shown as mean ± SEM of three independent experiments. c: Protein expression of OCT2 examined in 
lysates of proliferating or matured proximal tubular cells and human kidney tissue using Western blot-
ting. B-actin was used as a loading control. The experiment was performed three times on independent 
samples, a representative blot is presented.
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resUlTs
asP+ uptake by ciPTec is concentration dependent and sensitive to inhibition 
by TPa, cimetidine, metformin and quinidine
Wilmer et al. recently showed functional expression of the OCT2 transporter in the ciPTEC 
model [23]. To validate further the ciPTEC line as a human kidney cell model suitable to 
study cation transport, the uptake of the substrate ASP+ was evaluated using a fluorescence 
based method [24,26]. Figure 3.1 demonstrates the concentration dependent ASP+ uptake 
and OCT expression levels in proliferating and matured ciPTEC. A 6.3 ± 1.4 fold (mean 
± SEM) increase in OCT2 mRNA and elevated protein expression levels were observed in 
matured ciPTEC compared to proliferating cells at 33°C, while changes less than 2-fold were 
observed for OCT1 and OCT3. The increased expression for OCT2 was further demonstrated 
on a protein level by Western blotting. Furthermore, ASP+ uptake increased with 23 ± 5% in 
fully matured ciPTEC, with an apparent Km of 139 ± 37 µM for matured ciPTEC versus an 
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apparent Km of 110 ± 28 µM in proliferating ciPTEC. Taken together, these findings suggest 
ASP uptake in matured ciPTEC is mainly influenced by OCT2.
The ciPTEC line was validated further by examining the effects of known substrates and/or 
inhibitors of the transporter, namely, TPA, cimetidine, metformin, quinidine, and verapamil 
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figure 3.2 known ocT2 substrates inhibit asP+ uptake by ciPTec cells.
Concentration-inhibition curves of ASP+ uptake by TPA (a), cimetidine (c), metformin (e) and quini-
dine (g). The experiment was performed three times in triplicate. Values are given as mean ± SEM 
described as percentage of ASP+ uptake in the absence of the inhibitor. Presented IC50 curves are an 
average of three independent experiments. Nonlinear regression was calculated using the GraphPad 
Prism sigmoidal dose–response model. Corresponding Dixon plots of the reciprocal of OCT2 activity 
(1/V) versus a concentration range of the known inhibitors TPA (b), cimetidine (d), metformin (f) and 
quinidine (h). Measurements were performed using ASP+ concentrations of 30(▲), 20(■) and 10(●) 
µM. Lines of best fit were determined by least square linear regression analysis. Dixon plot experiments 
were performed three times in triplicate, representative plots are presented.
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(not shown) on ASP+ uptake. The results show that the drugs tested effectively inhibited the 
uptake of ASP+ by the ciPTEC line in a dose-dependent manner (Figure 3.2a, c, e and g). 
The calculated half maximal inhibitory concentration values (IC50) are given in Table 3.1. To 
investigate the mode of interaction, Dixon plots were constructed from the resulting inhibi-
tion curves (Figure 3.2b, d, f and h), which were analyzed by linear regression. These plots 
were consistent with a competitive or mixed-type inhibition for all compounds tested; the Ki 
values calculated are also presented in Table 3.1. Additional ASP+ uptake experiments without 
pre-incubation of the substrates and/or inhibitors of OCT2 did not alter the observed inhibi-
tion curves or IC50 values (data not shown).
UTs inhibit ocT-mediated transport
Cation transporters in the kidney are not only associated with exogenous xenobiotic transport 
(e.g. drugs), but could determine metabolic waste secretion as well. Therefore, seven UTs were 
selected to study their effect on OCT-mediated transport in ciPTEC. Their chemical struc-
tures and corresponding electrical charges at pH 7.4 are presented in Figure 3.3. The selection 
was based on the fact that these cationic compounds are protein bound or compartmentalized 
in patients with renal failure, and accumulate systemically due to insufficient clearance with 
regular dialysis therapy [27].
The effect of the different toxins on ASP+ uptake is presented in Figure 3.4. The UTs tested 
inhibited ASP+ uptake dose-dependently. The IC50 value ± SEM for acrolein was 44 ± 2 µM. 
The inhibition data of the other compounds did not allow for calculation of accurate IC50 val-
ues, since the lower plateau of inhibition was not reached. The well-characterized anionic 
UT, indoxyl sulphate [28], was used to confirm the specificity of the interaction. As expected, 
this toxin did not affect ASP+ uptake in ciPTEC (Figure 3.4h). Spermine, spermidine and 
cadaverine (Figure 3.4a, b and d, respectively), inhibited uptake significantly only at the 
highest concentration tested (5 mM). Of all UTs tested, acrolein, the end product of both 
spermine and spermidine metabolism, was the most potent (Figure 3.4g). In contrast, another 
polyamine, putrescine, was the least potent cationic UT (Figure 3.4c). Furthermore, both 
Table 3.1: apparent ic50 and ki values for the inhibition of asP+ uptake by known ocT inhibitors
Known inhibitors IC50 ± SEM (µM) Ki ± SEM (µM)
TPA 16 ± 2 13 ± 2
Metformin 3954 ± 1245 4271 ± 521
Cimetidine 8 ± 2 36 ± 4
Quinidine 30 ± 5 40 ± 5
Verapamil 10 ± 4 n.d.
n.d. not determined.
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guanidine and methylguanidine inhibited ASP+ transport significantly, of which guanidine 
showed a higher potency (Figure 3.4e-f, respectively).
For acrolein, the mode of interaction of this toxin with the transporter was studied in more 
detail. To this end, inhibition was determined using three different ASP+ concentrations and 
a Dixon plot was constructed from the individual inhibition curves, which was analyzed by 
linear regression (Figure 3.5). The Dixon plot is based on the acrolein concentrations within 
the linear part of the inhibition curve (200, 150, 100, 50, 25 and 0 µM). In agreement with the 
known OCT2 inhibitors and substrates, inhibition of ASP+ uptake by acrolein was consistent 
with a competitive or mixed type of interaction, and a Ki value of 93 ± 16 µM was calculated.
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High concentrations of cadaverine, guanidine and acrolein can affect cellular 
viability
The cytotoxic potential of the UTs was investigated by measuring ciPTEC viability after a 
30 min exposure period, corresponding to the exposure time during the OCT2 uptake assay. 
Exposure to spermine, spermidine, putrescine and methylguanidine did not result in reduced 
cell viability. For the other UTs a reduction in cell viability was observed only at a concentra-
tion of 5 mM (Represented by # in Figure 3.4, panels d, e and g). For cadaverine a reduction 
in viability of 13 ± 4% was observed when exposed to 5 mM, guanidine resulted in 14 ± 11% 
reduction in viability and for acrolein viability was reduced with 21 ± 10%. It should be noted 
that no effect on viability was observed at concentrations below 5 mM.
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figure 3.4 cationic UTs inhibit asP+ uptake by ciPTec cells.
Concentration-inhibition curves of ASP+ uptake by the polyamines; spermidine (a), spermine (b), pu-
trescine (c), cadaverine (d), and the guanidine compounds; guanidine (e) and methylguanidine (f). In 
(g) the ASP+ uptake is shown in the presence of acrolein, a metabolite of spermine and spermidine. In 
(h) indoxyl sulphate, an anionic UT, was used as a negative control. The experiment was performed 
three times in triplicate. Values are described as percentage of ASP+ uptake in the absence of the inhibi-
tor, and given as mean ± SEM. Nonlinear regression was calculated using the GraphPad Prism sigmoidal 
dose–response model. For acrolein the IC50 ± SEM value was estimated at 44 ± 2 µM. The symbol # 
indicates the detection of a significant decrease in viability for these concentrations, as determined by 
the MTT assay. For 5 mM cadaverine, guanidine and acrolein a residual cell viability of 87 ± 4%, 86 ± 
11% and 79 ± 10% was observed, respectively.
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a uremic mixture of toxins inhibits ocT-mediated transport
To determine the relevance of the observed inhibitory effects of UTs on ASP+-mediated 
transport, we determined the transport function in ciPTEC incubated with a mix of toxins, 
mimicking more closely the situation in patients with renal dysfunction (Figure 3.6). The poly-
amine, acrolein and guanidine mixture was prepared at 1000, 100, 10, 1, 0.1 and 0.01 times the 
free uremic plasma concentrations as reported in literature (Table 3.2). No inhibition of ASP+ 
uptake was observed after exposing the cells to a mixture of the polyamines (spermidine, 
spermine, cadaverine and putrescine; Figure 3.6a). When acrolein was added to the mixture, 
a large inhibition of ASP uptake was observed only at 1000 fold the uremic concentration 
(Figure 3.6b). Exposure of ciPTEC to a mixture of only the guanidino compounds (methyl-
guanidine and guanidine) induced a dose dependent inhibition of ASP+ uptake (Figure 3.6c). 
The observed transport inhibition at 1x the uremic concentration was 19% ± 6. With acrolein 
added to this mixture, inhibition did not increase any further (Figure 3.6d).
Interestingly, after exposing the ciPTEC to a mixture of all examined cationic UTs, a bipha-
sic inhibition curve was observed (Figure 3.6f). The estimated IC50 values of the first and sec-
ond inhibitory phase were 0.3 ± 0.3 and 122 ± 50 fold the uremic concentration, respectively. 
The observed inhibition of ASP+ uptake at a 1x the uremic concentration was 18% ± 11, which 
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figure 3.5 dixon plot of the reciprocal of ocT2 activity (1/V) versus a concentration range of ac-
rolein.
Measurements were done using ASP+ concentrations of 10, 20 and 30 µM. The experiment was per-
formed three times in triplicate. Lines of best fit were determined by least square linear regression analy-
sis; Ki: 93 ± 16.
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figure 3.6 a mixture of cationic UTs inhibit asP+ uptake by ciPTec cells at physiologically relevant concentrations.
Concentration-inhibition curves of ASP+ uptake by the following mixtures; polyamine mix (a), polyamines and 
acrolein (b), guanidino mix (c), guanidino compounds and acrolein (d), polyamines and guanidino compounds 
(e), polyamines, acrolein and guanidino compounds (f). Toxin concentrations were taken at 1,000, 100, 10, 1, 
0.1 and 0.01 times the uremic plasma concentrations reported in literature (see Table 3.2, in µM: spermidine 0.67, 
spermine 0.09, cadaverine 0.21, putrescine 0.88, acrolein 1.42, guanidine 2.18, and methylguanidine 7.66). Values 
are given as mean ± SEM, and described as percentage of ASP+ uptake in the absence of the inhibition mixture. 
Nonlinear regression was calculated using the GraphPad Prism sigmoidal or biphasic dose-response model. All 
experiments were performed at least three times in triplicate.
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was found to be significant (p<0.05). The cytotoxic potential of these mixtures on ciPTEC was 
investigated further using the MTT assay (Figure 3.7). After 30 min of exposure, significant 
reduction in cell viability was measured only at very high concentrations corresponding to 
1000 fold the reported uremic plasma concentration. No significant effect on viability was 
observed at lower concentrations.
discUssion
In the present study, we used a unique human proximal tubule cell line to investigate the 
interaction between OCT-mediated transport and UTs. OCTs and, especially OCT2, is 
considered important in the excretion of many endogenous or xenobiotic solutes. Therefore, 
interference with its transport function could affect renal clearance and lead to accumulation 
of toxic compounds. From our study, two main novel findings could be derived. First, the 
Table 3.2: normal and uremic serum concentrations of the selected polyamines, acrolein and gua-
nidino compounds reported in literature
Polyamines c-norm (µm) c-uremic (µm) ref.
Spermidine
0.07 ± 0.04 b
0.67± 0.30 b
0.05 ± 0.02 b
[29]
[30]
Spermine 0.20 ± 0.05 b
0.031± 0.04 b
0.09 ± 0.08 b
0.008 ± 0.007 b
[29]
[30]
Cadaverine b 0. 21 ± 0. 11 b [29]
Putrescine 0.24 ± 0.09 b
0.05 ± 0.03 b
0.88 ± 0.31 b
0.09 ± 0.03 b
[29]
[30]
Acroleina 0.53 ± 0.18c
31 ± 9d
1.42 ± 0.84c
170 ± 86d
[30]
[30]
Guanidino 
compounds
c-norm (µm) c-uremic (µm) ref.
Guanidine <0.2 b
<0.21 b
2.2 ± 1.2 b
2.05 ± 0.86 b
[31]
[32]
Methylguanidine b
<0.06 b
7.66 ± 4.38 b
2.13 ± 2.16 b
[31]
[32]
Values are shown as mean (C-norm); serum concentration in healthy population, and (C-uremic) high-
est mean uremic serum concentration in uremic patients.
a: Polyamine metabolite
b: Total serum concentration
c: Free concentration in serum
d: Protein bound concentration in serum
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transport of and inhibition by known substrates and inhibitors could be confirmed in our 
human ciPTEC model endogenously expressing OCT2. Secondly, cationic UTs were found 
to inhibit cellular ASP+ uptake. Such interaction may contribute to the progression of renal 
failure, as active tubular secretion is essential for the removal of cationic UTs while OCTs 
transport capacity is finite.
Knowledge of the clearance of cationic uremic retention solutes in humans is limited, 
but the human ciPTEC cell model can be a valuable tool to acquire mechanistic insights in 
renal cationic toxin uptake. In general, the availability of suitable human kidney cell models 
is scarce. A drawback of many human cell models available is their restricted endogenous 
transporter expression levels and functionality [33,34]. Moreover, primary renal cell cultures 
that are also often used in xenobiotic uptake studies quickly go into senescence [33]. With 
regard to cation transporters, our ciPTEC model is not hampered by these limitations. These 
immortalized human cells endogenously express functional OCT2 in concert with essential 
organic cation transporters, such as OCT1, OCT3, p-glycoprotein (ABCB1), breast cancer 
resistance protein (ABCG2) and multidrug and toxic compound extrusion MATE proteins 
(SLC47) (unpublished data). The co-expression of drug transporters at both the apical and 
basolateral site will allow for the development of transcellular transport assays. These assays 
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figure 3.7 ciPTec viability after 30 min exposure to the UT mixture.
CiPTEC were exposed to mixtures of all UTs, and mixtures of only polyamines, acrolein and the gua-
nidino compounds. Toxin concentrations were taken at 1000, 100, 10, 1, 0.1 and 0.01 fold the uremic 
plasma concentrations reported in literature (see Table 3.2, in µM: spermidine 0.67, spermine 0.09, 
cadaverine 0.21, putrescine 0.88, acrolein 1.42, guanidine 2.18, and methylguanidine 7.66). Viability 
was determined by the MTT assay, performed in triplicate. Results are shown as mean values ± SEM. 
Significance levels * p<0.05, **p<0.01
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will increase our understanding of renal excretion mechanisms, superior to the study of single 
transporters in over expression models.
The observed increase in the Vmax for ASP+ uptake in matured ciPTEC corresponds to 
an increased mRNA and protein expression of OCT2. Therefore, we expect OCT2 to be the 
dominant cation uptake transporter for cationic UTs in ciPTEC. Furthermore, inhibition of 
ASP+ uptake by the known substrates and inhibitors TPA, cimetidine, metformin, and quini-
dine, confirms functionality of OCT-mediated uptake in ciPTEC. Though some of the tested 
compounds can also function as substrates for OCT1 and OCT3, the apparent Ki values are 
in line with the values reported for other systems in which only OCT2 was over-expressed 
[35,36].
In the present study, the observed Ki values for the known inhibitors sometimes exceeded 
the measured IC50 values, although generally the differences are small. The variation in the 
numbers obtained could be influenced by, amongst others, the number of binding sites of the 
OCT transporters [37,38]. In the case of cimetidine, the highest concentrations of inhibitor 
(≥50µM) might have caused slight saturation of the system, thereby influencing the Ki values.
This investigation demonstrates that cationic UTs can interfere with ASP+ uptake. The 
observed inhibitory effect of the polyamines and guanidino compounds indicate that these 
compounds may be able to affect uptake and hamper the clearance of xenobiotics, includ-
ing exogenous toxins or drugs. The inhibition of ASP+ transport by methylguanidine and 
guanidine observed here, is comparable to the findings of Kimura et al. who reported the 
interference of various guanidino-compounds with OCT2 using a human embryonic kidney 
cell line (HEK293) over-expressing the transporter [39]. Using the same expression system, 
Winter et al. identified putrescine as a substrate for OCT2 [40]. In agreement, our findings 
indicate that high concentrations of putrescine inhibit ASP+ transport. Furthermore, Winter 
et al. observed that putrescine, spermidine, spermine and guanidine partially inhibited the 
accumulation of agmatine, an OCT2 and MATE substrate, in hMATE-HEK cells. Although 
they suggested that these compounds might influence bidirectional agmatine transport by 
hMATE1 [40], our findings argue that interference with OCT transporters by the polyamines 
might also hamper the cellular influx of these substrates and thereby limit the excretion and 
clearance of organic cations. Of course, since ASP+ is a substrate for the MATE transporters 
as well, these efflux transporters could have influenced our measurements [41]. However, any 
effect of these efflux transporters on the uptake of ASP+ would have resulted in an underesti-
mation of maximal uptake capacities in ciPTEC. Future research should therefore be directed 
to trans-epithelial transport studies, in order to clarify the overall effect of the polyamines and 
guanidine compounds on trans-tubular organic cation transport. In Figure 3.8, the proposed 
mechanism of cationic toxin clearance in the proximal tubule is depicted.
Next to polyamines and guanidino compounds, we identified acrolein (a breakdown prod-
uct of spermine and spermidine [42,43]) as an inhibitor of ASP+ uptake. Out of the tested 
inhibitors acrolein required the lowest exposure concentration to provoke a half-maximal 
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inhibition. Its Ki value lies within the range of acrolein levels that were reported in the plasma 
of uremic patients [42]. However, because we did not examine the eff ect of protein binding on 
ASP+ uptake, we cannot speculate on the OCT interaction in ESRD, during which systemic 
protein binding of drugs and endogenous compounds can be altered [44-46].
Previously, Igarashi et al. showed that acrolein reduced cell growth due to cytotoxicity. 
Th eir fi ndings suggested that accumulation of both free and protein bound acrolein in plasma 
of chronic kidney disease (CKD) patients could be suffi  cient to cause cell damage [47,48]. 
Indeed, we also observed decreased viability of cells exposed to acrolein, however, this was 
detected only at high concentrations. Th erefore, we can exclude that the inhibitory eff ect 
of acrolein on ASP+ uptake is related to its cytotoxic eff ect. Additionally, the Dixon plot of 
acrolein inhibition indicated a competitive or mixed type inhibition as the mode of interac-
tion. Th us, it is most likely that acrolein has a direct eff ect on the binding site that is essential 
for transport, or functions as a substrate for this transporter. Furthermore, we have shown 
that exposure to several compounds, including acrolein, did not lead to maximal inhibition 
of ASP+ uptake. Th e presence of OCT isoforms may explain the sub-maximal inhibition by 
blood urine 
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figure 3.8 scheme illustrating the proposed mechanisms of transport associated with organic cat-
ion (oc+) and cationic uremic toxin (UT+) secretion by renal proximal tubule cells.
Arrows indicate the direction of net substrate transport that occurs under physiological conditions. 
Solid lines depict what are believed to be the principal pathways of substrate transport; dotted lines 
indicate pathways that are believed to be of secondary importance. In vivo, organic cation transporters 
(OCTs) and the OATP4C1 transporter facilitate the uptake of cationic compounds into the cell. Th e 
MATE1/2-K and OCTN1/2 transporters facilitate the exchange of luminal H+ for intracellular OC+. 
Furthermore P-gp and BCRP mediate effl  ux of a wide variety of substrates. Cationic UT transport is 
presumed to be comparable to putative excretion of organic cations in the kidney. Furthermore, based 
on our fi ndings accumulation of cationic UTs in the blood may result in inhibition of OC+ uptake into 
the proximal tubule cell.
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the UTs. To elucidate the exact mechanism, further subtype specific studies are required, for 
example by testing acrolein uptake in HEK cells over-expressing one specific transporter.
The systemic accumulation of UTs in CKD patients is known to negatively influence 
the health of the patient and contribute to the progression of renal failure. Furthermore, 
interactions between UTs and liver transporters, and interactions with transport proteins at 
the blood-brain barrier have been described [7,49]. However, to date little data are available 
on the exact cationic uremic toxin levels in patients. Reports on polyamine serum values 
in patients are not always consistent, as was recently reviewed by Duranton et al. [50]. For 
instance, whereas earlier papers reported increased spermidine levels in CKD [51], more 
recent publications measured decreased values in patients suffering from renal failure [30,50]. 
Possibly, this discrepancy is due to improvements in dialysis techniques or to methodological 
changes in quantification techniques.
The present findings indicate that the concentrations of individual UTs that led to inhibi-
tion of OCT transport most likely exceed the systemic levels of UTs in patients and might 
therefore have low clinical relevance. Nevertheless, it should be noted that in uremia, a 
mixture of UTs is present, and the combination of retention solutes can have cumulative, or 
even synergistic, effects on cation transport in the proximal tubule. Our results showed that 
exposure to a mixture of toxins for 30 min can cause up to 18% inhibition of ASP uptake in 
vitro when concentrations are used that reflect the situation in uremic patients. Addition of 
the toxins as a mixture resulted in a stronger effect as compared to the separate exposures 
to these toxins. Interestingly, the biphasic dose response curve was observed only when a 
combination of guanidine compounds, polyamines and acrolein was studied. The biphasic 
nature of the UTs mixture suggests different modes of action of the individual compounds or 
may be related to specific interaction with different subtypes of OCT transporters.
In conclusion, OCT mediated organic cation transport can be reliably studied in the 
ciPTEC cell model. The exposure to cationic UTs was found to negatively affect substrate 
uptake in proximal tubule cells. Our findings indicate that the accumulation of UTs may 
hamper the clearance of OCT substrates, which can also be an important factor in kidney 
disease progression.
acknowledGmenTs
This work was supported by the BioMedical Materials institute [BMM, Project P3.01 BioKid], 
the Dutch Ministry of Economic Affairs, the Nierstichting Nederland and the Netherlands 
Institute for Regenerative Medicine (NIRM, grant No. FES0908). M.J.G. Wilmer and R. 
Masereeuw were supported by a collaboration research grant from AstraZeneca (grant 
No.A10-0324). J. Hoenderop was supported by a EURYI award.
81
Cationic uremic toxins interact with organic cation transporters
ch
ap
te
r 3
references
1. Vanholder r, de smet r. Pathophysiologic effects of uremic retention solutes. J. Am. Soc. Nephrol. 
10: 1815-1823, 1999.
2. krieter dH, Hackl a, rodriguez a, chenine l, moragues Hl, lemke Hd, wanner c, canaud 
b. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. 
Nephrol. Dial. Transplant. 25: 212-218, 2010.
3. meyer Tw, walther Jl, Pagtalunan me, martinez aw, Torkamani a, fong Pd, recht ns, 
robertson cr, Hostetter TH. The clearance of protein-bound solutes by hemofiltration and 
hemodiafiltration. Kidney Int. 68: 867-877, 2005.
4. meyer Tw, Hostetter TH. Uremia. N. Engl. J. Med. 357: 1316-1325, 2007.
5. momper Jd, Venkataramanan r, nolin Td. Nonrenal drug clearance in CKD: Searching for the 
path less traveled. Adv. Chronic Kidney Dis. 17: 384-391, 2010.
6. nolin Td. Altered nonrenal drug clearance in ESRD. Curr. Opin. Nephrol. Hypertens. 17: 555-559, 
2008.
7. sun H, frassetto l, benet lZ. Effects of renal failure on drug transport and metabolism. Pharma-
col. Ther. 109: 1-11, 2006.
8. nies aT, koepsell H, damme k, schwab m. Organic cation transporters (OCTs, MATEs), in vitro 
and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. 105-167, 2011.
9. kimura n, okuda m, inui k. Metformin transport by renal basolateral organic cation transporter 
hOCT2. Pharm. Res. 22: 255-259, 2005.
10. Zolk o, solbach Tf, konig J, fromm mf. Structural determinants of inhibitor interaction with 
the human organic cation transporter OCT2 (SLC22A2). Naunyn. Schmiedebergs Arch. Pharmacol. 
379: 337-348, 2009.
11. fujita T, Urban TJ, leabman mk, fujita k, Giacomini km. Transport of drugs in the kidney by 
the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 95: 25-36, 2006.
12. ciarimboli G, ludwig T, lang d, Pavenstadt H, koepsell H, Piechota HJ, Haier J, Jaehde U, 
Zisowsky J, schlatter e. Cisplatin nephrotoxicity is critically mediated via the human organic 
cation transporter 2. Am. J. Pathol. 167: 1477-1484, 2005.
13. dhondt a, Vanholder r, Van biesen w, lameire n. The removal of uremic toxins. Kidney Int. 
Suppl. 76: S47-59, 2000.
14. eloot s, van biesen w, dhondt a, de smet r, marescau b, de deyn PP, Verdonck P, Vanholder 
r. Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea 
and guanidino compounds: a kinetic analysis. Nephrol. Dial. Transplant. 24: 2225-2232, 2009.
15. Giovannetti s, cioni l, balestri Pl, biagnini m. Evidence that guanidines and some related 
compounds cause haemolysis in chronic uraemia. Clin. Sci. 34: 141-148, 1968.
16. Glorieux Gl, dhondt aw, Jacobs P, Van langeraert J, lameire nH, de deyn PP, Vanholder rc. 
In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and 
infection. Kidney Int. 65: 2184-2192, 2004.
17. macallister rJ, whitley Gs, Vallance P. Effects of guanidino and uremic compounds on nitric 
oxide pathways. Kidney Int. 45: 737-742, 1994.
18. d’Hooge r, de deyn PP, Van de Vijver G, antoons G, raes a, Van bogaert PP. Uraemic gua-
nidino compounds inhibit gamma-aminobutyric acid-evoked whole cell currents in mouse spinal 
cord neurones. Neurosci. Lett. 265: 83-86, 1999.
19. Tadolini b, Hakim G, orlandini G, casti a. Intracellular location of polyamines associated to red 
blood cells. Biochem. Biophys. Res. Commun. 134: 1365-1371, 1986.
Chapter 3
82
20. kushner d, beckman b, nguyen l, chen s, della santina c, Husserl f, rice J, fisher Jw. Poly-
amines in the anemia of end-stage renal disease. Kidney Int. 39: 725-732, 1991.
21. radtke Hw, rege ab, lamarche mb, bartos d, bartos f, campbell ra, fisher Jw. Identifica-
tion of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J. Clin. 
Invest. 67: 1623-1629, 1981.
22. stabellini G, mariani G, Pezzetti f, calastrini c. Direct inhibitory effect of uremic toxins and 
polyamines on proliferation of VERO culture cells. Exp. Mol. Pathol. 64: 147-155, 1997.
23. wilmer mJ, saleem ma, masereeuw r, ni l, Van der Velden TJ, russel fG, mathieson Pw, 
monnens la, Van den Heuvel lP, levtchenko en. Novel conditionally immortalized human 
proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res. 339: 
449-457, 2010.
24. wilde s, schlatter e, koepsell H, edemir b, reuter s, Pavenstadt H, neugebauer U, schroter r, 
brast s, ciarimboli G. Calmodulin-associated post-translational regulation of rat organic cation 
transporter 2 in the kidney is gender dependent. Cell. Mol. Life Sci. 66: 1729-1740, 2009.
25. mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation 
and cytotoxicity assays. J. Immunol. Methods 65: 55-63, 1983.
26. schlatter e, monnich V, cetinkaya i, mehrens T, ciarimboli G, Hirsch Jr, Popp c, koepsell H. 
The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. J. Membr. Biol. 189: 
237-244, 2002.
27. de deyn PP, robitaille P, Vanasse m, Qureshi ia, marescau b. Serum guanidino compound lev-
els in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. 
Correlations between nerve conduction velocities and altered guanidino compound concentra-
tions. Nephron 69: 411-417, 1995.
28. niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J. Med. Sci. 72: 1-11, 2010.
29. saito a, Takagi T, chung TG, ohta k. Serum levels of polyamines in patients with chronic renal 
failure. Kidney Int. Suppl. 16: S234-237, 1983.
30. igarashi k, Ueda s, yoshida k, kashiwagi k. Polyamines in renal failure. Amino Acids 31: 477-
483, 2006.
31. de deyn P, marescau b, lornoy w, becaus i, lowenthal a. Guanidino compounds in uraemic 
dialysed patients. Clin. Chim. Acta 157: 143-150, 1986.
32. marescau b, nagels G, Possemiers i, de broe me, becaus i, billiouw Jm, lornoy w, de deyn 
PP. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insuf-
ficiency. Metabolism. 46: 1024-1031, 1997.
33. ahlin G, Hilgendorf c, karlsson J, szigyarto ca, Uhlen m, artursson P. Endogenous gene 
and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery 
programs. Drug Metab. Dispos. 37: 2275-2283, 2009.
34. Jenkinson se, chung Gw, van loon e, bakar ns, dalzell am, brown cd. The limitations of re-
nal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal 
tubule. Pflugers Arch. 464: 601-611, 2012.
35. Gorboulev V, Ulzheimer Jc, akhoundova a, Ulzheimer-Teuber i, karbach U, Quester s, bau-
mann c, lang f, busch ae, koepsell H. Cloning and characterization of two human polyspecific 
organic cation transporters. DNA Cell Biol. 16: 871-881, 1997.
36. motohashi H, Uwai y, Hiramoto k, okuda m, inui k. Different transport properties between 
famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol. 
503: 25-30, 2004.
83
Cationic uremic toxins interact with organic cation transporters
ch
ap
te
r 3
37. lumen aa, acharya P, Polli Jw, ayrton a, ellens H, bentz J. If the KI is defined by the free en-
ergy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby 
canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer? 
Drug Metab. Dispos. 38: 260-269, 2010.
38. Volk c, Gorboulev V, budiman T, nagel G, koepsell H. Different affinities of inhibitors to the 
outwardly and inwardly directed substrate binding site of organic cation transporter 2. Mol. Phar-
macol. 64: 1037-1047, 2003.
39. kimura n, masuda s, katsura T, inui k. Transport of guanidine compounds by human organic 
cation transporters, hOCT1 and hOCT2. Biochem. Pharmacol. 77: 1429-1436, 2009.
40. winter Tn, elmquist wf, fairbanks ca. OCT2 and MATE1 provide bidirectional agmatine 
transport. Mol. Pharm. 8: 133-142, 2011.
41. astorga b, ekins s, morales m, wright sH. Molecular determinants of ligand selectivity for the 
human multidrug and toxin extruder proteins MATE1 and MATE2-K. J. Pharmacol. Exp. Ther. 341: 
743-755, 2012.
42. sakata k, kashiwagi k, sharmin s, Ueda s, irie y, murotani n, igarashi k. Increase in putrescine, 
amine oxidase, and acrolein in plasma of renal failure patients. Biochem. Biophys. Res. Commun. 
305: 143-149, 2003.
43. sharmin s, sakata k, kashiwagi k, Ueda s, iwasaki s, shirahata a, igarashi k. Polyamine 
cytotoxicity in the presence of bovine serum amine oxidase. Biochem. Biophys. Res. Commun. 282: 
228-235, 2001.
44. reidenberg mm, drayer de. Alteration of drug-protein binding in renal disease. Clin. Pharmaco-
kinet. 9 Suppl 1: 18-26, 1984.
45. rowland yeo k, aarabi m, Jamei m, rostami-Hodjegan a. Modeling and predicting drug phar-
macokinetics in patients with renal impairment. Expert review of clinical pharmacology 4: 261-274, 
2011.
46. Vanholder r, Van landschoot n, de smet r, schoots a, ringoir s. Drug protein binding in 
chronic renal failure: evaluation of nine drugs. Kidney Int. 33: 996-1004, 1988.
47. igarashi k, kashiwagi k. Modulation of cellular function by polyamines. Int. J. Biochem. Cell Biol. 
42: 39-51, 2010.
48. sakata k, kashiwagi k, sharmin s, Ueda s, igarashi k. Acrolein produced from polyamines as 
one of the uraemic toxins. Biochem. Soc. Trans. 31: 371-374, 2003.
49. Hosoya k, Tachikawa m. Roles of organic anion/cation transporters at the blood-brain and 
blood-cerebrospinal fluid barriers involving uremic toxins. Clinical and experimental nephrology 
15: 478-485, 2011.
50. duranton f, cohen G, de smet r, rodriguez m, Jankowski J, Vanholder r, argiles a, euro-
pean Uremic Toxin work Group. Normal and pathologic concentrations of uremic toxins. J. Am. 
Soc. Nephrol. 23: 1258-1270, 2012.
51. Takagi T, chung TG, saito a. Determination of Polyamines in Hydrolysates of Uremic Plasma by 
High-Performance Cation-Exchange Column Chromatography. J. Chromatogr. 272: 279-285, 1983.

4 
Uremic toxins induce ET-1 release by human 
proximal tubule cells, which regulates organic 
cation uptake time-dependently
Carolien M.S. Schophuizen1, Joost G.J. Hoenderop2, Rosalinde Masereeuw3,4*, and 
Lambert P. van den Heuvel1, 5*
Cells: volume 4, pages 234-252, 2015
Departments of 1Pediatric Nephrology, 2Physiology, 3Pharmacology and Toxicology, 
Radboudumc, Nijmegen, The Netherlands.
4 Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, 
Utrecht University, The Netherlands
5Department of Pediatrics, Catholic University Leuven, 3000 Leuven, Belgium
Chapter 4
86
absTracT
In renal failure, the systemic accumulation of uremic waste products is strongly associated 
with the development of a chronic inflammatory state. Here, the effect of cationic uremic tox-
ins (UTs) on the release of inflammatory cytokines and endothelin-1 (ET-1) was investigated 
in conditionally immortalized proximal tubule epithelial cells (ciPTEC). Additionally, we 
examined the effects of ET-1 on the cellular uptake mediated by organic cation transporters 
(OCTs).
Exposure of ciPTEC to cationic UTs initiated production of the inflammatory cytokines 
IL-6 (117 ± 3%, p<0.001), IL-8 (122 ± 3%, p<0.001), and ET-1 (134 ± 5%, p<0.001). ET-1 
exposure was accompanied by a down-regulation of OCT mediated 4-(4-(dimethylamino)
styryl)-N-methylpyridinium-iodide (ASP+) uptake in ciPTEC at 30 min (23 ± 4%, p<0.001), 
which restored within 60 min of incubation. Exposure to ET-1 for 24 h increased the ASP+ 
uptake significantly (20 ± 5%, p<0.001). These effects could be blocked by BQ-788, indicating 
activation of an ET-B-receptor-mediated signaling pathway. Downstream the receptor, iNOS 
inhibition by (N(G)‐monomethyl‐l‐arginine) L-NMMA acetate or aminoguanidine, as well 
as protein kinase C activation, ameliorated the short-term effects.
These results indicate that uremia may initiate the release of cytokines and ET-1 from 
human proximal tubule cells, in vitro. Furthermore, ET-1 exposure was found to regulate 
proximal tubular OCT transport activity in a differential, time-dependent, fashion.
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inTrodUcTion
Renal transport processes are essential for the maintenance of body homeostasis. In the 
kidney, clearance of exogenous compounds and endogenous waste products from the circula-
tion is facilitated by both glomerular filtration and active tubular secretion. The proximal 
tubule basolateral membrane transporters are responsible for the uptake of substrates from 
the circulation. While the apical transporters present in the proximal tubule facilitate their 
subsequent urinary release. In patients suffering from chronic kidney disease (CKD) or end-
stage renal disease (ESRD), insufficient renal clearance and the subsequent accumulation of 
waste products lead to the development of uremia. Many solutes that accumulate in uremia 
have been identified [1]. However, we have only just begun to understand the effects that 
these compounds can exert on biological processes and their influence in the development 
of secondary morbidities. Previously, we demonstrated competitive inhibition of a selection 
of cationic uremic toxins (UTs) on organic cation uptake in a human conditionally immor-
talized proximal tubule epithelial cell model (ciPTEC) that endogenously expresses various 
renal transport proteins [2,3]. The clearance of cationic UTs (polyamines, guanidines and 
acrolein) largely depends on tubular secretion due to their high protein binding and/or 
compartmentalization [4,5]. In renal failure, the accumulation of these solutes is associated 
with inflammation, cardiovascular morbidity and perturbed erythropoiesis [6-8]. Moreover, 
conventional (hemo)dialysis methods are insufficient for their removal.
The development of a chronic inflammatory state is common in renal patients, and uremia 
has been identified as an important causative factor [9]. Increased levels of the vasoactive 
peptide endothelin-1 (ET-1), and pro-inflammatory cytokines such as IL-6, IL-8, and TNFα 
have been observed both before and after the start of dialysis therapy [10-14]. IL-6 promotes 
various inflammatory events, including the activation of lymphocytes, and is identified as a 
strong pro-fibrotic factor. Both IL-6 and IL-8 levels are correlated with increased mortality 
and poor disease outcome in renal failure [15]. TNFα is also known as an important factor 
in the development of renal fibrosis, and induces the production of additional inflammatory 
mediators such as ET-1 [16-18].
In healthy subjects, ET-1 functions as a potent peptide regulating the vascular tone, blood 
flow, and water and salt homeostasis. In the nephron, ET-1 mediates these processes through 
its tight regulatory effect on intracellular calcium, sodium and chloride channels, the pro-
duction of phospho kinases and nitric oxide (NO) [19]. However, in patients suffering from 
renal disease, increased systemic ET-1 levels are also linked to a decline in renal function, 
the development of interstitial fibrosis, proteinuria, cardiomyopathy and glomerulosclerosis 
[20-22]. Our laboratory has previously demonstrated that exposure to nephrotoxicants can 
induce an ET-1-mediated signaling cascade in the proximal tubule. Upon stimulation, the 
proximal tubule produces ET-1 which can lead to activation of regulatory pathways includ-
ing NOS and protein kinase C (PKC), ultimately resulting in a reduction of efflux transport 
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mediated by two apical membrane transporters P-glycoprotein (P-gp) and MRP2 [23-25]. On 
the other hand, long-term exposures resulted in an upregulation of the transport proteins, 
accompanied by nephroprotection [26,27]
In the present study, we investigated if a selection of cationic UTs, which were previously 
shown to interfere with tubular organic cation uptake, can act as nephrotoxicants and induce 
the local production of inflammatory mediators. Furthermore, we investigated if ET-1 can 
regulate the uptake of cationic compounds in human renal proximal tubule epithelial cells. 
To this end, the production of IL-6, IL-8, TNFα and ET-1 were assessed, and the short- and 
long-term effects of ET-1 on the regulation of organic cation influx transport in the human 
renal cell model were studied.
maTerials and meTHods
chemicals
Spermine, spermidine, cadaverine, putrescine dihydrochloride, acrolein, guanidine 
hydrochloride, methylguanidine hydrochloride, and 4-(4-(dimethylamino)styryl)-N-
methylpyridinium iodide (ASP+) were purchased from Invitrogen (Eugene, OR, USA). 
Tetrapentylammoniumchloride (TPA), insulin, transferrin, selenium, tri-iodothyronine, hy-
drocortisone, epidermal growth factor, Endothelin-1 (ET-1), BQ788, aminoguanidine (AG), 
and 8-Br-cGMP were purchased from Sigma-Aldrich Co. (Zwijndrecht, the Netherlands). 
Sn-1,2-dioctanoyl glycerol (DOG) was obtained from Enzo Life-sciences (Raamsdonksveer, 
Netherlands). N(G)‐monomethyl‐l‐arginine (L-NMMA) acetate was purchased from Tocris 
bioscience (Bristol, United Kingdom)
cell culture
A previously developed and characterized immortalized human proximal tubule epithelial 
cell line, ciPTEC, obtained from a healthy volunteer urine samples [2,28] was cultured in Dul-
becco’s modified eagle medium DMEM-HAM’s F12 (Lonza; Basel, Switzerland) containing 
10% v/v fetal calf serum (FCS) (Greiner Bio-One; Alphen a/d Rijn, the Netherlands), 5 µg/ml 
insulin, 5 µg/ml transferrin, 5 ng/ml selenium, 36 ng/ml hydrocortisone, 10 ng/ml epidermal 
growth factor and 40 pg/ml tri-iodothyronine. CiPTEC were in culture for up to 40 passages, 
no antibiotics or phenol red was present during this time. Since the cell model was established 
after immortalization using hTERT and the temperature sensitive SV40t oncogenes, the 
cells proliferate at 33°C and differentiate at 37°C culture conditions [2]. Regular culture was 
performed at 33°C 5% (v/v) CO2, media was refreshed every 2/3 days. For experiments, cells 
were seeded at a density of 1:3 and left to attach for 24 h at 33° C. Subsequently, the cells were 
transferred to 37°C to mature for 7 days prior to the experiments.
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enzyme-linked immuno sorbent assays
To quantify the production of IL-6, IL-8, and TNFα or ET-1 by ciPTEC under various culture 
conditions Enzyme-Linked Immuno Sorbent Assays (ELISAs) were performed. DuoSet® ELI-
SA Development Systems; IL-6 #DY206, IL-8 #DY208, TNFα #DY210, ET-1 #DY1160 (R&D 
systems, Abingdon, UK) were used to accurately measure these compounds in complete cul-
ture medium supernatant. For all assays, 500 µL of media of exposed cells was harvested after 
the designated incubation period. The samples were centrifuged for 5 min at 7,500xg and the 
supernatant stored at -20°C for a maximum of 2 months. For IL-6 and IL-8 the samples were 
diluted 500 times in phosphate buffered saline (PBS) or reagent diluent (PBS + 1% v/v FCS), 
respectively. The samples for TNFα and ET-1 were diluted 5x and 10x in PBS, respectively. The 
assays were subsequently performed according to the manufacturers’ protocol. The optical 
density of each well was measured immediately using the VictorX multilable plate reader 
(PerkinElmer, Waltham, MA, USA) set to 460 nm. To correct for optical imperfections in the 
plate, the readings at 540 nm were subtracted from these measurements.
Additionally, we tested the effect of a combination of cationic UTs on cytokines and 
ET-1 production. To mimic uremic conditions, a mixture of toxins was used comparable 
to 10 or 1 times the uremic plasma concentrations reported in literature; viz. spermidine 
0.67 µM, spermine 0.09 µM, cadaverine 0.21 µM, putrescine 0.88 µM, acrolein 1.42 µM, 
guanidine 2.18 µM, and methylguanidine 7.66 µM [29-32].
qPcr
Total RNA was isolated using TRIzol (Life Technologies Europe BV, Zoetermeer, the Neth-
erlands) and chloroform extraction according to the manufacturers’ protocol. 2 μg of total 
RNA served as a template for single-strand cDNA synthesis in a reaction using oligo (dT) and 
random primers in a M-MLV reverse transcriptase reaction mixture (Catalog #28025-013, 
Invitrogen, Bleiswijk, The Netherlands) according to the manufacturers’ protocol (Doc. Rev: 
100702). The mRNA expression levels were detected using gene specific primer-probe sets 
(Hs00174961_m1; Applied Biosystems, Foster City, CA, USA) and TaqMan Universal PCR 
Master Mix (Applied Biosystems). The CFX96 Real Time PCR system (Bio-Rad Laboratories, 
Veenendaal, The Netherlands) was used to perform the qPCR reactions and data was analyzed 
using the CFX ManagerTM software (Bio-Rad Laboratories). The reference gene GAPDH was 
used to normalize the mRNA expression levels. Data are expressed as fold increase compared 
to proliferating ciPTEC.
ocT mediated asP+ uptake
CiPTEC were cultured until confluence, in glass bottom Petri dish as described above. 
Cells were exposed to 100 nM ET-1 for 24 h, 30 min or taken as control. After washing the 
monolayer in Hepes Tris buffer (HT-Buffer: 132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 5.5 mM d-Glucose, HEPES 10 mM, pH was set to 7.4 using 1.5 M Tris in MQ, 37°C) 
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HT-buffer containing 100 µM ASP+ was added and the cells were incubated for 15 min at 
37°C. Intracellular uptake of the fluorescent compound (dimethylamino)styryl)-N-methyl-
pyridinium-iodide (ASP+) was measured using a Zeiss Apotome Fluorescence microscope. 
Images were recorded over a time period of 15 min, starting 2 min after addition of 10 µM 
ASP+ to enable a good focus on the cellular monolayer (Zeiss Axiovision imaging software 
4.7.2). Fluorescence intensity over time was quantified for at least 6 individual cells for each 
condition, by plotting the Z-axis profile of the virtual stack using ImageJ software (ImageJ 
1.46r, NIH, Bethesda, MA, USA).
To enable high throughput evaluation of organic cation uptake following stimulation by 
ET-1, in combination with pharmacological modulation of the signaling pathway, a fluores-
cence reader based method was used. Matured cells, cultured in 12 wells plates (seeded at 
approx. 150.000 cells/well) were treated with fresh medium containing the test-compounds, 
inhibitor or control medium for the designated incubation period. Subsequently, the cells 
were washed with Hepes Tris buffer (pH7.4). HT-buffer containing 10 µM ASP+ was added 
and the cells were incubated for 15 min at 37°C. Next, the uptake was arrested by washing 
twice with ice-cold stop solution (0.5mM TPA in HT-buffer). Then the cells were lysed for 
30 min lysis buffer (0.05% w/v Saponin, 0.05% v/v triton in MilliQ) and the cell homogenate 
transferred to a 96 wells plate (Greiner). The fluorescence measurement was performed three 
times at 450-642nm VictorX multilable plate reader (PerkinElmer, Waltham, MA, USA).
data analysis
Values are given as mean ± standard error of the mean. Fluorescence levels are normalized to 
the unexposed control samples after subtraction of the background fluorescence at baseline 
(t=0). Mean values were considered to be significantly different when p<0.05 using a one-way 
ANOVA followed by Dunnett’s multiple comparison test. Software used for statistical analysis 
was GraphPad Prism (version 5.00 for Windows; GraphPad Software, San Diego CA).
resUlTs
Various cationic UTs induce il-6, il-8, Tnfα and eT-1 production by ciPTec
Production of the pro-inflammatory cytokines IL-6, IL-8 and TNFα by ciPTEC was measured 
in culture supernatant after exposure to a selection of cationic UTs (Figure 4.1A), which have 
previously been shown to interfere with tubular organic cation uptake. To assess the potencies 
of the individual UTs on cytokine production, ciPTEC were exposed to 100 µM of guanidine, 
cadaverine, putrescine, methylguanidine, spermine, spermidine or 10 µM of acrolein for 24 h. 
Acrolein was used at a lower concentration to prevent severe cytotoxicity [33]. Average base-
line IL-6, IL-8 and TNF-α production by ciPTEC over 24 h were determined to be 51 ± 5.4 ng/
mL, 79 ± 37 ng/mL and 227 ± 35 pg/mL respectively. Compared to controls, IL-6 production 
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figure 4.1: Tnfα, il-6, il-8 and eT-1 excretions by ciPTec after exposure to cationic UTs.
(A) TNFα, IL-6 and IL-8 excretion was measured 24 h after incubation of ciPTEC with 10 µM acrolein, 
100 µM of guanidine, cadaverine, putrescine, methylguanidine, spermine, spermidine, or 10 µg/mL 
LPS. (B) TNFα, IL-6 and IL-8 excretion was measured 24 h after incubation of ciPTEC with a mixture 
of above stated cationic UTs, corresponding to 1-fold or 10-fold the levels reported in uremic patients. 
(C) ET-1 production by ciPTEC after 24 h of incubation with the mixture of cationic UTs or 10 µg/mL 
LPS. Data are expressed as the percentage of cytokines or ET-1 produced compared with untreated 
cells, set at 100%. Results are shown as normalized means ± SEM. For each condition at least 3 experi-
ments were performed in triplicate (*:p< 0.05 **:p<0.01 ***: p<0.001 ANOVA).
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increased significantly after stimulation by guanidine (126 ± 5%, p<0.05), putrescine (126 ± 
1%, p<0.05), spermine (141 ± 2%, p<0.001) and spermidine (142 ± 6%, p<0.001). IL-8 produc-
tion was stimulated by 100 µM of cadaverine (135 ± 15%, p<0.01), methylguanidine (134 ± 
9%, p<0.001) spermine (128 ± 12%, p<0.01) and spermidine (145 ± 25%, p<0.001). We also 
detected a significant rise in TNFα production after exposure to 100 µM of putrescine (126 ± 
1%, p<0.05) and methylguanidine (130 ± 7%, p<0.05; Figure 4.4.1A). Lipopolysaccharide (LPS, 
10 µg/mL) was used as a positive control, which caused a significant increase in IL-6 (181 ± 
14%, p<0.001), IL-8 (282 ± 23%, p<0.001) and TNFα levels (284 ± 9%, p<0.001).
When ciPTEC were exposed to a mixture of the selected cationic UTs for 24 h (i.e. toxin 
concentrations corresponding to those found in uremic patients, see methods section for 
actual concentrations used; a significant increase in IL-6 (117 ± 3%, p<0.001) and IL-8 (122 ± 
3%, p<0.001) cytokine levels could be detected (Figure 4.1B). When increasing the UT mix-
ture to 10-fold the concentrations reported in patients, IL-6 and IL-8 levels increased even 
further, until 150 ± 2% and 127 ± 2% (p<0.001) when compared to control cells, respectively. 
TNFα levels did not rise upon exposure to these uremic mixtures.
Production of the vasoactive peptide and inflammatory mediator ET-1 by ciPTEC was 
measured in culture supernatant after exposure to the mixture of the selected cationic UTs for 
24 h. Figure 4.1C depicts the ET-1 release by ciPTEC. Average baseline ET-1 production by 
ciPTEC over 24 h was determined to be 14.6 ± 4 pg/mL (11 ± 4 pg/mg protein). Exposure to 
the 1-fold and 10-fold cationic UT mixture for 24 h increased ET-1 production by ciPTEC, up 
to 128 ± 7% (p<0.01) and 134 ± 5% (p<0.001), respectively. Exposure of ciPTEC to the indi-
vidual cationic uremic compounds for 24 h did not lead to significantly affected ET-1 release 
(data not shown). Remarkably, LPS did not induce ET-1 production by ciPTEC.
differential effect of eT-1 exposure on organic cation transport.
To investigate if ET-1 could affect the functionality of the organic cation transporters (OCT) 
present in ciPTEC, we measured the intracellular uptake of the fluorescent compound ASP+ 
after exposure to ET-1. A dose-response curve showed a significant increase in ASP+ uptake at 
concentrations of 100 nM and 1 µM ET-1 (Supplemental figure S1). As a control, TPA was used 
which inhibited ASP uptake by approx. 70%. In Figure 4.2, representative fluorescence images 
(A) and their quantified fluorescent signals (B) are shown for the ASP+ uptake by ciPTEC in the 
presence or absence of 100 nM ET-1 exposure. A significant increase in maximal uptake was 
observed after 24 h of incubation, while 30 min of exposure diminished the uptake compared to 
unexposed cells. By using a fluorescent reader based method, more conditions were tested in a 
high throughput fashion (Figure 4.3A). Again, after 30 min of pre-incubation with 100 nM ET-
1, a 23 ± 4% (p<0.001) decrease in ASP+ uptake was measured. This effect was not observed after 
increasing the pre-incubation time to 3 or 6 h. However, after 24 h of pre-incubation, a 20 ± 5% 
(p<0.001) increase in ASP+ uptake was observed. Addition of the ET-1 receptor inhibitor BQ-
788 during the exposures normalized the ASP+ uptake levels for all time points (Figure 4.3B).
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In humans, OCT2 (SLC22A2) is considered one of the most important renal OCT [34], 
we examined its mRNA expression levels after exposure to 100nM ET-1 for 30 min or 24 h 
and compared these results to the control situation. Additionally, the expression levels of 
OCT1 and OCT3 were examined as these are expressed in ciPTEC as well [3,35]. Exposure to 
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figure 4.2: changes in asP+ uptake by ciPTec in response to exposure to eT-1.
CiPTEC were incubated for 30 min or 24 h with 100 nM ET-1 before measuring the intracellular up-
take of the fluorescent cationic compound ASP+ (10 µM). (A) Representative confocal images of 24 h 
ET-1 exposed (top row), 30 min ET-1 exposed (middle row) or control cells (bottom row) taken at 2, 
8 or 15 min after addition of ASP+. (B) ASP+ accumulation in cells was determined over the 15 min 
time period for 24 h ET-1 exposed (●), 30 min ET-1 exposed (▲) or control cells (■). Fluorescence 
intensity over time was quantified for at least 6 individual cells for each condition. Images were captured 
by real time imaging. Prior to addition of the fluorescent compound, brightfield images (panel A) were 
taken. The addition of the fluorescent substrate resulted in minor cell movement, thereby affecting cell 
positioning to some extent.
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ET-1 did not significantly alter OCT1, 2 or 3 expression levels on short or long term (Supple-
mental figure S2).
inos inhibition attenuates the inhibitory effects of eT-1 exposure on organic 
cation uptake
Previous studies demonstrated that ET-B receptor activation can initiate an NO mediated 
signaling pathway that regulates drug transport in the proximal tubule [24]. Therefore, we 
investigated if the differential regulation of intracellular organic cation uptake induced by 
ET-1, resulted from nitric oxide synthase (NOS) activation. ciPTEC were pre-incubated 
with 100 nM ET-1 in the absence or presence of the nonselective NOS‐inhibitor l‐arginine 
analogue N(G)‐monomethyl‐l‐arginine (L-NMMA). Figure 4.4A shows that L-NMMA alone 
did not influence ASP+ uptake by ciPTEC, but attenuated the ET-1 mediated down-regulation 
in ASP+ uptake at 30 min. This effect was not observed after the 24 h pre-incubation period. 
Pre-incubation with the selective inducible NOS inhibitor AG in the presence or absence of 
ET-1 produced similar results, attenuating only the short-term ET-1 mediated effect (Figure 
4.4B).
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figure 4.3: regulatory effects on ocT mediated asP+ uptake through eT-1 receptor.
Pre-incubation of ciPTEC with 100 µM ET-1 for 30 min up to 24 h inhibits the cellular uptake of 10 µM 
of the fluorescent substrate ASP+. (A) The effects of 100 μM ET-1 on steady state (15 min) ASP+ accumu-
lation. (B) ASP+ accumulation of ciPTEC after pre-incubation with a combination of 100 nM ET-1 with 
the ET-B receptor inhibitor BQ788 (1µM), which blocked the effect of ET-1 at all time points. Values 
are depicted as means ± SEM for at least 3 experiments performed in triplicate (*:p< 0.05 **:p<0.01 ***: 
p<0.001).
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Pkc activation restores short-term organic cation uptake in ciPTec after 
eT-1 exposure
Cyclic guanosine monophosphate (cGMP) activation was simulated by the addition of 1 µM 
of 8-br-cGMP, a cell permeable analog of cGMP, which was previously identified as an im-
portant signaling molecule in ET-1 regulated MRP2 transport in the proximal tubule [36]. 
After pre-incubation of ciPTEC with 1 µM 8-Br-cGMP alone, the intracellular ASP+ levels 
did not differ from the control conditions (Figure 4.5A). Also, combining the pre-incubation 
to ET-1 exposure with 8-Br-cGMP could not prevent either the inhibitory effect on ASP+ 
uptake at 30 min, or the stimulation observed after 24 h. These results point towards an 
absence of protein kinase G and cGMP as signaling molecule in this ET-1-mediated pathway. 
Protein kinase C was stimulated by pre-incubation with the PKC activator sn-1,2-dioctanoyl 
glycerol (DOG), which is a cell permeable analog of the PKC-activating second messenger 
diacylglycerol (DAG). Pre-incubation of ciPTEC with 1 µM DOG alone did not alter ASP+ 
uptake compared to the non-exposed control situation (Figure 4.5B). Combining ET-1 and 
DOG during 30 min of pre-incubation restored the ASP+ uptake by ciPTEC to the control 
situation. This effect of DOG was not observed after 24 h of ET-1 incubation, suggesting that 
two separate pathways regulate organic cation transport.
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figure 4.4: nos-inhibition reverses the short-term action of eT-1 on asP+ uptake.
CiPTEC monolayers were incubated for 15 min in medium containing 10 µM ASP+ without or with pre-
incubation with (A) 100 nM ET-1, 100 μM L-NMMA or ET-1 plus L-NMMA, (B) 100 nM ET-1, 100 μM 
aminoguanidine (AG) or ET-1 plus 100 µM AG. Subsequently, the reaction was stopped, the cells were 
lysed and the fluorescent signal was measured as described in the methods section. Values are presented 
as means ± SEM for at least 3 experiments performed in triplicate. (*:p< 0.05 **:p<0.01 ***: p<0.001).
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discUssion
The results of the present study indicate that exposure of human proximal tubule epithelial 
cells to cationic UTs leads to cytokine and ET-1 production by ciPTEC. We demonstrated 
that the production of IL-6, IL-8, and TNFα was stimulated by the exposure to high levels of 
individual cationic toxins, supporting the inflammatory response often observed in uremia. 
At clinically relevant concentrations, a mixture of these selected toxins induced the endog-
enous production of IL-6, IL-8 and ET-1. Additionally, ET-1 was identified as time-dependent 
regulator of organic cation uptake through interaction with the ET-B receptor.
In patients suffering from renal failure, the accumulation of UTs was reported to be as-
sociated with the development of a chronic inflammatory state [9]. Various clinical studies 
have demonstrated a correlation between increasing IL-6, IL-8 and TNFα cytokine levels and 
reduced glomerular filtration rate [11,12]. Inefficient clearance of the inflammatory media-
tors in combination with increased cytokine production could cause these effects. The results 
of the present study confirm that exposure to a cationic uremic mixture of acrolein, spermine, 
spermidine, cadaverine, putrescine, guanidine and methylguanidine induced the production 
of IL-6 and IL-8 by using the human renal cell line, ciPTEC.
The observed increase in IL-6 and IL-8 production ranged from 26-45%. When compared 
to the 81-182% increase in IL-6 and IL-8 release after LPS stimulation this level could be 
considered modest. However, LPS is one of the most potent inducers of cytokine production. 
Patients suffering from ESRD were reported to show a 35% rise in IL-6 levels [11]. The local 
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figure 4.5: kinase pathways on ciPTec asP+ uptake levels after exposure to eT-1.
ciPTEC monolayers were incubated for 15 min in medium containing 10 µM ASP+ without or with pre-
incubation with (A) 100 nM ET-1, 1 μM DOG or ET-1 plus DOG, (B) 100 nM ET-1, 1 μM 8-br-cGMP 
or ET-1 plus 100 µM 8-br-cGMP. Subsequently, the reaction was stopped, the cells lysed and the fluores-
cent signal was measured as described in the methods section. Values are expressed as means ± SEM for 
at least 3 experiments performed in triplicate. (*:p< 0.05 **:p<0.01 ***: p<0.001).
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production of these cytokines in response to a uremic milieu can promote local profibrotic 
or inflammatory processes in-vivo, since IL-6 production is associated with the induction of 
fibrotic gene expression, and IL-8 is a potent neutrophil chemoattractant [37,38]. We could 
therefore consider the 26-45% increase in production of IL-6 and IL-8 by proximal tubule 
epithelial cells clinically relevant. It is, however, important to take into account that our in 
vitro settings cannot be translated directly to the clinical situation, especially with regard to 
protein binding and intracellular solute concentrations. Not only are organic solutes often 
able to bind to human serum albumin, they can also interact with other proteins such as 
α1-acid glycoprotein and lipoproteins, and even red blood cells and platelets [39]. On the 
other hand, it is known that ESRD can affect systemic protein binding of drugs and endog-
enous compounds due to displacement [40-42]. Protein binding could, therefore, affect the 
free fraction of uremic solutes available to cells. Nevertheless, intracellular levels often easily 
exceed the free serum concentrations due to active uptake processes[43,44].
The absence of TNFα production by ciPTEC after exposure to the UT mixture contrasts to 
the effects of the individual compounds putrescine and methylguanidine. In the mixture, the 
concentrations of these compounds were much lower as compared to the experiments per-
formed with the individual compounds, which might explain this effect. Additionally, TNFα 
is known to possess a very short half-life in whole blood [45], and low concentrations are 
reported to denature rapidly in culture medium at 37°C [46,47]. Since ciPTEC were exposed 
for 24 h, the initial TNFα peak could have subsided before the measurement was performed.
Many cytokines, including IL-6, are known to stimulate ET-1 production. Furthermore, 
the proximal tubule can endogenously produce ET-1 upon stimulation with various nephro-
toxicants, as was previously demonstrated in non-human species [24,48,49]. Here we show 
that, next to the production of IL-6 and IL-8, the mixture of cationic UTs also promoted a 
modest ET-1 release by ciPTEC. The local production of ET-1 in the renal tubule has been 
recognized as an early response to tubular injury, and was identified as a key regulator of efflux 
transporters, Mrp2 and P-gp [23,26,36,48-50]. In these studies the threshold for ET-1 action 
on transporters was determined between 0.5-10 nM (1.25-24.9 ng/mL). In our study, the 
ET-1 release by ciPTEC was well below this threshold (Figure 4.1). The quantity of hormone 
released by ciPTEC is small, and much diluted by the cell culture medium. However, since the 
cells produce this compound endogenously, the threshold level could be reached in the direct 
vicinity of the cells.
The results of the present study also demonstrate that next to the regulation of MRP2 and 
P-gp, ET-1 can differentially regulate cation uptake in ciPTEC. Because ET-1 is a hydrophilic 
compound, surface receptors are necessary to regulate intracellular responses to the peptide. 
The regulatory effects of ET-1 on the OCT-mediated ASP+ uptake were clearly mediated 
through the action of the ET-B-receptor, since the addition of the ET-B-receptor blocker BQ-
788 ameliorated both effects observed after 30 min and 24 h.
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The inhibition of OCT-mediated ASP+ transport by ET-1 after 30 min is in line with earlier 
reports. Terlouw et al. previously hypothesized that the reduction in efflux activity by trans-
porters could protect the cell form injury after exposure to a nephrotoxic substance by saving 
ATP for more immediate processes that are necessary for cell survival [24,49]. Although the 
reduction in ASP+ uptake by ciPTEC after 30 min suggests a similar protective mechanism 
for organic cations, the reduced influx is unlikely to serve as an ATP saving mechanism. 
Organic cation uptake processes are mostly mediated by polyspecific solute carriers like 
OCT2 (SLC-22 family), which are membrane potential and substrate concentration gradi-
ent dependent, and therefore functions as facilitated diffusion carriers for organic cations, 
but are independent of proton gradients. In addition, two other types of apically expressed 
transporters might be involved, viz. the Carnitine/Organic Cation Transporters OCTN1 and 
OCTN2 (SLC22A4 and SLC22A5 [51,52]) and the proton antiporters, MATE1 and MATE2k 
(multi-antimicrobial extrusion proteins). Schmidt-Lauber et al. reported active uptake of 
ASP+ through OCTN1 and MATE1 in transporter-transfected HEK293 cells and human 
synovial fibroblasts (hRASF) [53]. In ciPTEC, the exact role of these transport proteins in the 
uptake of cationic organic substrates, such as ASP+ or uremic retention solutes, is yet unclear. 
Future studies should be directed to further elucidate their role.
Solute carriers do not rely directly on ATP binding or hydrolysis [54,55]. Based on our 
results, we suggest that the short-term reduction in organic cation influx by ET-1 signaling 
provides protection by minimizing intracellular accumulation of potentially toxic compounds. 
In acute situations, this would reduce intracellular damage until other clearance processes 
are activated to handle the toxic threat. On the other hand, the increased influx transport 
observed after 24 h was unexpected. This observation could not be linked to increased mRNA 
levels of OCT2 neither OCT1 or OCT3, of which detection on mRNA level in ciPTEC was 
remarkable, since they are generally considered of less importance in human kidney [34,35] 
(supplemental figure S2).We cannot exclude the involvement of another important mecha-
nism in the short-term regulation of transporter activity known as endocytic membrane re-
trieval, or insertion as suggested previously [56,57]. This mechanism has also been described 
in the short-term regulation of the proximal tubular type IIa Na-Pi cotransporter, and the 
pH-regulated insertion of H+-ATPases in the proximal tubule [58-61]. Furthermore, rapid 
insertion of MRP2 in response to tubulotoxic insults has been described [26,62]. If OCT func-
tionality is regulated by such rapid dynamic endocytic retrieval or insertion processes, the 
regulation depends on an intracellular vesicular pool of transporters and its regulation will 
therefore not directly affect mRNA expression levels. The development of specific antibodies 
directed at the human organic cation transporters, together with immunocytochemisty or 
protein expression studies, could in the future provide more insight in the involvement of the 
regulatory mechanisms of organic cation uptake in ciPTEC. Furthermore, post-translational 
modifications, such as phosphorylation could affect transporter activity. In the intracellular 
loops of the (human) SLC-22 family, several potential phosphorylation sites have been identi-
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fied [63]. For rOCT1, phosphorylation events are known to stimulate conformational changes 
at the substrate binding site, thereby increasing the affinity for its substrates [64]. In various 
studies focusing on ASP+ uptake in rabbit or human models, PKC stimulation was found to 
either induce or inhibit substrate uptake, depending on the species [65].
In ciPTEC, PKC stimulation by DOG in combination with ET-1 restored organic cation 
uptake after 30 min of pre-incubation. These observations suggest that PKC activation in 
ciPTEC stimulates organic cation uptake, however, this is in contrast to previous studies 
with hOCT2-HEK293 cells and isolated human proximal tubules [57,65]. The reason for this 
discrepancy is unclear, but considering the many intracellular processes affected by PKC this 
may suggest that multiple regulatory pathways are involved. Still, the findings of the present 
study are in agreement with the known interaction between ET-1 and the protein kinase path-
way in the regulation of other renal transporters (viz. Mrp2 and P-gp) [23,66,67].In killifish 
renal proximal tubules, dogfish shark salt glands and rat brain capillaries, ET-1 also reduced 
Mrp2 or P-gp-mediated transport by stimulating the PKC pathway . It would, therefore, be 
interesting to evaluate in future studies how ET-1 production by ciPTEC would affect the 
transport by Mrp2 or P-gp in this cell model.
Next to the PKC pathway, our results demonstrated that inhibition of iNOS by AG or 
L-NMMA restored ASP+ uptake at 30 min after ET-1 exposure. In the human proximal 
tubule, iNOS is constitutively expressed [68,69]. It mediates the regulation of local inflam-
matory responses, following cytokine production during endotoxemia, or after exposure to 
nephrotoxicants [48,49]. Similar to the iNOS induced effects observed in the present study, 
Heemskerk et al. demonstrated a reduction in OCT1 and OCT2 uptake transport during 
acute endotoxemia, while the functional expression of the efflux transporters MRP2 and P-gp, 
increased [25,70]. Therefore, iNOS is considered an important player in the regulation of the 
short-term tubular response to external assaults. These short-term effects of the inflammatory 
mediator ET-1 on the regulation proximal tubular cation uptake could provide clues on pos-
sible pathways involved in acute kidney injury.
Though numerous studies have investigated the mechanisms involved in renal proximal 
tubular transport, the mechanisms behind these regulatory pathways is often analyzed within 
relatively short time frames. We observed a time-dependent ET-B receptor mediated effect of 
ciPTEC exposure to ET-1, leading to an increased cellular uptake of cationic substances. The 
mechanisms behind this long-term (24 h) regulation could not be explained by the known 
NO, PKC or cGMP mediated pathways. These observations are reminiscent of both the 
biphasic and NO-independent pathways that were described for the efflux transporter P-gp 
[71,72], for which a second pathway, next to NO mediated regulation, was identified involv-
ing activation of Toll Like Receptor 4 and translocation of NF-κB. Further research would be 
warranted to investigate this pathway in the regulation of proximal tubular organic cation 
uptake. Investigating the increase in substrate uptake following long term ET-1 exposure 
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might provide clues about possible treatment strategies to promote renal secretory clearance 
in uremia, or shed further light on protective mechanisms of the renal proximal tubule.
In conclusion, our findings implicate that cationic UTs can directly induce the local 
production of inflammatory cytokines and ET-1. Furthermore, ET-1 exposure was found to 
enable regulation of organic cation uptake by proximal tubule cells. These findings might 
suggest that systemic accumulation of UTs in patients suffering from CKD could influence 
renal tubular clearance processes through local production of inflammatory or vasoactive 
mediators. However, further studies on OCT regulation and functionality in response to UT 
exposure are required to elucidate the exact processes that connect these events.
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absTracT
The need for improved renal replacement therapies is a stimulance for innovative research for 
the development of a cell based bioartificial kidney, or so called Renal Assist Device (RAD). 
A key requirement for such device is the formation of a “living membrane” consisting of a 
tight kidney cell monolayer with preserved functional organic ion transporters, on suitable 
artificial membrane surfaces. In this work, we applied a unique conditionally immortalized 
proximal tubule epithelial cell (ciPTEC) line with an optimized coating strategy on poly-
ethersulfone (PES) membranes to develop a “living membrane” with a functional proximal 
tubule epithelial cell layer. PES membranes were coated with combinations of 3,4-dihydroxy-
L-phenylalanine and human Collagen IV (Coll IV). The optimal coating time and concen-
trations were determined to achieve retention of vital blood components while preserving 
high water transport and optimal ciPTEC adhesion. The ciPTEC monolayers obtained were 
examined through immunocytochemistry to detect zona occludens-1 (ZO-1) tight junction 
proteins. Reproducible monolayers were formed when using a combination of 2 mg/ml L-
DOPA (4 min coating, 1 h dissolution) and 25 μg/ml Coll IV (4 min coating). The successful 
transport of 14C-creatinine through the developed “living membrane” system was used as an 
indication for organic cation transporter functionality. Addition of metformin or cimetidine 
significantly reduced the creatinine transepithelial flux, indicating active creatinine uptake in 
ciPTEC, most likely mediated by the organic cation transporter, OCT2 (SLC22A2).
In conclusion, this study shows the successful development of a “living membrane” con-
sisting of a reproducible ciPTEC monolayer on PES membranes, an important step towards 
the development of a bioartificial kidney.
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inTrodUcTion
The number of patients with end-stage renal disease (ESRD) is progressively increasing and 
the need for renal replacements therapies is rising [1]. Worldwide, over 2 million patients 
suffer from ESRD and each year that number grows by 5%. Since transplant options are 
limited [2], approximately 70% of patients receive (hemodialysis or peritoneal) dialysis treat-
ment. While dialysis therapy has already prolonged many ESRD patients’ lives, the treatment 
cannot completely replace renal function. Mortality (15-20% per year) and morbidity of 
these patients remain high, whereas their quality of life is generally low. Hemodialysis (HD) 
therapy removes mainly small, unbound substances from the circulation, while leaving large, 
compartmentalized and protein-bound uremic retention solutes untouched [3]. Although 
the introduction of high-flux (HF) or hemodiafiltration (HDF) therapy promotes enhanced 
removal of middle molecular weight solutes, the removal of protein-bound retention solutes 
remains limited [4,5].
Since renal secretion of such protein-bound compounds is predominantly mediated by 
the proximal tubule epithelial cells (PTEC) [6,7], the need for improved renal replacement 
therapy has stimulated innovative research into the development of a bioartificial kidney, or 
so called Renal Assist Devices (RAD) [8]. These innovative devices aim to complement the 
hemodialysis treatment, by coupling artificial membranes with functional kidney cells. To 
achieve efficient clearance of uremic retention solutes, proximal tubular epithelial cells need 
to be seeded on the inner surface of hollow fiber membranes. This situation is comparable 
to the native tubule, where the basement membrane separates proximal tubule cells from 
the circulation. While the patients’ blood flows over the outer surface, the uremic retention 
solutes can bind to the transport proteins present on the basolateral surface of human PTEC, 
facilitating their subsequent secretion into the hemodialysis filtrate. This approach could 
provide a means to further diminish the systemic accumulation of uremic retention solutes, 
reduce the incidence of secondary morbidities in patients, and shorten dialysis duration or 
frequency, thereby improving the quality of life in ESRD.
The development of a RAD brings along very specific biotechnological challenges, as 
was recently reviewed by Jansen et al. 2014 [9]. First of all, an important challenge in the 
development of a RAD is the limited availability of reliable and well characterized human 
proximal tubule cells capable of transepithelial excretion of uremic retention solutes. This 
“living membrane” should consist of tight cellular monolayers maintaining their typical 
polarity and functionality. Second, one side of the membrane to be used in a RAD needs 
to be suitable for blood contact (low cell adhesion), whilst the other side should facilitate 
cellular adhesion. Surface topography was identified as an important feature affecting cell 
adhesion and membrane hemocompatibility, the two properties being favored by higher sur-
face roughness and smoothness, respectively [10]. Several studies, which attempted to create 
“living membranes” with renal epithelial cells, have used existing membranes (mostly hollow 
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fibers) used in dialysis and / or blood purification. Polyethersulfone (PES), polysulfone (PSF), 
polyacrylonitrile (PAN) and cellulose acetate membranes, were evaluated for their ability 
to support monolayer growth of renal epithelial cells [11-13]. Since these membranes are 
designed for low cell adhesion, and maximum hemocompatibility during blood filtration, it 
is necessary to apply a coating consisting of extracellular matrix components. This actually 
describes the third challenge in RAD development; the optimization of coating conditions. In 
some cases, coatings have been reported to improve the attachment of renal tubule epithelial 
cells, but often coatings failed to maintain trans-monolayer transport activity and monolayer 
integrity [14-18]. Human collagen type IV (Coll IV) based coatings are promising for attach-
ment and functional culture of proximal tubule cells [15], since Coll IV is endogenously pres-
ent in the basal lamina and promotes mesenchymal cell differentiation towards the epithelial 
lineage [19]. However, it is necessary to improve its adhesion to the artificial membrane. 
The treatment of polymeric surfaces with biomolecules via covalent reactions is generally 
inconvenient given the susceptibility of different activated groups to hydrolysis, which can 
lead to low efficiency of surface biofunctionalization [20]. An easy two-step water based bio-
functionalization method has been proposed that promotes the formation of a thin adherent 
polydopamine (PDA) film [10,17,21] using self-polymerizing 3,4-dihydroxy-L-phenylalanine 
(L-DOPA); and exploits the reactivity of the PDA film to covalently bind the biomolecule Coll 
IV on the membrane surface [10,20]. However, in these earlier studies, the application of the 
coatings was not optimized with regard to membrane transport characteristics (high water 
permeance and retention of vital proteins such as BSA and IgG).
The selection of renal cell lines suitable for RAD application poses another challenge. The 
use of animal cell models, such as porcine (primary or LLC-PK1), monkey (JTC-12) and 
canine (MDCK) renal epithelial cells, provides insight in the functionality of a RAD, both 
in-vitro as well as in-vivo [13,16,22-25]. However, their clinical application is highly restricted. 
Moreover, species differences in renal proximal tubule physiology are in favor of a renal cell 
line of human origin [26,27]. Studies using freshly isolated primary human proximal tubule 
cells in a RAD have shown promising results [10,28,29]. However, their limited availability, 
low proliferative capacity, and donor-to-donor variation, severely restrict the use of these 
cells. The utilization of a functional human proximal tubule epithelial cell line overcomes 
these drawbacks. Previously, some of the co-authors of this study have developed a human 
conditionally immortalized proximal tubule epithelial cell (ciPTEC) line, with intact proximal 
tubular characteristics and endogenous expression of various functional transport proteins 
[30,31]. Among the advantages of this cell line is the switch between a proliferative state at 
33 °C to a differentiation state at 37 °C, permitted by transduction with the temperature sensi-
tive Simian virus 40 (SV40) large T antigen. The genetic switch allows for cell proliferation 
arrest when the cells are confluent and fully differentiated, promoting the formation of tight 
and functional monolayers [30].
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In this work, we show for the first time the development of a stable, functional “living 
membrane” by culturing ciPTEC on PES based membranes with a molecular weight cut off 
50 kDa. This cut off prevents albumin leakage, blocks possible immunoglobulin transfer, 
and avoids the loss of vital blood component in case of cell monolayer integrity failure. The 
membranes were coated with a double coating consisting of L-DOPA and Coll IV on the 
more porous rough membrane side to maximize the beneficial effect of both membrane 
topography and coating on cell adhesion. This coating was carefully optimized to preserve 
high membrane permeability and create a tight cell monolayer. The selective active transport 
of creatinine through the “living membranes” was investigated in the presence and absence 
of specific inhibitors, and compared to a commercially available polyester Transwell® system.
maTerials and meTHods
membrane coatings
Flat polyethersulfone membranes (Sartorius, Germany), which showed good hemocompat-
ibility properties [32], with a molecular weight cut off of 50 kDa (indicated, as PES - 50) 
were coated with a double layer of 3,4-dihydroxyl-L-phenylalanine (L-DOPA) (D9628, Sigma 
Aldrich, Zwijndrecht, The Netherlands) and human collagen IV (Coll IV, C6745, Sigma 
Aldrich, Zwijndrecht, The Netherlands) L-DOPA solutions with concentrations ranging from 
1 to 2 mg/ml in Tris buffer 10 mM (pH 8.5) were prepared and dissolved at 37°C. Complete 
dissolution was obtained after 1 h, followed by filter sterilization. Subsequently, the L-DOPA 
solution was used to either coat the membranes immediately after powder dissolution, with 
minimum polymerization degree (referred to as L-DOPA (1 h)), or left to polymerize for 
2 more hours (referred to as L-DOPA (3 h)) before coating the membranes. For the sake of 
simplicity, we defined the dissolution time as the time that the L-DOPA is kept in solution 
before coating the membrane. The membranes were first pre-incubated in Hanks’ balanced 
salt solution (HBSS; Life Technologies, Bleiswijk, the Netherlands) for 10 min. Next, the 
L-DOPA solutions were applied to the membrane surface. The solution was aspirated, and 
the membranes were left to dry for 5 min. Then, a Coll IV solution (25 µg/ml or 50 µg/ml) 
in HBSS was used for the second step of the coating. After fluid aspiration and drying, the 
membranes were washed three times in HBSS to remove any remaining solvent or unbound 
compound. Diverse L-DOPA dissolution times (1 and 3h) and coating times of membranes 
(1 and 4 min) were tested and their effects on membranes properties were evaluated in terms 
of membrane morphology and pure water permeance. An overview of the coating conditions 
tested is given in Figure 5.1. The PES-50 membrane has an asymmetric structure: one mem-
brane side is denser (and therefore determines the transport properties) and smooth, while 
the other membrane side is more porous and rough. The double coating was performed on 
the more porous membrane side, under static conditions, by contacting the coating solution 
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with the membrane surface. To obtain single sided coating of the flat PES membranes, the 
coating solution was first poured in glass Petri dishes and the membrane was gently placed on 
the top of the solutions with the porous side in contact with the liquid. The selection of final 
concentrations, dissolution times and coating times for both the L-DOPA and the Coll IV 
solution was based on cell adhesion, cell monolayer formation and tight junction expression. 
Reproducibility of the coating was investigated in terms of water and protein transport prop-
erties. For cell culturing, polyester Corning (Corning Costar, NY, USA) custom Transwell® 
supports were used. In these Transwells (12mm in diameter), the polyester cell membrane 
was replaced by PES - 50 membrane used for the double coating development. Here, mem-
brane coating was performed on one side of the membrane by applying the solutions to the 
apical (cell-facing) side of the Transwell®. Since the PES membrane is sealed on the perimeter 
to the plastic holder, the basolateral side of the membrane did not come into direct contact 
with the coating solution. Supplemental figure A1 provides a schematic overview of a coated 
Transwell® membrane. As a reference, we employed double-coated (positive control) polyester 
Transwell® membranes, which are frequently used for in-vitro PTEC culture [30,33].
membrane morphological and surface composition analysis
Membrane morphology was determined by scanning electron microscopy (FEI/Philips 
XL30 FEG ESEM). Surface samples were prepared and kept overnight at 30°C and gold 
sputtered before examination by SEM at a voltage of 5 kV. The membrane surface chemical 
structures and composition of the coated and uncoated PES-50 were characterized using an 
Attenuated total reflection-Fourier transform infrared spectra (ATR-FTIR) (Spectrum two,, 
Perkin Elmer, Waltham, USA) instrument. Elementary analysis of the membrane composi-
tion was performed by Energy Dispersive Spectroscopy analysis (EDS -EDAX Apollo X for 
ESEM, New Jersey, USA).
membrane transport properties
Pure water, bovine serum albumin (BSA, A2153, Sigma Aldrich, Zwijndrecht, the Nether-
lands) and immunoglobulin G (IgG, I9640, Sigma Aldrich, Zwijndrecht, the Netherlands) 
solution permeance was determined using an air-pressurized dead end ‘Amicon type’ ultra-
filtration cell (hosting 4 cm Ø membrane samples) and ultrapure water. The flux (J) of water 
and protein solution through the membranes at each pressure was determined by collecting 
the mass of the permeated liquid over time and correlating it to the membrane unit surface 
area. The permeance (L, in L m-2 h-1 bar-1) of water or protein solution was estimated by 
normalizing the water or protein solution flux (J, in L m-2 h-1) by the applied transmembrane 
pressure (ΔP, in bar). The permeance is, in fact, calculated from the slope of the linear part of 
the flux vs. transmembrane pressure relationship:
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L =  J 
∆P  [1]
Clean water permeation tests were performed by using ultrapure water (MilliQ 18 MΩ.cm, 
Millipore; Billerica, MA, U.S.A) solutions inside stirred Amicon cells (Millipore; Billerica, 
MA, U.S.A), where the membranes were placed with the thin layer facing the feed solution. 
Automatic collection of permeate mass during time was performed by means of a Labview 
based software, the mass was converted to volume given the water density equal to 998 kg. 
m-3 at 20°C [34]. Uncoated flat membranes were tested after immersing them in pure water for 
1 hour to remove preservatives added during the manufacturing process. Membranes double 
coated with L-DOPA and Coll IV were immersed in HBSS buffer for 30 min before they were 
used. Subsequently, the membranes were subject to a flushing step with ultrapure water at the 
highest working pressure (0.75 bar). Then, down to up pressure cycles were applied to each 
membrane.
The extent of protein transport through the membrane was evaluated by estimating the 
apparent sieving coefficient (SCa).
SCa =   C  
Cb [2]
where Cp is the protein concentration in the permeate and Cb is the protein concentration in 
the feed protein solution. SCa=1 means that the protein passes freely through the membrane, 
while SCa=0 means that the membrane rejects the protein completely.
Phosphate buffered saline (PBS) containing BSA or IgG, were used at a concentration of 
1 mg/ml and 0.02 mg/ml, respectively. Three different pressures (0.25, 0.50, 0.75 bar) were 
applied and sample collection occurred every 15 minutes for 1 hour. The protein solution was 
continuously mixed at the top of the membrane surface to prevent polarization concentration 
effect and delay membrane fouling. BSA and IgG concentration was evaluated by spectropho-
tometric analysis in quartz cuvettes at 280 nm.
cell culture
A previously developed ciPTEC cell line [30] was used for functional testing of the coated 
membranes. In short, this immortal cell line was developed by transducing primary human 
proximal tubule epithelial cells, obtained from urine samples of healthy volunteers, with a 
SV40t, and hTERT gene. SV40t stimulates cellular proliferation at 33°C, while it is silenced 
by culturing the cells in a 37°C environment. As a consequence, at 37°C the cells are able 
differentiate and form a tight monolayer. The hTERT ensures the cellular quality, by keep-
ing the length of the telomeres intact during proliferation. We have previously evaluated 
the characteristics of this cell line, on a morphological and functional level [7,31]. CiPTEC 
p
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were cultured in Dulbecco’s modified eagle medium DMEM-HAM’s F12 (Lonza; Basel, 
Switzerland) containing 10% v/v fetal calf serum (FCS) (Greiner Bio-One; Alphen a/d Rijn, 
the Netherlands), 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml selenium, 36 ng/ml hydro-
cortisone, 10 ng/ml epidermal growth factor and 40 pg/ml tri-iodothyronine, all purchased 
from Sigma-Aldrich Co. (Zwijndrecht, the Netherlands). Culture media were phenol-red and 
antibiotic free. To prevent de-differentiation of ciPTEC during regular culturing, cells were 
used in experiments up to a maximum of 40 passages, during which proximal tubular char-
acteristics remained unaltered [30]. Proliferating ciPTEC were seeded onto the polyester or 
PES membrane Transwell® inserts at a density of 133.000 cells/cm2. To promote initial cellular 
attachment and proliferation, ciPTEC were cultured for 24 h at 33°C 5% (v/v) CO2 and after 
this time period the temperature was changed to 37°C for 7 days to promote the formation of 
a differentiated monolayer.
immunocytochemistry
To investigate morphological characteristics and monolayer integrity of matured ciPTEC 
cultured on polyester [30,33] and PES-50 Transwell® inserts, immunocytochemistry was 
performed and after 7 days the expression of the tight junction protein, ZO-1 (zonula oc-
cludens – 1), was studied. Matured ciPTEC were fixed using 2% (w/v) paraformaldehyde 
in HBSS supplemented with 2% (w/v) sucrose for 5 min and permeabilized in 0.3% (v/v) 
Triton X-100 in HBSS for 10 min. To prevent non-specific binding of antibodies, cells were 
exposed to block solution containing 2% (w/v) bovine serum albumin fraction V (Roche, 
Woerden, the Netherlands) and 0.1% (v/v) Tween-20 in HBSS for 30 min. Cells were in-
cubated with antibodies diluted in block solution against the tight junction protein zonula 
occludens 1 (ZO-1, 1:50 dilution, Invitrogen, Carlsbad, CA) for 1 h, followed by incubation 
with goat-anti-rabbit-Alexa488 conjugate (1:200, Life Technologies Europe BV, Bleiswijk, the 
Netherlands) for 30 min. Finally, DAPI nuclei staining (300 nM, Life Technologies Europe 
BV) was performed for 5 min. Protein expression and localization were examined using the 
Olympus FV1000 Confocal Laser Scanning Microscope (Olympus, Tokyo, Japan) and images 
were captured using the Olympus software FV10-ASW version 1.7. To semi-quantify the 
fluorescent staining of ZO-1, a grid of 8.5 µm2 was placed on top of the confocal images using 
ImageJ software (ImageJ 1.46r, NIH, USA) [35]. The number of intersections between the 
grid and the ZO-1 signal was determined for each condition.
Transepithelial transport measurements
Transepithelial transport of [14C]-creatinine by matured ciPTEC monolayers cultured on 
either polyester or PES Transwell® inserts was measured using a Transwell® culture system. 
A schematic overview of the set-up, is provided in the supplemental file (Figure 5.A1). Poly-
ester Transwells® (diameter 12mm, pore size 0,4µm) were coated with L-Dopa alone or in 
combination with Coll IV (25 mg/ml, for 2 hours), and compared to double coated polyester 
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or PES-50 Transwells®. Mature cell monolayers were washed in modified Krebs-Henseleit 
buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands) including 10mM Hepes (pH 7.4). Sub-
sequently, all membranes tested were pre-incubated for 2 h at 37°C, 5% (v/v) CO2 in Krebs-
Henseleit-Hepes buffer (0.5 mL apically, 1.5 mL basolaterally). Transport was initiated by the 
basolateral addition of either [14C]-creatinine (0.75 µM, 2 μCi/ml) or [3 H]-inulin (0.45 µM, 
20 μCi/ml) with or without cimetidine (100 µM) or metformin (100 µM) as competitors for 
OCT2 transport (Sigma-Aldrich Co., Zwijndrecht, the Netherlands). At the start of the mea-
surement, a 20 μL reference sample was taken from the basolateral exposure compartment. 
After 30 min of incubation with gentle agitation at 37°C a 200 μL sample was removed from 
the apical chamber. The activity of [3H] and [14C] in the samples was determined by liquid 
scintillation counting (Beckman). Fluxes of [14C]-creatinine or [3H]-inulin were determined 
for each separate Transwell®. The flux of [3H]-inulin was used as an internal leakage marker. 
The basolateral to apical flux (J) was calculated with:
J =  dQ  
S*dt [3]
where dQ = amount transported [pmol]; dt = duration of transport [minutes]; S = surface 
area [cm2].
data analysis
Water, BSA and IgG transport measurements in each experiment were performed at least 
in triplicates (N≥3 for each coating condition). Results are presented as mean ± standard 
deviation. Statistical analysis was performed with the Microsoft Excel® software (Microsoft 
Corporation, Seattle, USA) using a one-way ANOVA or a Student’s T-test when appropriate.
Quantification of ZO-1 staining on Transwell® polyester or PES membranes was performed 
in triplicates for each coating condition. The results are presented as mean ± sem. Results 
were normalized by taking the double coated Polyester Transwell® as 100% reference. One-
way ANOVA followed by a Dunnett’s post-test, was performed using GraphPad Prism version 
6.00 for Windows, (GraphPad Software, La Jolla California USA).
For basolateral creatinine transport experiments in the commercially available polyester 
Transwells® the experiments were performed at least in triplicate in three independent 
experiments. The custom PES Transwells® were tested in duplicate in three independent 
experiments. Results are presented as mean ± SEM. Statistical analysis was performed with 
GraphPad Prism, using a two way ANOVA combined with a Bonferroni’s post-test.
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resUlTs – discUssion
The biofunctionalization strategy of flat PES-50 membranes was optimized first to develop 
functional ciPTEC monolayers. Artificial membranes should provide a solid base for cells to 
form tight monolayers and facilitate active transepithelial solute transport. In the nephron, 
the proximal tubule is responsible for the reabsorption of 65% of all the water filtered by 
the glomerulus; the very high permeability of the tissue was estimated to be about 1x105 L 
m-2 h-1 bar-1 [36]. The hydraulic permeability of native PES-50 membrane is 2 orders of mag-
nitude lower than the value reported for natural tissue, the membrane was chosen on the base 
of its capacity to retain vital blood components, consistent with other research in the field 
[22]. For this reason, water transport through the coated membranes was one of the main 
parameters to optimize, in order to preserve the highest permeance possible.
A recent study proposed the application of an overnight double coating [10]. However, 
when we applied such a coating, a significant decrease in membrane water permeance, (39 ± 
23 L m-2 h-1 bar-1) was detected in comparison to uncoated membranes (738 ± 110 L m-2 h-1 bar-
1). Further reduction of the permeance was expected when applying the second coating layer 
consisting of Coll IV. To avoid significant transport limitations, we investigated shorter L-
DOPA dissolution times. In a first attempt, L-DOPA was used for the coating immediately 
after the dissolution step (L-DOPA (1 h)). The average value of water permeance did not 
change significantly (654 ± 70 L m-2 h-1 bar-1) with respect to uncoated membrane values 
(Figure 5.1, I). After applying the Coll IV coating on top of the L-DOPA layer (Figure 5.1, II), 
the average value of water permeance decreased to 347± 151 L m-2 h-1 bar-1. However, the high 
coefficient of variation (0.44) indicated a non-reproducible coating. These results indicate 
that short coating times do not cause significant changes, whilst overnight coating results 
in a dramatic reduction in membrane transport properties. Since the variable “time” plays a 
central role in the macroscopic transport properties of the coated membrane, we compared 
the effects of prolongation of the L-DOPA dissolution time (Figure 5.1; II, III and IV), to 
prolongation of the coating time to L-DOPA and Coll IV from 1 to 4 min (Figure 5.1; II, V).
When applying L-DOPA coating alone, prolongation of the L-DOPA dissolution time 
slightly increases the average membrane water permeance, although this effect was not 
significantly different from the non-coated PES-50 membranes (dark symbols, Figure 5.2a). 
Literature reports that L- DOPA coating can increase the membrane hydrophilicity due to 
the coexistence of carboxylic and amino groups in the L- DOPA molecule [37]. In fact, the 
effect of L-DOPA coating on hydrophilization of different materials has been shown by the 
reduction of water contact angle under the same experimental conditions used in the present 
study (pH, Tris buffer molarity and L-DOPA concentration) [21,37,38] we therefore expect 
that our membranes are slightly hydrophilized, too. Nevertheless, the application of L-DOPA 
to porous membranes can reduce the membrane transport properties. This decrease mostly 
occurs to UF membranes where the pore dimensions allow migration of L-DOPA monomers 
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and oligomers inside the membrane structure with consequent reduction or blockage of the 
inner porosity [39,40]. The transport properties of reverse osmosis (RO) and microfiltration 
(MF) membranes was reported to be less affected by L-DOPA coatings, due to the different 
pore size [40]. Since we used PES-50 UF membranes, the coating time as well as the L-DOPA 
dissolution time required optimization to avoid complete suppression of the membrane 
permeance.
The Coll IV coating on top of the L-DOPA layer (Figure 5.1, conditions I – IV) decreased 
the membrane water permeance significantly (open symbols in Figure 5.2a). The permeance 
for the double coated membranes with L-DOPA (3 h) and Coll IV for 1 min was 194 ± 35 L 
m-2 h-1 bar-1, which is significantly lower than the uncoated membranes. However, when com-
pared to overnight L-DOPA coating (Figure 5.1; VI), the membrane permeance improved 
markedly. Furthermore, prolongation of L-DOPA dissolution to 3 h enhanced the coating 
reproducibility, as demonstrated by the low standard deviation of the permeance values. 
Figure 5.2b presents the optimization procedure of the double coating using different coating 
times of L-DOPA (1 h) (Figure 5.1; II, V and VI). The water permeance for double-coated 
membranes with 4 min coating was A 2.7 fold higher (146 ± 10 L m-2 h-1 bar-1) than for 
overnight L-DOPA (only) coating. Prolongation of coating time to 4 min also improved the 
double coating reproducibility, as demonstrated by the low standard deviation of the perme-
ance results. These results indicate that optimization of the L-DOPA dissolution, and coating 
figure 5.2 Pure water permeance of double coated Pes-50 membranes.
Pure water permeance of PES-50 membranes coated with L-DOPA (2 mg/ml) and Coll IV (25 µg/ml) as 
a function of: a) L-DOPA dissolution time for PES membranes coated for 1 min with L-DOPA solution 
only (♦), or L-DOPA followed by Coll IV (□); b) double coating with L-DOPA followed by Coll IV 
with varying coating times (○), or L-DOPA solution after overnight coating (●). Data are presented as 
mean ± standard error, * p<0.05; ** p<0.01; ***p<0.005; N≥3 for each experimental point.
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times significantly improves the membrane permeance and coating reproducibility, when 
compared to overnight coating.
The progressive reduction of membrane water permeance correlated with the observed 
morphological changes at the porous side of the membrane surface where the double coat-
ing was applied. Figure 5.3 presents SEM images of uncoated, only L-DOPA and double 
coated membranes surfaces. The single L-DOPA coating slightly affected the porous layer 
morphology (data not shown). After application of L-DOPA (3 h), an estimated 40% re-
duction in the macroporosity visible at the upper surface of the flat membranes could be 
observed compared with the original membranes (Figure 5.3b). Application of Coll IV to the 
L-DOPA coating resulted in complete occlusion of membrane surface pores as compared to 
membranes coated with L-DOPA only, for all L-DOPA dissolution times tested (Figure 5.3c). 
The lack of visible differences in surface morphology in the presence of the single L-DOPA 
coating in comparison with native membranes was consistent with the average rate of PDA 
layer deposition (2 nm/h) reported in previous studies for the same experimental conditions 
(L-DOPA concentration, temperature, pH and Tris buffer molarity) [21,41]. The analysis of 
membrane surface chemical composition confirmed that the thickness of the coating was in 
the nm range, as the beam penetration for both EDAX and FT-IR analysis was deeper than 
the single or double coating applied. In fact for both the FT-IR spectrum and the elementary 
composition, the underlying PES material is still dominant (Figure 5.4). Dopamine mono-
mers and small oligomers have previously been demonstrated to play a primary role in the 
initiation of the PDA deposition and its consequent polymerization at the membrane surface 
[21,40,41]. In these studies, maximal monomer deposition rate was observed during the first 
hours after L-DOPA dissolution. This finding may explain why, in our case, a short coating 
time was sufficient to modify the PES-50 membranes, providing good collagen IV adhesion 
and reproducibility of transport properties.
figure 5.3 scanning electron microscopy analysis of (un)coated Pes-50 membranes.
Representative Scanning Electron Microscopy analysis of PES-50 membranes porous side surface mor-
phology with L-DOPA (2 mg/ml) and Coll IV (25 µg/ml) with different L-DOPA dissolution times: a) 
uncoated; b) 1 min coating with L-DOPA (3h) only; c) 4 min coating with L-DOPA (1h) and Coll IV. 
Magnification 100X. At least three independent membranes were examined for each condition.
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The optimized coatings were tested further for optimal cell monolayer formation by 
ZO-1 tight junction protein expression, a marker that indicates monolayer integrity and 
polarity of epithelial cells. The tested coating conditions are described schematically in Figure 
5.1, under the cellular adhesion heading (Figure 5.1; conditions VII-XII). Standard double 
coated polyester Transwell® inserts, were used as a positive control (Figure 5.5a). Uncoated 
PES-50 membranes provided poor cell adhesion of ciPTEC (Figure 5.5b) while single coating 
with Coll IV (25mg/ml) or L-DOPA (2mg/ml) did not improve this (Figure 5.5c,d). After 
application of the double coating, cellular adhesion and the expression of ZO-1 improved 
figure 5.4 surface chemical composition of Pes-50 membranes uncoated and coated with l-doPa 
(2 mg/ml) and coll iV (25 µg/ml).
Above ATR-FTIR spectra for: purple) uncoated PES-50; green) 4 min coating with L-DOPA (1h) only; 
yellow) 4 min coating with L-DOPA (1h) and Coll IV. Below EDAX analysis of (from left to right: un-
coated PES-50; 4 min coating with L-DOPA (1h) only; 1 min coating with L-DOPA (3h) only; 1 min 
coating with L-DOPA (3h) and Coll IV; 4 min coating with L-DOPA (1h) and Coll IV.
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(Figure 5.5e-f). The observed clear ZO-1 expression indicates polarization of the monolayer, 
improving epithelial characteristics [42] and limits paracellular leakage. No significant dif-
ference in monolayer formation and ZO-1 expression was detected between conditions XI 
and XII (Figure 5.5e,f), which varied either the coating or dissolution time. Furthermore, 
quantification of the ZO-1 has indicated that ciPTEC expressed ZO-1 protein in a similar 
fashion on both double coated PES-50 as on polyester Transwells®, which are considered the 
golden standard in ciPTEC transepithelial studies (Figure 5.5g). Lowering the concentration 
of L-DOPA reduced the reproducibility of cellular adhesion, even in the presence of a higher 
Coll IV concentration, thus suggesting the importance of a good L-DOPA layer to foster Coll 
IV membrane coating. Furthermore, increasing the Coll IV concentration to 50 µg/ml after 
2 mg/ml L-DOPA coating did not improve monolayer quality with respect to 25 µg/ml Coll 
IV (Figure 5.A2, supplemental Figure A2).
The coatings were investigated further in terms of protein rejection and fouling phenom-
ena during protein solution permeance. Table 1 shows a comparison of transport properties 
of uncoated and membranes with optimized coatings (Figure 5.1; conditions I, IV and V). The 
permeance of IgG and BSA solutions for the uncoated PES-50 membranes is 53 ± 11 and 57 ± 
7 L m-2 h-1 bar-1, respectively, about 96% lower than the water permeance through the same 
membranes (P<0.05). There was no significant difference in protein solution permeance for 
the coated membranes, as values ranged from 37 ± 27 L m-2 h-1 bar-1 to 65 ± 24 L m-2 h-1 bar-1. 
Both BSA (66 kDa) and IgG (150 kDa) were almost completely rejected by both uncoated and 
coated membranes: the SC < 0.1, consistently to what is expected for a 50 kDa membrane.
Given the similarity between the transport properties and the similar cell behavior for 
the membranes with the optimized coatings, the transport of inulin and creatinine was 
measured on membranes coated with the coating which required the shortest experimental 
time: L-DOPA (1h) with a coating time of 4 min for both L-DOPA and Coll IV (Figure 5.1, 
XII). Transepithelial transport of [14C]-creatinine was measured in presence and absence of 
Table 1 comparison of the transport properties of uncoated PES-50 membrane and coated with L-
DOPA (2 mg/ml) and Coll IV (25 µg/ml) with two approaches: 1) 1 min coating with L-DOPA (3h) and 
1 min Coll IV; 2) 4 min coating with L-DOPA (1h) and 4 min Coll IV.
Uncoated 1 min l-DOPA (3 h) + 1 min Coll IV
4 min l-DOPA (1 h) 
+ 4 min Coll IV
Pure water permeance [L m−2 h−1 bar−1] 738 ± 110 194 ± 35 146 ± 10
BSA solution permeance [L m−2 h−1 bar−1] 57 ± 7 44 ± 8 37 ± 27
IgG solution permeance [L m−2 h−1 bar−1] 53 ± 11 65 ± 24 51 ± 12
BSA SCa = CP/Cb [–] 0.03 ± 0.01 0.06 ± 0.02 0.02 ± 0.01
IgG SCa = CP/Cb [–] 0.02 ± 0.01 0.05 ± 0.03 0.04 ± 0.03
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transporters substrates, acting as competitors to inhibit uptake. In the kidney, approximately 
20% of creatinine is actively transported by organic cation transport proteins [43]. The func-
tionality of the basolateral cation uptake by organic cation transporters (OCTs) in ciPTEC 
has previously been demonstrated [7]. Here, Figure 5.6 presents the transmembrane flux of 
[14C]-creatinine (0.75 µM, Figure 5.6 a, b, c) and [3H]-inulin (0.45 µM, Figure 5.6 d, e, f) by 
ciPTEC cell monolayers, cultured on double coated PES-50, polyester Transwell® membranes 
or Coll IV coated polyester Transwell® membranes. The paracellular leakage of [3H]-inulin 
across the monolayer was used as an indicator of passive diffusion, hence, monolayer tight-
ness, since active transcellular transport has not been reported for this compound [44]. In all 
cases, the inulin leakage was very low, indicating that a tight monolayer was achieved. The 
observed average leakage of 0.8 ± 0.1 pmol min-1 cm-2 (0.1% of the total inulin amount) is 
comparable to observations made in previous studies that utilized MDCK or LCC-PK cells 
[45]. In accordance, the organic cation transport inhibitors, metformin and cimetidine, did 
not affect inulin transport across the cell monolayers. The creatinine flux through the double-
coated “living” PES-50 membranes (2.8 ± 0.1 pmol min-1 cm-2) was 3.5 times higher than the 
inulin flux (0.8 ± 0.03 pmol min-1 cm-2). Importantly, the creatinine flux was significantly 
decreased by the inhibitors, metformin (24 ± 6% decrease, P<0.05) and cimetidine (18 ± 0.2% 
decrease, P<0.05), indicating that the developed “living” membrane actively secretes creati-
nine. The results of the “living” PES-50 membranes were comparable to those obtained for 
cells cultured on the golden standard Polyester - Coll IV Transwell® system (see Figure 5.6 and 
supplemental Figure A3 which compare the permeance of inulin and creatinine through the 
various membranes).
Various studies have used cellular over-expression models to demonstrate transepithelial 
creatinine transport. We currently show this trans-epithelial secretory pathway is endog-
enously present and functional in ciPTEC. Limited data are available for creatinine fluxes in 
human renal cells. Brown et al. 2008 reported transepithelial creatinine fluxes for primary 
human proximal tubule epithelial cells [46]. Although we observed lower creatinine fluxes in 
ciPTEC, the transport capacity is maintained for up to 40 passages (unpublished data). This 
underscores the robustness of this model and its potential application in a RAD. The use of an 
immortal cell line provides unlimited proliferative capacity, providing the option to expand 
the surface area of the living membrane necessary to reach the required clearance levels.
Previous studies have shown that the proximal tubule cell can take up free L-DOPA 
through the organic cation transport system, thereby influencing cellular processes [47,48]. 
However, since the L-DOPA coating was fully polymerized before application of Coll IV, and 
several additional pre-culture washing steps had been applied, no free L-DOPA is expected 
to be present when culturing the cells. This is supported by the finding that no detrimental 
effect of the coating was observed for either transepithelial 14C-creatinine transport or for the 
morphology of ciPTEC.
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Although we focused here on creatinine transport as a marker for endogenous secretion 
processes in ciPTEC, creatinine is not the only substance that has to be cleared from the 
blood. Many cationic and anionic waste products, including indoxyl sulfate, hippuric-acid, 
kynurenic acid, polyamines and guanidines, are retained in patients suffering from uremia 
[49]. Previously, we reported that ciPTEC functionally express various membrane transport 
proteins that are involved in the uptake and excretion of uremic toxins (UTs) [7,30,50]. There-
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figure 5.6 basolateral to apical creatinine and inulin fluxes.
Basolateral to apical fluxes of (a,b,c) [14C]-creatinine (0.75 μM) and (d,e,f) [3 h]-inulin (0.45 μM) across 
ciPTEC monolayers. Measurements were performed in the presence or absence of the inhibitors met-
formin (100 µM) or cimetidine (100 µM). Depicted are ciPTEC monolayers cultured on: (a,d) PES-
50 Transwell® inserts coated with L-DOPA(1h) and Coll IV; (b,e) Polyester Transwell® membranes coat-
ed with L-DOPA(1h) and Coll IV; (c,f) Polyester Transwell® membranes coated with Coll IV only. All 
coatings were applied for 4 minutes at the following concentration: L-Dopa 2mg/ml, Coll IV 25mg/mL. 
Data are presented as mean ± standard error, N=3 *P<0.05
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fore a device based on cultured monolayers of ciPTEC grown on modified PES-50 surfaces 
could provide the ideal tool in the removal of these compounds. The use of sophisticated 
bioanalysis techniques such as LC-MS/MS might provide more opportunities for the tran-
sepithelial transport measurements of these toxic compounds by ciPTEC monolayers [51]. 
As a next step in RAD development, long term stability and preservation of functionality in 
ciPTEC monolayers should be evaluated. Furthermore, the introduction of dynamic culture 
conditions could improve both the formation of tight junctions and cellular transport proper-
ties [52]. Recent work suggests beneficial effects of shear stress on renal epithelia, leading 
to increased endocytosis [45] and sodium reabsorption by the NHE3 receptor [53,54]. 
Evaluation of the shear stress on the functionality of a transporting ciPTEC monolayer would 
provide valuable information for the development of a bioartificial device.
conclUsions - oUTlook
In this study, we showed the proof of concept for creating a “living membrane” by combining 
functional ciPTEC with PES-50 membranes coated with L-DOPA and Coll IV. The coating 
was optimized to achieve retention of vital blood components whilst preserving high water 
permeance and optimal cell monolayer formation. The transport of creatinine through the 
developed “living membrane” was comparable to golden standard systems for studying tran-
sepithelial transport across proximal tubule monolayers in-vitro. The results reported here are 
promising for the development of a bioartificial kidney. Further investigations are required to 
establish the long-term stability of these functional renal cell monolayers. Future studies will 
be directed towards producing “living membranes” on hollow fiber PES-based membranes 
and to evaluate up-scaling in a bioreactor system to develop a clinically relevant device.
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absTracT
Proximal tubule epithelial cells are commonly used as a model to investigate renal toxicity, 
drug-drug interactions, or to examine renal clearance processes. Previously, we developed a 
conditionally immortalized proximal tubule epithelial cell line (ciPTEC) that enables study-
ing active transepithelial transport of organic cationic solutes under static culture conditions. 
Here, we evaluated the effects of fluid flow by shear stress on the cell monolayer quality, as well 
as the transepithelial creatinine transport capacity of the ciPTEC monolayer.
To simulate fluid flow, confluent ciPTEC monolayers were cultured for seven days under 
dynamic conditions on a 2D plate rocker. Dynamic cell culture conditions increased cilia 
length significantly (6.9 ± 0.9 µm), compared to statically cultured cells (5.7 ± 0.4 µm, p=0.01). 
Monolayer height increased from 9.7 ± 4.8 µm to 15.5 ± 5.2 µm (p<0.005). The expression of 
various organic cation transporters was induced, leading to increased cellular ASP+ uptake 
(until 151 ± 28%, p<0.05) Furthermore, the transepithelial creatinine flux in dynamically 
cultured cells cultured was 1.4 x higher than the flux in statically cultured cells (2.9 ± 0.4 pmol 
min-1 cm-2 vs. 2.1 ± 0.4 pmol min-1 cm-2, respectively; p<0.001). When cells cultured on a 2D 
rocker were exposed to a mixture of cationic uremic toxins (UTs), the viability decreased sig-
nificantly indicating higher cellular sensitivity (IC50 static: 27.9 ± 2.7 fold the uremic plasma 
concentration reported in literature vs. IC50 shaking: 16.8 ± 2.3 fold the uremic concentration 
of the UTmix, p<0.01).
In conclusion, culturing ciPTEC under shear stress conditions on a 2D plate rocker 
increased the mRNA expression of various transport proteins, stimulated transepithelial 
organic cation transport, and enhanced sensitivity to cationic UTs. These findings strongly 
suggest that the introduction ciPTEC to apical shear-stress can stimulate further differentia-
tion of this cell type.
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inTrodUcTion
Renal proximal tubule epithelial cells (PTEC) are routinely used to study cellular clearance 
processes, drug-drug interactions or renal toxicity. To this end, a wide variety of epithelial cell 
models are being cultured on plastic culture surfaces, or specialized membranes that allow 
the formation of an apical and basolateral compartment [1]. PTEC are highly polarized, have 
a distinct basolateral to apical orientation, and express a specific set of solute transporters on 
either side. The proximal tubular transport proteins facilitate the clearance of large, charged 
or protein bound (retention) solutes from the circulation into the pro-urine [2]. As these 
solutes can freely pass the glomerulus, active secretion in the renal tubule is necessary for 
their removal. Although renal replacement therapy, such as hemodialysis, can prolong the 
life expectancy of patients suffering from end-stage renal disease, the clearance of uremic 
retention solutes is inefficient and systemic accumulation can promote the development of 
secondary morbidities [3,4].
Our previous work has shown that a human conditionally immortalized tubule epithe-
lial cells (ciPTEC) endogenously express functional organic cation transporter 2 (OCT2, 
SLC22A2) in concert with other essential organic cation transporters, such as OCT1, OCT3, 
p-glycoprotein (P-gP, ABCB1), breast cancer resistance protein (BCRP, ABCG2) and multi-
drug and toxic compound extrusion MATE proteins (SLC47) [5,6]. These transporters can 
facilitate the clearance of drugs and waste products, such as creatinine and specific cationic 
uremic toxins (UTs) [7-9]. Furthermore, ciPTEC form functional cell monolayers on poly-
ethersulfone based dialysis membranes. An optimized coating comprising both L-DOPA 
and collagen type IV promoted cell monolayer formation, while facilitating organic cationic 
transepithelial transport [8]. Current research actively explores the possibilities to utilize the 
functional properties of cultured renal epithelial cells in an add-on device to renal hemo-
dialysis therapy. Such a bioartificial kidney, or so-called renal assist device (RAD), aims to 
remove uremic retention solutes in dialysis patients more efficiently. However, a RAD would 
require cellular monolayers to function within a dynamic system, characterized by fluid flow. 
While ciPTEC were shown to actively transport cationic compounds when cultured under 
static conditions, thus far the effects of fluid flow on ciPTEC solute transport has not been 
elucidated.
Over the last 30 years, the effect of flow on cultured cells has steadily gained interest. Nu-
merous studies have investigated the effect of flow induced shear stress on vascular endothelial 
cells [10]. The vascular shear is estimated between 20 and 40 Dyn/cm2 and has been reported 
to regulate many processes, such as angiogenesis, release of vasoactive substances, perme-
ability and the expression of adhesion molecules [11-13]. In contrast, fluid flow in the renal 
tubule is expected to be much lower and mainly dependent on the single nephron glomerular 
filtration rate [14,15]. A number of studies have evaluated the in-vitro effect of fluid flow on 
renal proximal tubule epithelium, by making use of innovative flow chamber devices. Duan 
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et al. reported flow induced rearrangement of the cytoskeleton, increased the Na+ and HCO3- 
absorption, and enhanced basolateral Na+/K+-ATPase expression [16,17]. Furthermore, Jang 
et al. described a dual chamber microfluidic device in which the proximal tubular epithelium 
was exposed to apical flow, leading to enhanced cellular albumin and glucose reabsorption, 
alkaline phosphatase activity and substrate efflux through the P-glycoprotein (P-gp) trans-
porter [18].
The effects of fluid flow observed in these studies prompted us to investigate the effects of 
flow on ciPTEC organic cation transport. To simulate fluid-flow in our cell model, cells were 
cultured under dynamic conditions on a 2D plate rocker. Such a simple system provides the 
possibility to use standard or Transwell® cell culture dishes, and the use of small amounts 
of culture medium avoiding dilution of compounds transported [19]. Here, we applied the 
shear-stress to ciPTEC for up to 7 days. We examined the effects of the dynamic culture 
conditions on the monolayer quality, and evaluated the transepithelial creatinine transport 
capacity of the ciPTEC cell model.
meTHods
cell culture
Experiments were performed using the previously developed, immortalized and well charac-
terized human ciPTEC, obtained from a healthy volunteer’s urine sample [5]. CiPTEC were 
routinely cultured in Dulbecco’s modified eagle medium DMEM-HAM’s F12 (Lonza; Basel, 
Switzerland) containing 10% v/v fetal calf serum (FCS) (Greiner Bio-One; Alphen a/d Rijn, 
the Netherlands), 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml selenium, 36 ng/ml hydro-
cortisone, 10 ng/ml epidermal growth factor and 40 pg/ml tri-iodothyronine, all purchased 
from Sigma-Aldrich Co. (Zwijndrecht, the Netherlands). Culture media were phenol-red 
and antibiotic free. To prevent dedifferentiation of ciPTEC during regular culturing, cells 
were used up to a maximum of 40 passages, during which proximal tubular characteristics 
remained unaltered [5]. For experiments performed on regular plastic cell culture surfaces, 
cells were seeded at 30% density and left to attach for 24 h at 33° C. When seeded on 12 well 
polyester Transwell® permeable supports (Corning Costar, NY, USA), membranes were 
first treated with a collagen IV coating as described previously [8], to promote monolayer 
formation. Collagen IV (25 µg/mL) solution was applied to the membrane surface for 4 min. 
After aspiration and drying (5 min), the membranes were washed three times in HBSS to 
remove any remaining solvent or unbound compound. Proliferating ciPTEC were seeded 
onto polyester Transwell® membrane inserts at a density of 133.000 cells/cm2. Routine culture 
was performed at 33°C, 5% (v/v) CO2, media was refreshed every 2 or 3 days. Subsequently, 
the temperature was changed to 37°C to induce monolayer maturation for 7 days prior to 
performing the experiments.
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dynamic culture conditions
An UltraCruz™ 2D rocker (Heidelberg, Germany) with a tilt angle of 13° was used to gener-
ate flow at a range of 30 oscillations per min. Cell layers cultured under shaking conditions 
were seeded as stated above. After the initial 24 h attachment period, the temperature was 
changed to 37°C and at the same time the cells were transferred to the 2D rocker for 7 days of 
maturation under so called dynamic culture conditions. The characteristic fluid shear stress 
(the shear stress at the center of dish bottom when the dish is horizontal) in the round culture 
dishes, was quantified using the formula describing detailed analysis for the circular rocking 
dish presented in the supplementary material of in a publication by Zhou et al. 2010 [19]. 
In the case of the plastic 12 well plates (well diameter: 22.1 mm, fluid height: 2.6 mm) the 
maximal flip angle was set at the critical flip angle of 0.23 Rad, rotating at 1 cycle/sec, leading 
to a characteristic shear stress of 0.056 Pa or 0.56 Dyn/cm2. For the Transwell® membranes 
(well diameter: 13 mm, fluid height: 0.44 mm), the maximal flip angle was also set at 0.23 Rad. 
Note that 0.23 Rad was the maximal angle for which the basolateral compartment retained 
fluid contact. The shaker was set to rotate at 1 cycle/sec, leading to a characteristic shear stress 
of 0.026 Pa or 0.26 Dyn/cm2. As a control, cells were cultured under static conditions in the 
same incubator.
immunocytochemistry
Cells cultured on Transwell® membranes were washed twice with pre-warmed Hank’s Bal-
anced Salt Solution (HBSS) (Gibco, Life, Technologies, Bleiswijk, the Netherlands). Then 
the ciPTEC monolayers were fixed for 5 min at room temperature using a fixation solution 
containing 2% (w/v) Paraformaldehyde, 4% (w/v) sucrose in HBSS. Subsequently the cell 
monolayers were washed twice in wash buffer; 4% (w/v) FCS, in HBSS. The cell layer was 
permeabilized using HBSS containing 0.3% (w/v) Triton, and again washed in wash buffer 
for 5 min. After blocking the samples for 30 min in block solution (HBSS containing 2% (v/v) 
FCS, 4% (w/v) BSA and 0.1% (w/v) Tween20), the samples were incubated overnight at 4°C 
with Acetyl-α-Tubulin antibody 1:500 (Acetyl-α-Tubulin (Lys40) (D20G3) XP® Rabbit, Cell 
Signaling, BioKe, Leiden, The Netherlands) added apical in block solution. The next day, after 
three subsequent washing steps (10 min), the filters with the cell monolayers were cut out 
of the Transwell® insert. The second antibody goat anti-rabbit Alexa 568 (Life Technologies, 
Bleiswijk, The Netherlands) was diluted 1:200 in block solution, and incubated for 30 min 
with 30 µL per membrane. For double staining with either the tight junction protein ZO-1 or 
RPGRIP1L the RPGR interacting basal body protein (affinity purified guinea pig-anti-RP-
GRIP1L (SNC040)) previously described by Arts et al. [20]. Membranes were incubated for at 
least 60 min at room temperature, with this first antibody diluted to 1:50 or 1:500 respectively. 
The second antibody Goat anti Rat Alexa 488 (FITC) or goat anti guinea pig were added at a 
1:200 dilution (Life Technologies, Bleiswijk, The Netherlands). Subsequently, the membranes 
were washed and the nuclei stained with DAPI 1:1000 in block solution (Molecular Probes, 
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Life Technologies, Bleiswijk, The Netherlands). After a final washing step, the membranes 
were mounted on slides with the monolayer facing up, and covered with a cover glass. The 
immunofluorescence was imaged using the Olympus FV1000 Confocal Laser Scanning 
Microscope (Olympus, Hamburg, Germany). Monolayer height was calculated after imaging 
the cell monolayer in a z-stack, by subtracting the initial height at the level of the polyester 
membrane from the endpoint, i.e. the final image at which the immunofluorescent signal 
was still detectable. Cilia length was quantified by determining the distance between the 
RPGRIP1L signal and the ciliary tip, for at least 5 independent z-stack images per condition. 
The cilia length was calculated using the neurite tracer option from the segmentation plug-in 
present in the ImageJ software (ImageJ 1.46r, NIH, USA).
Transepithelial resistance determination
Transepithelial resistance of matured ciPTEC monolayers on Transwell® inserts was measured 
using the Millicell electrical Resistance volt-ohm system (Millipore, Billerca, USA). Measure-
ments were performed as described in the manufacturer’s protocol.
qPcr
Total RNA was isolated using TRIzol (Life, Technologies, Bleiswijk, the Netherlands) 
and chloroform extraction according to the manufacturers’ protocol. 2 μg of total RNA 
served as a template for single-strand cDNA synthesis in a reaction using oligo (dT) and 
random primers in a M-MLV reverse transcriptase reaction mixture (Catalog #28025-013, 
Invitrogen, Bleiswijk, The Netherlands) according to the manufacturers’ protocol (Doc. 
Rev: 100702). The mRNA expression levels were detected using gene specific primer-
probe sets MATE1 (SLC47A1, hs00217320_m1), MATE2k (SLC47A2, hs00945650_m1), 
OCT1 (SLC22A1, Hs00427552_m1), OCT2 (SLC22A2, hs01010723_m1), OCT3 (SLC22A3, 
Hs01009568_m1), OATP4C1 (SLCO4C1, hs00698884_m1) and TaqMan Universal PCR 
Master Mix (all obtained from Applied Biosystems, CA, USA). The CFX96 Real Time PCR 
system (Bio-Rad Laboratories, Veenendaal, The Netherlands) was used to perform the qPCR 
reactions and data was analyzed using the CFX ManagerTM software (Bio-Rad Laboratories, 
Veenendaal, The Netherlands). The reference gene GAPDH was used to normalize the mRNA 
expression levels. Data are expressed as fold increase ± standard range compared to ciPTEC 
cultured under static conditions.
asP+ uptake assay
ASP+ uptake by ciPTEC was measured as described before [9]. In short, OCT activity 
was measured in freshly harvested matured cell suspensions by addition of 100 µM of the 
fluorescent OCT substrate ASP+ in HEPES-TRIS (Hepes-Tris (10 mM), NaCl (132 mM), 
KCl (4.2 mM), CaCl2 (1 mM), MgCl2 (1 mM), D-glucose (5.5 mM), pH was set to 7.4 using 
1.5 M Tris in MQ, 37°C) buffer at 37°C [5,21]. The fluorescence intensity was monitored on a 
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Cytofluor 4000 Fluorescence/Bioluminescence Reader (excitation 485 nm, emission 590 nm) 
for the complete incubation period. ASP+ uptake was calculated by subtracting the initial 
fluorescence at t=0 from the endpoint.
Transepithelial creatinine transport assay
Transepithelial transport of [14C]-creatinine by matured ciPTEC monolayers cultured on 
polyester Transwell® inserts was measured. Mature cell monolayers were washed in modified 
Krebs-Henseleit buffer (Sigma-Aldrich Co., Zwijndrecht, the Netherlands) including 10 mM 
Hepes (pH was set to 7.4 using 1M HCL solution). Subsequently, all membranes tested were 
pre-incubated for 2 h at 37°C, 5% (v/v) CO2 in Krebs-Henseleit-Hepes buffer (0.5 mL apically, 
1.5 mL basolaterally). Transport was initiated by the basolateral addition of either [14C]-
creatinine (0.75 µM, 2 μCi/ml) or [3 H]-inulin (0.45 µM, 20 μCi/ml) with or without digoxin 
(10 µM) or cimetidine (100 µM) as competitors for organic cation transport (Sigma-Aldrich 
Co., Zwijndrecht, the Netherlands). At the start of the measurement, a 20 μL reference sample 
was taken from the basolateral exposure compartment. After 15 and 30 min of incubation with 
gentle agitation at 37°C a 200 μL sample was removed from the apical chamber. The activity 
of [3H] and [14C] in the samples was determined by liquid scintillation counting (Beckman). 
Fluxes of [14C]-creatinine or [3H]-inulin were determined for each separate Transwell®. The 
flux of [3H]-inulin was used as an internal leakage marker. The basolateral to apical flux (J) 
was calculated with the following formula:
J =  dQ
S*dt (1)
where dQ = amount transported [pmol]; dt = duration of transport [min]; S = surface area 
[cm2].
Toxicity assay
An (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability as-
say was performed to measure cellular toxicity of the compounds tested [22]. In short, cells 
were seeded onto culture dishes as described and cultured at 37°C for 7 days, under shaking or 
static conditions. The culture medium was then removed and the cells were exposed for 24 h 
to a UT mixture dissolved in culture medium at a concentration range from 1 to 1,000 fold 
the concentration reported in uremic patients. After incubation, the medium was changed 
to 5 mg/ml MTT in PBS and the plate was incubated for four h at 37°C. The intracellular ac-
cumulated precipitate was solubilized in 200 µL dimethylsulfoxide. The absorbance was read 
using a Dynatech MR 580 plate reader using a wavelength of 570 nm from which background 
was subtracted.
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detection of ros formation
Cells were cultured on 12 well plates as described above. After washing the mature cell layers 
in modified Krebs-Henseleit buffer (Sigma-Aldrich, Zwijndrecht, the Netherlands) including 
10 mM Hepes (pH 7.4), the ROS production was measured using the H2-DCFDA detection 
kit (Invitrogen, Bleiswijk, The Netherlands). This fluorescent probe detects several ROS vari-
ants including hydrogen peroxide, hydroxyl radicals and peroxynitrite. After entering the cell, 
H2DCFDA is converted to the fluorescent 2’,7’-dichlorofluorescein (DCF) due to oxidation by 
ROS. For this assay 1 mM H2-DCFDA was prepared in water-free DMSO (Sigma; D2650). 
This stock was further diluted (in Krebs-Henseleit Hepes buffer, 37°C) to reach a concentra-
tion of 10 µM. ciPTEC were pre-incubated with 500 µl H2-DCFDA (10 µM) for 30 min at 
37°C at 5% CO2 (v/v). After incubation, the cells were washed once in warm Krebs-Henseleit 
Hepes. Subsequently, ciPTEC were treated with 1 mM H2O2 (positive control), 1x, or 10x UT-
mix in Krebs-Henseleit Hepes buffer. Fluorescence detection was performed during 30 min, 
using a Victor X3 fluorescence plate reader at excitation 464 nm and emission 530 nm.
facs analysis
Flow cytometry was used to study the expression of vimentin, a mesenchymal cell marker, 
and the presence of E-cadherin, a calcium-dependent cell-cell adhesion protein present in 
epithelia [23,24]. CiPTEC were seeded as described above in 12-well plates and allowed to 
adhere overnight at 33°C followed by maturation for 7 days at 37°C under shaking or static 
conditions. After this maturation period, cells were treated for 24 h with a cationic UT mix-
ture, viz. spermidine 0.67 µM, spermine 0.09 µM, cadaverine 0.21 µM, putrescine 0.88 µM, 
acrolein 1.42 µM, guanidine 2.18 µM, and methylguanidine 7.66 µM [22,25-28]. CiPTEC 
were harvested using trypsin-EDTA and centrifuged at 600 x g during 5 min. The harvested 
cells were fixed and permeabilized using 4% (w/v) PFA and 0.1 % (v/v) saponin in HBSS 
on ice for 10 min. Supernatant was removed and the cell pellet was resuspended in 100 µL 
PBS containing 1 mL mouse-anti-human Vimentin-PE (Abcam, Cambridge, UK) followed by 
30 min incubation at RT. For E-cadherin staining cell pellets were resuspended in rat anti-E-
cadherin antibody (1:100 in HBSS) and incubated at room temperature for 30 min. Next, cells 
were centrifuged again and pellets were resuspended in goat-anti-rat Alexa 488 conjugate 
(1:200, Life Technologies Europe BV, Bleiswijk, The Netherlands) and incubated at room tem-
perature for 30 min. After a final centrifuge step, cells were resuspended in HBSS buffer and 
measured using a flowcytometer (FACSCalibur BD, software BD CellQuest Pro version 6.0, 
Becton Dickinson, Franklin Lakes, NJ) gating on live cells (a total of 15,000 cells counted). 
Analysis was performed using Flow Jo software (TreeStar, Ashland, USA).
data statistical analysis
Average values are depicted as mean ± SEM. Except for the qPCR data, where values are 
depicted as mean ± standard range. Statistical significance (p<0.05) was calculated using 
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Prism version 6.00 for Windows, GraphPad Software, La Jolla California USA using an 
unpaired t-test or two-way ANOVA followed by Dunnett’s post test where appropriate. ASP+ 
uptake is shown as a percentage of the maximum. Nonlinear regression is calculated using the 
GraphPad Prism one binding-site competition. The presented curves are an average of three 
independent experiments. For the MTT assay, viability was expressed as a percentage of the 
values obtained from untreated control cells within the same experiment. MTT assays were 
performed in triplicate and repeated at least three times.
resUlTs
dynamic cell culture conditions increase ciPTec monolayer height and cilia 
length.
CiPTEC were cultured on collagen IV coated Transwell® polyester membranes, which permits 
the cells to form a polarized monolayer with clear apical and basolateral orientation [6,29]. 
After 7 days of culture, immunofluorescence microscopic analysis of the tight junction pro-
tein ZO-1 was performed (Figure 6.1A). This protein is considered a marker for the integrity 
and polarity of the epithelial cell layer. Both the ciPTEC cultured under static conditions, 
and those cultured on the 2D plate rocker formed a confluent monolayer. Furthermore, we 
examined the expression of primary cilia. Next to villi, primary cilia are important mechano-
sensory organelles that can sense tubular flow [30,31]. Confluent ciPTEC monolayers express 
primary cilia on their apical surface, as shown in Figure 6.1B and C. The α-acetylated tubulin 
network within the cell is visible, but the highest intensity was present in the cilium body. No 
significant differences were observed in the number of ciPTEC expressing cilia when cultured 
under static or dynamic conditions.
To evaluate the effect of dynamic culture conditions on cilia length, an antibody was used 
that specifically targets RPGRIP1L, a protein localized at the ciliary base. The fluorescent 
signal from this protein provided a clear starting point to measure cilia length under both 
culture conditions (Figure 6.1B, C). The monolayer height increased significantly, from 9.7 ± 
5.2 µm to 15.5 ± 4.8 (p<0.005; Figure 6.1D). Dynamic cell culture on a 2D rocker did induce 
the formation of slightly longer cilia (6.9 ± 0.9 µm), compared to statically cultured cells (5.7 ± 
0.4 µm, p=0.01; Figure 6.1E), though no differences were observed in TEER (Figure 6.1F).
Upregulation of membrane transporter mrna expression in dynamically 
cultured ciPTec
The mRNA expression levels of various proximal tubular transport proteins are depicted 
in Figure 6.2. For ciPTEC cultured on a plastic surface, higher expression of organic cation 
transporter 2 (OCT2) was observed when cultured dynamically on a 2D plate rocker (fold 
increase: 3.5 ± 2, p=0.05). Furthermore, ciPTEC grown on the 2D plate rocker expressed 
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figure 6.1: representative images of ciPTec cell morphology, expression of primary cilia, and 
ciPTec epithelial cell characteristics under static or dynamic culture conditions.
(A) Immunofluorescence staining of the tight junction protein ZO-1 (green), α-acetylated tubulin (red) 
and nuclei (blue) after formation of a confluent monolayer magnification 60x. (B) Immunofluorescence 
staining of to visualize primary cilia, stained are α-acetylated tubulin (red) and the basal body protein 
RPGRIP1L (green), magnification 40x. (C) Zoom of cross-sectional views z-section images, stained 
were α-acetylated tubulin (red) and the basal body protein rp-grp (green). Note the apical localization 
of the primary cilia. (D) ciPTEC monolayer heights measured by confocal microscopy in z-sectioned 
images (N≥16 membranes). (E) Cilia length measured in z-stacked images using the RPGRIP1L basal 
body as starting point (N=8 confocal images). (F) Transepithelial electrical resistance measurements 
(N=12 membranes). Values are given as mean ± SEM *p<0.05, **p< 0.01.
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increased mRNA levels of multidrug and toxin extrusion protein 1 (MATE1) (fold increase: 
2.1 ± 0.6, p=0.02). Remarkably, when the same experiment was performed with ciPTEC 
cultured on polyester Transwell® membranes, a significant increase was also observed for 
MATE1, MATE2K, solute carrier organic anion transporter family member 4A1 (SLCO4C1), 
and OCT1 (Figure 6.2).
increased transmembrane organic cation transport by ciPTec cultured on a 2d 
plate rocker
Next, we evaluated if the observed increased transporter expression translated to enhanced 
organic cation uptake. Using a fluorescence-based method, the uptake of the substrate ASP+ 
was evaluated [21,32]. Figure 6.3A demonstrates the concentration dependent ASP+ uptake, 
which increased up to 151 ± 28% (p<0.05) in matured ciPTEC cultured under shaking con-
ditions compared to statically cultured ciPTEC. Inhibition of ASP+ uptake with the potent 
inhibitor tetra-pentylammonium (TPA) resulted in a maximum inhibition of 75%.
Transepithelial transport of [14C]-creatinine was measured in presence and absence of 
cimetidine and/or digoxin, known inhibitors of organic cation transporters (OCTs, MATEs), 
and SLCO4C1, respectively [7,9,33-35]. Figure 6.3B presents the transmembrane flux of 
[14C]-creatinine (0.75 µM) and [3H]-inulin (0.45 µM) by ciPTEC cell monolayers. The para-
cellular leakage of [3H]-inulin across the monolayer was used as an indicator of monolayer 
tightness since passive diffusion is the primary mode of transport for this compound [36]. 
The creatinine flux through the ciPTEC monolayers cultured under shaking conditions (2.9 ± 
0.4 pmol min-1cm-2) was 1.4x higher than the flux (2.1 ± 0.4 pmol min-1cm-2) measured under 
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figure 6.2: cells cultured on a 2d plate rocker show increased mrna expression levels of important 
cation influx (oaTP4c1, ocT1, ocT2) and efflux (maTe1, maTe2k) transporters. Expression 
was measured in ciPTEC cultured on a 12 wells culture plate (■, PL) or in ciPTEC monolayers cultured 
on Transwell® membranes (o, TW). Average results are shown of three separate measurements in dupli-
cate, values are given as mean ± standard range *p<0.05, **p< 0.01.
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static conditions (p<0.001). The creatinine flux was significantly decreased by addition of 
cimetidine (static: 17%, p<0.005, shaken: 25% p<0.001), indicating active transport of creati-
nine. For the ciPTEC monolayers cultured under dynamic conditions, addition of digoxin, 
a selective inhibitor of the SLCO4C1 transporter, further stimulated inhibition of creatinine 
transport (41%, p<0.005). Maximal inhibition (44%, p<0.005) was reached when the combi-
nation of cimetidine and digoxin was applied. The inulin leakage was similar between the two 
conditions, indicating comparable cellular monolayer integrity.
cationic UTs show decreased viability in dynamically cultured cells
Since OCT expression and functionality increased in ciPTEC cultured on a 2D plate rocker, 
we investigated whether a selection of cationic UTs affected the viability of these cells under 
shaking or static conditions. Previously, this selection of UTs showed to inhibit OCT medi-
ated transport in ciPTEC, likely due to competitive inhibition [7]. Here, we exposed ciPTEC, 
either statically or on a plate rocker, to a mixture of toxins (UTmix) comparable to 1000, 100, 
10, 1, 0.1 and 0.01 times the uremic plasma concentrations reported in literature; viz. spermi-
dine 0.67 µM, spermine 0.09 µM, cadaverine 0.21 µM, putrescine 0.88 µM, acrolein 1.42 µM, 
guanidine 2.18 µM, and methylguanidine 7.66 µM [25-28]. After 24 h of incubation with the 
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figure 6.3: ciPTec cultured on a 2d plate rocker show increased organic cation transmembrane 
transport.
(a) Concentration-inhibition curves of ASP+ uptake by tetra-pentylammonium (TPA), in ciPTEC cul-
tured on a shaking (▼) platform or under static (■) conditions. Values are given as mean ± SEM de-
scribed as percentage of ASP+ uptake. Presented curves are an average of three independent experi-
ments. (b) Basolateral to apical fluxes of [14C]-creatinine (0.75 μM, white) and [3 H]-inulin (0.45 μM, 
grey) across ciPTEC monolayers cultured on collagen IV coated Polyester Transwell® membranes, using 
a 2D plate rocker (dashed) or under static conditions (clear). Measurements were performed in the pres-
ence or absence of the inhibitors cimetidine (Cim, 100 µM) or digoxin (Dig, 10 µM). Data are presented 
as mean ± SEM, N=3. Statistical significance: between static and shaking conditions, or between the 
cells cultured on a shaking platform *** p<0.005.
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UT mixture, cells cultured on the rocking platform proved more sensitive to its toxic effects 
(Figure 6.4). The IC50 value calculated from the inhibition curve was significantly higher for 
the statically cultured cells (IC50: 27.9 ± 2.7 times the UTmix) compared to shaking conditions 
(IC50: 16.8 ± 2.3) (p<0.01).
no increase in ros production.
Since it is known that dynamic culture conditions can promote ROS formation [37], CM-
H2DCFDA measurement was performed. Basal ROS production did not differ between the 
two culture conditions (Figure 6.5). After addition of the ROS inducing agent H2O2, a time 
dependent ROS production was measured. Although the overall ROS production in the dy-
namically cultured cells appeared higher than under static conditions, the difference was not 
statistically significant (p=0.06). ROS production after exposure to the 1x or 10x mixtures of 
UTs for 30 min did not differ from the unexposed cells. Furthermore, dynamic cell culture in 
the presence or absence of UTs had no significant effect on vimentin or E-cadherin expression 
levels (data not shown).
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figure 6.4: ciPTec viability after 24h of exposure to a UT mixture under shaking (□) or static (●) 
conditions.
CiPTEC were exposed to mixtures of selected cationic UTs. Toxin concentrations were taken at 1000, 
100, 10, 1, 0.1 and 0.01 fold the uremic plasma concentrations reported in literature [25-28]. Viability 
was determined by the MTT assay, performed in triplicate. Results are shown as mean values ± SEM.
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discUssion
In an effort to elucidate the effects of simulated shear stress on ciPTEC monolayer quality, as 
well as the transepithelial creatinine transport capacity of the proximal tubular epithelial cell 
monolayer, we simulated shear stress by culturing ciPTEC on a 2D plate shaker. By using this 
method to induce fluid flow on the epithelial surface, mRNA expression of various transport 
proteins, as well as the transepithelial creatinine membrane transport increased. Furthermore 
we observed enhanced sensitivity to cationic UTs in cells cultured on the 2D plate shaker.
Cell models are commonly used to simulate and study processes taking place in organ 
systems in the human body. Culture methods are constantly being refined to enhance cellular 
properties to better approximate the physiological situation. During the last 30 years, various 
in-vitro culture systems have been developed that would provide suitable supports for the 
formation of epithelial monolayers. More advanced culture systems aim to include an element 
of flow to produce shear stress comparable to the physiological situation; thereby stimulating 
further differentiation of cultured cells. In mouse proximal tubule, a shear force of 1 Dyn/
cm2 has been reported [14]. However, a more recent study that modeled shear in a laminar 
flow chamber based on tubular fluid velocity resulting from single nephron glomerular filtra-
tion rate, reported a much lower mechanical stress of 0.17 Dyn/cm2 [15]. In the present study, 
the 2D-plate rocker was able to simulate a characteristic shear stress on cultured ciPTEC 
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figure 6.5: ros formation by ciPTec monolayers cultured under dynamic or static conditions. 
ROS production was measured using the H2-DCFDA detection kit in: untreated (dashed line) or 
H2O2 treated (solid line) cells cultured statically (black) or on a 2D plate rocker (grey) in the presence 
of the DCFDA probe (8 mg/ml). DCFDA fluorescence is depicted as relative fluorescence units in trip-
licate of three experiments.
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monolayers grown on Transwell® membranes up to 0.26 Dyn/cm2, which is in the range of 
previously reported values. The use of such a shaking platform provides an easy to perform 
method to simulate flow. Multiple conditions can be measured at the same time without the 
use of an intricate setting involving a myriad of pumps, tubings and connectors. Furthermore, 
similar culture dishes and media volumes can be used for the static control situation as for 
the flow stimulated cells, making the conditions highly comparable. However, an important 
limitation that should be taken into account is the lack of unidirectional flow. Various stud-
ies have indicated that bending of the primary cilium relays signals from the extracellular 
compartment into the cell. For the renal tubule, this regulatory process has been shown to 
depend on Ca2+ signaling [38], and the modification of signaling pathways such as WNT 
[39-41], JAK-STAT [42], or mTOR [43]. However, on a 2D plate rocking system, the change in 
direction could also affect cellular signaling processes. It would therefore be very interesting 
to compare the activation of these different signaling pathways under unidirectional and bi-
directional flow conditions. Furthermore, the use of ciPTEC monolayers grown on Transwell® 
inserts on a 2D plate rocking system might be limited to short term exposure experiments, as 
this model does not provide clearance of waste products produced by the cells, which other 
flow devices might offer.
In the present study, dynamic culture conditions increased ciPTEC monolayer height 
and induced lengthening of the primary cilia. Monolayer height is used as a marker for the 
degree of polarization within an epithelial layer, since a well-differentiated proximal epithelial 
monolayer consists of tall columnar cells with a clear apical and basolateral orientation. We 
did not observe any change in the TEER for monolayers cultured on the 2D plate rocker. 
The resistances measured here are comparable to the values reported for confluent PTEC 
monolayers in literature, indicating intact monolayer integrity [44]. The observed lengthen-
ing of the primary cilia on the cell monolayers cultured under flow conditions might indicate 
activation of flow-induced differentiation. That cilia are essential for proper tubular epithelial 
morphology was shown in studies of polycystic kidney disease (PKD). In PKD, ciliary short-
ening and protein defects are key contributors to loss of tubular phenotype and renal cyst 
development [45,46]. Furthermore, studies in mouse and human renal proximal epithelia 
reported primary cilia lengthening during recovery from either ischemia reperfusion injury, 
or acute tubular necrosis [47,48]. A cilium-based signaling pathway was presented, that 
mediates epithelial repair and differentiation necessary to restore a functional epithelial layer. 
This epithelial redifferentiation is proposed to be activated by the return of urine flow, which 
induces increased Ca2+ signaling, activation of non-canonical Wnt and the downregulation of 
both mTOR and STAT6 pathways [49,50]. This flow induced transition from a proliferative to 
a more differentiated cellular state, might also be initiated by inducing fluid flow in ciPTEC 
monolayers. However, further investigation into the activation of these signaling pathways in 
ciPTEC is necessary to evaluate the mechanisms behind flow induced monolayer differentia-
tion.
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Flow induced epithelial redifferentiation may promote an increase in solute transporter 
expression levels. Here we observed increased mRNA expression levels for various organic 
cation transporting proteins, after 7 days of culture under flow conditions. The effect was 
more pronounced in ciPTEC monolayers cultured on semi-permeable Transwell® mem-
branes, which already promote epithelial differentiation into a polarized monolayer. Such a 
stimulating effect of fluid flow on cellular functionality and solute transport was seen before 
in a microfluidic device developed by Jang et al [18]. In the present study bidirectional dy-
namic flow induced a similar enhancement of cation transporter activity. This indicates that 
culturing ciPTEC on a 2D rocker may stimulate organic cation uptake.
Proximal tubular solute uptake is an important first step in the active removal of organic 
solutes from the circulation. However, subsequent apical excretion of these compounds is 
crucial for efficient drug or solute clearance. By measuring the transepithelial transport of 
[14C]-labeled creatinine, we examined if the clearance processes in this ciPTEC model are 
affected by fluid flow. While in clinical practice creatinine is used as a marker for glomerular 
filtration rate, proximal tubular secretion can account for 10 to 20% of urinary creatinine 
excretion [51]. The significant increase in transepithelial transport of this endogenous com-
pound in dynamically cultured ciPTEC monolayers is in line with the observed increased 
mRNA transporter expression levels. The higher efficiency by which both cimetidine and 
digoxin inhibited the creatinine transport in cells cultured under dynamic conditions, further 
support a more active or prominent role of the transport proteins such as OCTs [52] and 
OATP4C1 [35].
Various studies have reported shear stress or fluid flow induced oxidative stress in cultured 
vascular cells [53,54]. The measurement of the oxidation of H2DCFDA by hydroxyl radicals 
or hydrogen peroxide molecules in the present study, indicated that culturing ciPTEC on 
a 2D plate rocker does not significantly stimulate additional production of reactive oxygen 
species. Although UTs are known to promote the formation of reactive oxygen species [37], 
the addition of a cationic toxin mixture did not induce formation of hydroxyl radicals in 
ciPTEC. Based on these findings, the observed viability decrease is therefore unlikely to be 
mediated by oxidative stress. We should, however, take into account that the viability was 
measured by using the MTT viability assay, which is based on measuring mitochondrial func-
tion, while H2DCFDA detects all cellular ROS and does not target mitochondrial functioning 
specifically. Mitochondrial ROS detection, for example by using dihydroethidium (MitoSOX) 
probes, might provide more insight into the specific mitochondrial ROS production. The 
increased sensitivity of ciPTEC to UTs could be related to an increase in epithelial character 
of the monolayer. Tubular epithelial cells are prone to a de-differentiation process known as 
Epithelial to Mesenchymal Transition (EMT). In EMT, tubular epithelial cells develop a more 
fibroblast-like character in response to cellular stress [55,56]. The fibroblast like character 
can render the cell more resistant external assaults, and stimulates migration as well as pro-
liferation [57]. Although fluid flow is thought to stimulate ciPTEC to retain their epithelial 
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characteristics during exposure to UTs, no significant effects on the respective mesenchymal 
and epithelial markers vimentin or E-cadherin were detected after 24 h of exposure, indicat-
ing no induction of EMT by this set of cationic UTs.
The human ciPTEC model is a valuable tool to acquire mechanistic insights in renal clear-
ance of uremic retention solutes. In previous studies, the renal epithelial characteristics and 
cationic toxin handling of this cell model were characterized extensively [5,6,8,9] . Further-
more, science has been exploring the possibilities to utilize the functional properties of renal 
cells, in terms of their active role in the clearance of uremic retention solutes, in an add-on 
device to renal hemodialysis therapy, a bioartificial kidney, or so called Renal Assist Device 
(RAD). Such a RAD would consist of a cassette that contains multiple semi-permeable hollow 
fibers, or membranes, on which tight cellular PTEC monolayers are grown. By attaching such a 
device in series with an existing hemodialysis unit, the dialyzed blood flows over these “living-
membranes”, thereby enabling further active clearance of uremic waste products. Our results 
indicate that the application of fluid flow can improve the RNA expression of various cation 
transporters, cellular sensitivity and increases transepithelial creatinine transport. Though we 
observed increased ciPTEC toxicity after 24h incubation with UTs in 12 wells plates under 
dynamic culture conditions, it would not have to mean similar toxic effects would take place 
in a bioartificial device. The 12 wells plate set up cannot not take into account the presence 
of continuous waste removal, which would be an important feature of a RAD. Furthermore, 
we also observed mRNA up-regulation of various efflux proteins, which could lead to a faster 
clearance of UTs in a continuously perfused system. However, as mRNA levels do not always 
directly correspond to protein expression, it would be sensible to investigate the absolute 
expression levels as well as functionality of these transporters. For accurate measurements of 
the actual intracellular accumulation of these retention solutes, specialized LC-MS/MS based 
techniques may provide a valuable tool in the detection of these compounds.
In conclusion, culturing ciPTEC under fluidic conditions on a 2D plate rocker stimulated 
the endogenous transporter functionality of the cell monolayer. The increased transporter 
expression and transport observed under dynamic culture conditions, indicates that the use 
of a relatively simple system to model fluid flow can have a positive effect on cell function-
ality. Enhancing the endogenous organic cation transport of ciPTECs could make this cell 
line even more interesting to investigate renal clearance processes in pharmacological and 
physiological studies. Furthermore, transepithelial solute transport is an important feature 
in the development of innovative bioartificial renal replacement therapies. The positive effect 
of flow on proximal tubular transepithelial transport could provide an extra rationale for the 
development of a flow based RAD.
Chapter 6
148
acknowledGmenTs
We are grateful to Dr Heleen Arts (Radboud University Medical Centre, Nijmegen, the Neth-
erlands), for making the affinity purified guinea pig-anti-RPGRIP1L (SNC040) available to 
us [20].
149
Dynamic cell culture conditions improve transepithelial cation transport
ch
ap
te
r 6
references
1. Terryn s, Jouret f, Vandenabeele f, smolders i, moreels m, devuyst o, steels P, Van kerkhove 
e. A primary culture of mouse proximal tubular cells, established on collagen-coated membranes. 
Am. J. Physiol. Renal Physiol. 293: F476-485, 2007.
2. Pelis rm, wright sH. Renal transport of organic anions and cations. Compr Physiol 1: 1795-1835, 
2011.
3. moradi H, sica da, kalantar-Zadeh k. Cardiovascular burden associated with uremic toxins in 
patients with chronic kidney disease. Am. J. Nephrol. 38: 136-148, 2013.
4. Vanholder r, smet rd, Glorieux G, dhondt a. Survival of hemodialysis patients and uremic 
toxin removal. Artif. Organs 27: 218-223, 2003.
5. wilmer mJ, saleem ma, masereeuw r, ni l, Van der Velden TJ, russel fG, mathieson Pw, 
monnens la, Van den Heuvel lP, levtchenko en. Novel conditionally immortalized human 
proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res. 339: 
449-457, 2010.
6. Jansen J, schophuizen cm, wilmer mJ, lahham sH, mutsaers Ha, wetzels Jf, bank ra, van 
den Heuvel lP, Hoenderop JG, masereeuw r. A morphological and functional comparison of 
proximal tubule cell lines established from human urine and kidney tissue. Exp. Cell Res. 323: 87-
99, 2014.
7. schophuizen cm, wilmer mJ, Jansen J, Gustavsson l, Hilgendorf c, Hoenderop JG, van den 
Heuvel lP, masereeuw r. Cationic uremic toxins affect human renal proximal tubule cell function-
ing through interaction with the organic cation transporter. Pflugers Arch. 465: 1701-1714, 2013.
8. schophuizen cm, de napoli ie, Jansen J, Teixeira s, wilmer mJ, Hoenderop JG, Van den Heu-
vel lP, masereeuw r, stamatialis d. Development of a living membrane comprising a functional 
human renal proximal tubule cell monolayer on polyethersulfone polymeric membrane. Acta Bio-
mater. 14: 22-32, 2015.
9. schophuizen cm, wilmer mJ, Jansen J, Gustavsson l, Hilgendorf c, Hoenderop JG, van den 
Heuvel lP, masereeuw r. Cationic uremic toxins affect human renal proximal tubule cell function-
ing through interaction with the organic cation transporter. Pflugers Arch. 465: 1701-1714, 2013.
10. ando J, yamamoto k. Flow detection and calcium signalling in vascular endothelial cells. Cardio-
vasc. Res. 99: 260-268, 2013.
11. dewey cf, Jr., bussolari sr, Gimbrone ma, Jr., davies Pf. The dynamic response of vascular 
endothelial cells to fluid shear stress. J. Biomech. Eng. 103: 177-185, 1981.
12. resnick n, yahav H, khachigian lm, collins T, anderson kr, dewey fc, Gimbrone ma, Jr. 
Endothelial gene regulation by laminar shear stress. Adv. Exp. Med. Biol. 430: 155-164, 1997.
13. davies Pf, mundel T, barbee ka. A mechanism for heterogeneous endothelial responses to flow 
in vivo and in vitro. J. Biomech. 28: 1553-1560, 1995.
14. chou cl, marsh dJ. Measurement of flow rate in rat proximal tubules with a nonobstructing 
optical method. Am. J. Physiol. 253: F366-371, 1987.
15. essig m, friedlander G. Tubular shear stress and phenotype of renal proximal tubular cells. J. Am. 
Soc. Nephrol. 14 Suppl 1: S33-35, 2003.
16. duan y, Gotoh n, yan Q, du Z, weinstein am, wang T, weinbaum s. Shear-induced reorganiza-
tion of renal proximal tubule cell actin cytoskeleton and apical junctional complexes. Proc. Natl. 
Acad. Sci. U. S. A. 105: 11418-11423, 2008.
Chapter 6
150
17. duan y, weinstein am, weinbaum s, wang T. Shear stress-induced changes of membrane trans-
porter localization and expression in mouse proximal tubule cells. Proc. Natl. Acad. Sci. U. S. A. 107: 
21860-21865, 2010.
18. Jang kJ, mehr aP, Hamilton Ga, mcPartlin la, chung s, suh ky, ingber de. Human kidney 
proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr. Biol. 5: 1119-
1129, 2013.
19. Zhou X, liu d, you l, wang l. Quantifying fluid shear stress in a rocking culture dish. J. Biomech. 
43: 1598-1602, 2010.
20. arts HH, doherty d, van beersum se, Parisi ma, letteboer sJ, Gorden nT, Peters Ta, marker 
T, Voesenek k, kartono a, et al. Mutations in the gene encoding the basal body protein RP-
GRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. Nat. Genet. 39: 882-888, 2007.
21. wilde s, schlatter e, koepsell H, edemir b, reuter s, Pavenstadt H, neugebauer U, schroter r, 
brast s, ciarimboli G. Calmodulin-associated post-translational regulation of rat organic cation 
transporter 2 in the kidney is gender dependent. Cell. Mol. Life Sci. 66: 1729-1740, 2009.
22. mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation 
and cytotoxicity assays. J. Immunol. Methods 65: 55-63, 1983.
23. ivaska J. Vimentin: Central hub in EMT induction? Small GTPases 2: 51-53, 2011.
24. Hills ce, Jin T, siamantouras e, liu ik, Jefferson kP, squires Pe. ‘Special k’ and a loss of cell-
to-cell adhesion in proximal tubule-derived epithelial cells: modulation of the adherens junction 
complex by ketamine. PLoS ONE 8: e71819, 2013.
25. saito a, Takagi T, chung TG, ohta k. Serum levels of polyamines in patients with chronic renal 
failure. Kidney Int. Suppl. 16: S234-237, 1983.
26. igarashi k, Ueda s, yoshida k, kashiwagi k. Polyamines in renal failure. Amino Acids 31: 477-
483, 2006.
27. de deyn P, marescau b, lornoy w, becaus i, lowenthal a. Guanidino compounds in uraemic 
dialysed patients. Clin. Chim. Acta 157: 143-150, 1986.
28. marescau b, nagels G, Possemiers i, de broe me, becaus i, billiouw Jm, lornoy w, de deyn 
PP. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insuf-
ficiency. Metabolism. 46: 1024-1031, 1997.
29. Jansen J, schophuizen cm, wilmer mJ, lahham sH, mutsaers Ha, wetzels Jf, bank ra, van 
den Heuvel lP, Hoenderop JG, masereeuw r. A morphological and functional comparison of 
proximal tubule cell lines established from human urine and kidney tissue. Exp. Cell Res. 323: 87-
99, 2014.
30. Praetorius Ha, spring kr. The renal cell primary cilium functions as a flow sensor. Curr. Opin. 
Nephrol. Hypertens. 12: 517-520, 2003.
31. Guo P, weinstein am, weinbaum s. A hydrodynamic mechanosensory hypothesis for brush 
border microvilli. Am. J. Physiol. Renal Physiol. 279: F698-712, 2000.
32. schlatter e, monnich V, cetinkaya i, mehrens T, ciarimboli G, Hirsch Jr, Popp c, koepsell H. 
The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. J. Membr. Biol. 189: 
237-244, 2002.
33. mikkaichi T, suzuki T, onogawa T, Tanemoto m, mizutamari H, okada m, chaki T, masuda s, 
Tokui T, eto n, et al. Isolation and characterization of a digoxin transporter and its rat homologue 
expressed in the kidney. Proc. Natl. Acad. Sci. U. S. A. 101: 3569-3574, 2004.
34. Tsuda m, Terada T, Ueba m, sato T, masuda s, katsura T, inui k. Involvement of human mul-
tidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal 
epithelial cells. J. Pharmacol. Exp. Ther. 329: 185-191, 2009.
151
Dynamic cell culture conditions improve transepithelial cation transport
ch
ap
te
r 6
35. mikkaichi T, suzuki T, onogawa T, Tanemoto m, mizutamari H, okada m, chaki T, masuda s, 
Tokui T, eto n, et al. Isolation and characterization of a digoxin transporter and its rat homologue 
expressed in the kidney. Proc. Natl. Acad. Sci. U. S. A. 101: 3569-3574, 2004.
36. Perrone rd. Means of clinical evaluation of renal disease progression. Kidney Int. Suppl. 36: S26-
32, 1992.
37. itoh y, ezawa a, kikuchi k, Tsuruta y, niwa T. Protein-bound uremic toxins in hemodialysis 
patients measured by liquid chromatography/tandem mass spectrometry and their effects on 
endothelial ROS production. Anal. Bioanal. Chem. 403: 1841-1850, 2012.
38. Praetorius Ha, spring kr. Bending the MDCK cell primary cilium increases intracellular cal-
cium. J. Membr. Biol. 184: 71-79, 2001.
39. Goggolidou P. Wnt and planar cell polarity signaling in cystic renal disease. Organogenesis 10: 
86-95, 2014.
40. Gerdes Jm, liu y, Zaghloul na, leitch cc, lawson ss, kato m, beachy Pa, beales Pl, demar-
tino Gn, fisher s, et al. Disruption of the basal body compromises proteasomal function and 
perturbs intracellular Wnt response. Nat. Genet. 39: 1350-1360, 2007.
41. simons m, Gloy J, Ganner a, bullerkotte a, bashkurov m, kronig c, schermer b, benzing 
T, cabello oa, Jenny a, et al. Inversin, the gene product mutated in nephronophthisis type II, 
functions as a molecular switch between Wnt signaling pathways. Nat. Genet. 37: 537-543, 2005.
42. low sH, Vasanth s, larson cH, mukherjee s, sharma n, kinter mT, kane me, obara T, weimbs 
T. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation 
and is activated in polycystic kidney disease. Dev. Cell 10: 57-69, 2006.
43. boehlke c, kotsis f, Patel V, braeg s, Voelker H, bredt s, beyer T, Janusch H, Hamann c, Godel 
m, et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat. Cell Biol. 12: 
1115-1122, 2010.
44. wieser m, stadler G, Jennings P, streubel b, Pfaller w, ambros P, riedl c, katinger H, Grillari 
J, Grillari-Voglauer r. hTERT alone immortalizes epithelial cells of renal proximal tubules without 
changing their functional characteristics. Am. J. Physiol. Renal Physiol. 295: F1365-1375, 2008.
45. lehman Jm, michaud eJ, schoeb Tr, aydin-son y, miller m, yoder bk. The Oak Ridge Polycys-
tic Kidney mouse: modeling ciliopathies of mice and men. Dev. Dyn. 237: 1960-1971, 2008.
46. yoder bk, Hou X, Guay-woodford lm. The polycystic kidney disease proteins, polycystin-1, 
polycystin-2, polaris, and cystin, are co-localized in renal cilia. J. Am. Soc. Nephrol. 13: 2508-2516, 
2002.
47. Verghese e, weidenfeld r, bertram Jf, ricardo sd, deane Ja. Renal cilia display length altera-
tions following tubular injury and are present early in epithelial repair. Nephrol. Dial. Transplant. 
23: 834-841, 2008.
48. Verghese e, ricardo sd, weidenfeld r, Zhuang J, Hill Pa, langham rG, deane Ja. Renal 
primary cilia lengthen after acute tubular necrosis. J. Am. Soc. Nephrol. 20: 2147-2153, 2009.
49. weimbs T. Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the 
function of polycystin-1. Am. J. Physiol. Renal Physiol. 293: F1423-1432, 2007.
50. deane Ja, ricardo sd. Emerging roles for renal primary cilia in epithelial repair. International 
review of cell and molecular biology 293: 169-193, 2012.
51. van acker ba, koomen Gc, koopman mG, de waart dr, arisz l. Creatinine clearance during 
cimetidine administration for measurement of glomerular filtration rate. Lancet 340: 1326-1329, 
1992.
Chapter 6
152
52. filipski kk, mathijssen rH, mikkelsen Ts, schinkel aH, sparreboom a. Contribution of or-
ganic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86: 
396-402, 2009.
53. Hsieh HJ, cheng cc, wu sT, chiu JJ, wung bs, wang dl. Increase of reactive oxygen species 
(ROS) in endothelial cells by shear flow and involvement of ROS in shear-induced c-fos expression. 
J. Cell. Physiol. 175: 156-162, 1998.
54. chin lk, yu JQ, fu y, yu T, liu aQ, luo kQ. Production of reactive oxygen species in endothelial 
cells under different pulsatile shear stresses and glucose concentrations. Lab. Chip 11: 1856-1863, 
2011.
55. Vongwiwatana a, Tasanarong a, rayner dc, melk a, Halloran Pf. Epithelial to mesenchymal 
transition during late deterioration of human kidney transplants: the role of tubular cells in fibro-
genesis. Am. J. Transplant. 5: 1367-1374, 2005.
56. bolati d, shimizu H, Higashiyama y, nishijima f, niwa T. Indoxyl sulfate induces epithelial-
to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am. J. Nephrol. 34: 
318-323, 2011.
57. saxena m, stephens ma, Pathak H, rangarajan a. Transcription factors that mediate epithelial-
mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death 
Dis. 2: e179, 2011.


7 
Discussion

157
General discussion
ch
ap
te
r 7
inTrodUcTion
The renal proximal tubule is a versatile part of the nephron, which plays a crucial role in the 
active secretion and reuptake of numerous exogenous as well as endogenous compounds. 
These processes are mediated by a wide variety of transport proteins, present in the baso-
lateral and apical membranes of proximal tubule epithelial cells (PTEC). During chronic 
kidney disease (CKD), renal transport processes become disturbed, resulting in the systemic 
accumulation of waste products. The increase in knowledge on the uremic retention solutes 
that accumulate in CKD patients broadens our understanding of renal disease etiology and 
disease progression. These insights stimulate investigations towards improving the removal 
of specific uremic retention solutes by renal replacement therapy. To this end, we studied the 
handling and transport of cationic uremic solutes by ciPTEC. In this chapter, the implications 
of these findings are discussed and placed in the perspective of future research towards kid-
ney functioning and the possible development of a bioartificial kidney or renal assist device 
(RAD) for the treatment of CKD.
oPTimiZinG renal cell models To sTUdy clearance 
Processes in THe naTiVe kidney
Renal cell models are widely employed to study renal clearance and physiology [1-3]. While 
in-vivo studies are often indispensable for providing insight into the clinical relevance of 
observations made with in-vitro techniques, they are not as easily controlled. Interspecies 
variability and extrarenal influences, such as body temperature, hormone levels, nervous 
regulation, hemodynamics, and glomerular filtration rate (GFR), can complicate the inter-
pretation of the data. By making use of in-vitro models, many of these factors are taken out 
of the equation and enable the study of very specific processes in a high throughput fashion. 
Depending on the level of preservation of renal functionality, cell models can help in unravel-
ing renal physiology and clearance processes, and mechanisms leading to renal toxicity and 
failure. Furthermore, these cell models might prove useful in novel bioartificial treatment 
applications.
To study the function of renal cells in-vitro, cell models should reflect renal physiology. It 
is therefore essential to characterize the nephron-specific properties, such as polarized trans-
port, reuptake of solutes, and the formation of tight monolayers, in both established and novel 
cell lines. While established human renal epithelial cell lines, such as HK-2 or HEK293, are 
frequently employed in the study of renal processes [4,5], their low (endogenous) transporter 
expression levels make these models less suitable for tissue engineering purposes [6,7]. More 
recently, a conditionally immortalized human PTEC cell line (ciPTEC) was developed from 
human urine samples by Wilmer et al. [8]. This ciPTEC model expresses several functional in- 
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and efflux transporters, and can perform active albumin and sodium-dependent phosphate 
uptake. Due to its functional proximal-tubular characteristics and relative ease of obtaining 
large cell numbers, this cell model was used as a tool in studying renal pathophysiology [9,10], 
metabolism [11] and transport pathways (Chapters 3-6). As ciPTEC originated from exfoli-
ated cells isolated from a human urine sample, it may be argued that they would not make 
the ideal source for the establishment of a PTEC model. However, our functional and mor-
phological comparison between the established ciPTEC line and two newly immortalized cell 
lines obtained from kidney tissue, revealed comparable functional characteristics (Chapter 
2). The differences between these cell lines were found mainly in cell size and extracellular 
matrix (ECM) gene expression levels. The observed lower collagen I and -IV α1 expression 
in the cell lines originating from urine as compared to tissue-derived ciPTEC, may have been 
the result of the exfoliation process preceding their excretion [12,13]. This finding stresses 
the importance of primary cell source and isolation method on cell line characteristics. The 
somatic cell from which immortalized cell lines were developed, could have influenced the 
in-vitro characteristics of differentiated cells through epigenetic processes [14]. Epigenetic 
effects have been observed in pluripotent stem cell research, where the transient epigenetic 
memory of the somatic cells of origin influenced differential gene expression and altered dif-
ferentiation capacity [15]. As described in this thesis, methods to screen potential cell lines 
for tissue specific characteristics involves the use of a large variety of testing methods and can 
therefore be time consuming. In Chapter 2, the ciPTEC cell lines were characterized using a 
combination of gene and protein expression arrays, immunocytochemistry, and functional 
tests. These methods provided important information about the type and quality of the cell 
lines developed. However, the (limited) availability of specific antibodies to detect the expres-
sion levels of cell-type specific proteins hampers true identification. Proteome profiling, a 
recent development in cell type identification, might in future simplify the optimization of 
the cell system [16]. This technique is not dependent on antibody availability, specificity or 
quality [17], and could potentially be used to examine both the type, variant and quantity of 
transporters expressed in the models [18].
in vitro culture conditions
Next to the selection of a well-characterized and functional cell type, cell culture conditions 
are key factors in studying renal clearance processes. In current practice, cells are mostly cul-
tured statically and on plastic surfaces. Though these conditions are hardly organotypic, they 
often provide satisfactory results. However, for the development of a bioartificial RAD, stud-
ies on directional transepithelial clearance processes may be very important. While Chapters 
3 and 4 have shown that uptake of organic cations can be modeled in cell suspensions or on 
cell monolayers grown on plastic surfaces, the examination of transepithelial (uremic) solute 
transport required the use of a polarized cell system. By culturing monolayers of epithelial 
cells on semi-permeable membranes, such a polarized system can be obtained (figure 7.1). 
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The semi-permeable culture substratum, consisting of the ECM and the physical tissue culture 
support, has been identified as an important factor in influencing cell shape, size, attachment 
and degree of differentiation [19-24]. By culturing epithelial cell monolayers on specialized 
permeable surfaces, the functional differentiation of epithelial cells could be increased [25,26]. 
Commercially available polyester or polycarbonate semi-permeable surfaces are often used in 
the study of polarized cell systems [27]. However, as these materials are designed to promote 
ECM deposition and cell attachment, they are less suitable for application in a clinical device. 
Therefore, hemocompatible materials that are used in dialysis and/or blood purification 
therapy would provide promising alternatives. Several studies evaluated polyethersulfone 
(PES), polysulfone (PSF), polyacrylonitrile (PAN) and cellulose acetate membranes for their 
ability to support monolayer growth of renal epithelial cells [28-30]. In Chapter 5 we showed 
that ciPTEC are able to form polarized and functionally active cell monolayers on PES-based 
semi-permeable dialysis membranes by making use of an optimized coating, consisting of a 
thin adherent poly-dopamine (PDA) film to which the biomolecule collagen IV was cova-
lently bound. This double-coating strategy promoted cell attachment to the surface of the 
dialysis membrane [31]. The principle of membrane bioactivation for the development of 
renal epithelial monolayers had been described previously [32-34]. However, careful evalua-
tion of the membrane properties before and after coating was necessary, as addition of these 
extra layers should not obstruct the pores of membrane. In the case of the optimized coating 
as described in Chapter 5, the PES membranes tested retained permeance, and facilitated 
functional transepithelial transport of creatinine, with minimal passive inulin diffusion. In 
fact, we were able to show functionality of the transepithelial creatinine secretory pathway in 
confluent ciPTEC monolayers grown on these optimized PDA and collagen IV coated PES 
membranes (figure 7.1).
figure 7.1 schematic overview of the Transwell® set up.
Set up as used for the examination of basolateral to apical creatinine transepithelial transport and inulin 
leakage across ciPTEC monolayers. Radiolabeled substrates are indicated with the radioactive trefoil 
symbol, with the arrows indicating the direction of transport.
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The current set up for such a RAD would consist of a cassette containing multiple semi-
permeable PES-based hollow fibers, or membranes, on which tight cellular PTEC monolayers 
are grown (Figure 7.2). By attaching such a device in series with an existing hemodialysis unit, 
the dialyzed blood flows over these “living-membranes”, thereby enabling active secretion of 
uremic waste products. Altering the culture conditions to a more dynamic and organotypic 
set up is known to stimulate cell differentiation [35]. As shown in Chapter 6, the application 
of fluid flow improves the expression of various cation transporters, cellular sensitivity and 
increases transepithelial creatinine transport. These findings suggest that the introduction 
ciPTEC to apical shear-stress can stimulate further differentiation of this cell type. The rock-
ing system used is a simplified model for simulating epithelial fluid flow. Though flow can 
be simulated easily in such a rocking model, it cannot provide unidirectional or continuous 
perfusion. Various sophisticated microfluidic culture systems are currently being developed 
that permit continuous perfusion of culture media over cellular monolayers [36-38]. The use 
of these systems for the culture of epithelial cells could further stimulate differentiation and 
maintenance of an in-vivo like state over prolonged periods [39]. Though we obtained promis-
ing results using our simplified 2D rocking model, additional research is required to examine 
if living ciPTEC membranes are able to withstand unidirectional fluid flow whilst keeping 
the monolayer intact to prevent leakage. Furthermore, would be important to determine the 
functionality and clearance capacity of ciPTEC inside a bioreactor or RAD prototype, both 
during short term and long term culture.
Uremic solUTe HandlinG by ciPTec
In the healthy kidney, the clearance of many of the protein bound solutes occurs with high 
efficiency through active secretion [40]. However, over 150 solutes have been identified to 
accumulate systemically in patients suffering from ESRD [41,42]. Increasing knowledge on 
the importance of uremic waste product accumulation in the progression of CKD has led 
to an interest in the renal handling of uremic solutes. As described in Chapter 1, basolateral 
uptake and apical efflux are crucial for proximal tubular transepithelial secretion processes. 
Harnessing these functions to allow removal of uremic solutes from the circulation in a RAD 
requires insight in their cellular handling.
Uptake of uremic solutes
CiPTEC express a myriad of proximal tubular characteristics, as illustrated in Chapter 2. 
Functionality was shown for a variety of endogenously expressed organic solute transporters, 
such as OCT2, P-gP, MRP4 and BCRP. Their presence makes it possible to examine physi-
ological transport processes. However, a drawback of the ciPTEC model used, is the absence 
of the organic anion transporters OAT1 and OAT3. In cultured proximal tubule epithelial 
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cells, rapid loss of OAT expression is commonly observed [43]. Their endogenous expression 
has not been observed in a PTEC line so far. Therefore, studies regarding the functional-
ity of these transporters rely mostly on overexpression systems [44]. For the development 
of a bioartificial RAD, their absence is also considered a substantial limitation, because of 
their recognition as important transport proteins in the removal of anionic solutes [45,46]. 
However, such changes in phenotypic expression may be turned into an advantage when a 
specific detail of a complex process is studied. For instance, if a uremic solute is taken up by 
several carriers in-vivo, the absence of one of them in a cell line allows studying the other(s) 
more selectively. Though the eventual translation of results to the physiological situation will 
become more challenging.
CiPTEC express a functional set of endogenous organic cation transporters. Chapter 3 de-
scribes the validation of a cell suspension-based method, by which inhibition of the OCTs 
by uremic waste products was detected. The use of such a method enables testing of a range 
of solutes in a high throughput way, while keeping cellular integrity intact. For investiga-
tions towards transporter functionality this method has proven very effective [47-49]. As 
described in Chapter 3, uremic toxins (UTs) belonging to the group of guanidino compounds, 
polyamines, and the breakdown product acrolein, interfere with OCT-mediated uptake in 
ciPTEC (Chapter 3). Acrolein, a polyamine oxidation product [50-52], was the only solute for 
which a complete inhibition curve could be obtained. Acrolein inhibited the influx process in 
a competitive way. These observations suggest that endogenous OCTs expressed by proximal 
tubular cells can functionally mediate the influx of cationic UTs.
Similar findings have been reported for the proximal tubular transport of anionic uremic 
solutes. In 2012, Uwai Y et al. reported interaction of kynurenic acid with human organic 
anion transporters hOAT1 and hOAT3 [46]. More recently, p-cresyl sulfate was reported to 
be a good substrate for hOAT1 and hOAT3 [53]. In ciPTEC, because of the OATs’ absence, 
the uptake of these compounds is likely fully dependent on diffusion or on the endogenously 
expressed SLCO4C1 transporter [54]. In 2009, Toyohara et al. illustrated the importance of 
the renal SLCO4C1 transporter in the elimination of UTs thereby attenuating hypertension 
and renal inflammation [55]. In rats, SLCO4C1 overexpression decreased plasma levels of the 
cationic UTs guanidino succinate, asymmetric dimethylarginine, and trans-aconitate.
Transmembrane transport
While uptake of organic retention solutes through transporters, such as OCT and SLC04C1 is 
the first step in the removal of organic solutes from the circulation, their secretion into the 
tubular lumen is dependent on the collaboration between the basolateral influx transporters 
and proper functioning of apical efflux transporters. Various studies reported active tran-
sepithelial transport of endogenous compounds or xenobiotics, such as creatinine, digoxin, 
metformin and cimetidine [56-59]. However, limited data are available that describe in-vitro 
transepithelial uremic solute transport by human PTEC monolayers. The most common 
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approach to study this type of transport, is to use radiolabeled drugs such as verapamil or 
metformin, as model compounds [58,60]. For example, Brown et al. reported transepithelial 
fluxes of the prototypic model substrates PAH and creatinine by primary PTEC [56]. 
The observed active transepithelial creatinine transport described in Chapter 5 indicates 
the presence of functional endogenous organic solute secretion processes in ciPTEC. Fur-
thermore, with inulin as a leakage marker, cell monolayer tightness was confirmed, since 
active transcellular transport has not been reported for this compound [61]. However, further 
insight in the removal of specific cationic (and anionic) uremic waste products is necessary to 
evaluate if ciPTEC grown on PES-50 surfaces could potentially be used in the clinic. Applica-
tion of sophisticated bioanalysis techniques, such as LC-MS/MS, might provide opportunities 
for the transepithelial transport measurements of a large number of uremic solutes by ciPTEC 
monolayers [62-64].
investigating monolayer functionality under uremic conditions
As shown in Chapter 4, exposure of ciPTEC to a uremic milieu can initiate production of 
IL-6, IL-8 and ET-1, indicating the commencing of an inflammatory response. Inflammation 
is often observed in patients suffering from ESRD, and uremia has been identified as an im-
portant causative factor [65-67]. In ciPTEC, ET-1 was found to differentially regulate organic 
cation uptake through the ET-1-ET-B receptor axis. Both inducible nitric oxide (iNOS); a 
known mediator of local inflammatory responses during endotoxemia [68,69], and protein 
kinase C (PKC), were identified as important signal transducers. These mediators attenuated 
the ET-1 induced inhibition of organic cation uptake after 30 min, but had no effect after 24 h. 
These observations were reminiscent of both the biphasic and NO-independent pathways de-
scribed for the efflux transporter P-gp [70,71]. For P-gp, a second pathway, next to NO medi-
ated regulation, was identified involving activation of Toll-Like Receptor 4 and translocation 
of NF-κB [70,71]. Further research would be warranted to investigate whether (cationic) UTs 
could also regulate proximal tubular transport processes through this pathway. Recent studies 
have already reported down-regulation of SLCO4C1 transporter expression after exposure to 
the anionic uremic solutes indoxyl sulfate, p-cresyl-sulfate and p-cresyl glucuronide [72]. On 
the other hand, the upregulation of efflux transporters, such as BCRP, was reported after 48 h 
of exposure to these compounds [72,73]. Such regulatory effects are thought to be part of a 
renal protective mechanism, which has also been observed upon exposure of renal cells to 
nephrotoxicants [69,74,75]. Taken together, our findings indicate that uremic solutes should 
be considered as more than just substrates. They are able to influence ciPTEC functional-
ity not only by (competitive) inhibition of transport, but also through secondary regulatory 
pathways.
These observations, together with the observed toxicity of UT mixtures (Chapter 3) ra-
tionalize the need for further research towards ciPTEC monolayer stability under uremic 
conditions. A known phenomenon that should be taken into account in renal epithelial cells 
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exposed to uremic stress and inflammatory mediators, is epithelial-to-mesenchymal transi-
tion (EMT). Rastaldi et al. [76] detected the occurrence of proximal tubular EMT in human 
renal biopsies of different renal diseases. In-vitro studies have indicated that this process 
also occurs during uremic toxin exposure in experimental set ups, and thereby reduces the 
epithelial and transport characteristics of the epithelial cell lines tested [72,77,78]. No EMT 
was observed in the research described in this thesis, but cells were exposed to a selection of 
cationic uremic retention solutes in an experimental setting. Hence, it would be prudent to 
examine the effect of ciPTEC exposure to human uremic plasma, as uremic plasma comprises 
a much more complex mixture of organic and anorganic solutes. Furthermore, various stud-
ies are being set up in order to overcome EMT, and stimulate the maintenance of an epithelial 
phenotype of renal cells in culture. One strategy might be to utilize the mechanism that was 
discussed by Al-Lahham et al. [79]. In that study, a positive effect of culture media hyperto-
nicity was demonstrated. Their findings suggested that stimulation of the tonicity-responsive 
enhancer binding protein (TonEBP) could be used to maintain the epithelial phenotype of 
renal epithelial cells in culture.
Another sophisticated strategy for the improvement of monolayer stability, could involve 
the incorporation of bio-active molecules into the membrane scaffold [80]. In such bioactive 
membranes supramolecular polymers are used, which assemble into nano-fibers. Meshes are 
then formed by electro-spinning [81]. The bioactivity is incorporated in these nano-fibers by 
the addition of different ECM-peptides, such as collagen I, IV, fibronectin, and laminin, for 
stable binding [82]. In a study by Dankers et al. [83], tight and functional primary human re-
nal tubular epithelial cell monolayers could be maintained on such bioactive meshes during a 
19 days culture period. Incorporation of specific bioactive compounds into membranes could 
also be used to stimulate antifouling and cell differentiation. However, this type of membrane 
would also require optimization for the culture of renal proximal tubular cells such as ciPTEC.
Towards clinical aPPlicaTion
The proof of concept regarding ciPTEC monolayer function on coated flat PES membranes is 
the preliminary step towards the development of intricate prototype bioartificial devices made 
with bundles of multiple hollow fibers (figure 7.2). However, a long road of research lies ahead 
of us before such a concept can be applied in a pre-clinical or clinical setting. Integration of 
both synthetic and biological components into a single device brings along many challenges 
regarding the design, engineering, its functionality and durability, and can be associated with 
safety concerns.
The development of cell-based treatments in the field of tissue engineering is still gaining 
in popularity [84,85]. Somatic cell therapy medicinal products, gene therapy medicinal prod-
ucts, and tissue-engineered products are being developed for a wide variety of defects and 
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illnesses. These “advanced therapy medicinal products” (ATMPs) will have to be approved by 
the various international regulatory boards, prior to marketing [86]. ATMPs need to follow 
strict regulation with regard to the origin of cells, the level of cell manipulation, extent of 
replication competence of viruses, long time functionality, ability to proliferate or differenti-
ate, to initiate an immune response, the risk of oncogenicity, in-vivo potency, and mode of 
administration or use. It might seem premature to consider these aspects in such an early 
stage, as the aim of this work was to examine the transport and uremic solute handling by 
ciPTEC. However, during the research phase it is still relatively easy to apply and test changes 
to the system. If we recognize what is possible in a simple system, we can start to translate 
these findings into a more complex arrangement and, eventually, utilize this knowledge for 
the development of an artificial device.
safeTy asPecTs of GeneTically modified cells
A tissue-engineered bioartificial kidney or RAD, designed as a combined ATMP, would 
consist of a medical device, which follows the same basic principles as a dialysis unit, but 
is combined with viable renal epithelial cells that are substantially modified. In the case of 
ciPTEC, this manipulation involved the immortalization procedure performed using retro-
viral transduction of primary cells with two oncogenes [8]. Retroviral infection using both 
the essential catalytic subunit of human telomerase (hTERT) and the temperature-sensitive 
mutant U19tsA58 of SV40 large T antigen (SV40T) is a recognized effective method for the 
development of conditionally immortalized cell lines [87-89] The SV40T gene allows cells to 
proliferate at temperature of 33°C, whereas at 37°C inactivation of the large T antigen permits 
cellular differentiation [90]. Addition of the hTERT vector increases the cellular telomerase 
activity, resulting in maintenance of telomere length, thereby avoiding the occurrence of 
replicative senescence [91,92]. However, in ciPTEC the SV40 large T antigen blockade is not 
absolute at 37 °C, some residual SV40 protein can be detected after the temperature switch. For 
in-vitro use, this immortalization procedure is very effective. However, for clinical application 
a more robust cell line would need to be developed. There are some other aspects that should 
be taken into account when using retrovirally-immortalized cells in a clinical application. 
Although retroviral vectors are engineered to be defective in their replication, replication 
competent retroviruses may be generated when recombination between the transfer vector, 
packaging components or endogenous retroviral elements [93,94]. All ciPTEC cell lines that 
were described in this thesis were tested for the presence of endogenous replication compe-
tent retroviruses and found to be negative (data not shown). Furthermore, the stable cell lines 
were unable to form viral particles. However, a serious point of concern regarding the use 
of these vector-infected cells in humans is the increased risk of recombination events due to 
subsequent virus infections within the patient or activation of endogenous retroviruses. To 
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prevent recombination, additional safety measures, such as co-transduction with a suicidal 
gene or further splitting of the viral genome, might be necessary [95].
immunogenic effects
The introduction of foreign biological material to a human body will often be accompanied 
with the induction of an immune response by the host. In the case of organ transplantation, 
this process is recognized and well-studied [96]. With the application of immunosuppressants 
and careful matching of MHC complexes, it is possible to minimize this immune response 
and avert organ rejection [97]. In cell therapy, which is mostly based on the infusion of live 
marrow stromal cells (MSCs) into the circulation of the patient, the low antigenicity and 
immunomodulatory properties of MSCs allow allogeneic transplantation [98]. Whether the 
use of allogeneic methods would be feasible for production of an off-the-shelf RAD remains 
to be examined. Theoretically, it should be possible to culture endogenous renal cells from 
each patient that is to be treated with a bioartificial RAD. However, in practice, the number 
of cells necessary for a single or multiple devices, by far exceeds the yield from a renal biopsy 
or a urine sample, and would require extensive propagation [99]. In future, the use of induced 
pluripotent stem (iPS) cell technology might provide another option [100]. Not only can iPS 
cells propagate indefinitely given the right stimuli, they can also differentiate into other cell 
types in the human body. Various investigations are being performed to develop patient-
specific iPS treatment, thereby reducing the risk of immunogenic effects [101-104].
However, the development and characterization of conditionally immortalized, or iPS cell 
lines for each single patient are costly and time consuming. Therefore, the general application 
of a single isolated and fully characterized ciPTEC line still seems to be a promising strategy. 
Nevertheless, it is important to take the safety aspects into account. While cultured in a hollow 
fiber based bioartificial RAD, the cells are separated from the circulation by a semi-permeable 
membrane. Particles smaller than the pore size of the membranes’ molecular weight cut-off, 
such as immunoglobulin or soluble MHC complexes, might pass the membrane and elicit an 
immune response. Therefore, the immunogenic effects of applying ciPTEC in a bioartificial 
device need to be evaluated thoroughly, both in-vitro as well as in-vivo.
oTHer innoVaTiVe aPProacHes in THe TreaTmenT of 
renal failUre and Uremia
Various approaches to remove uremic retention solutes in patients are being investigated by 
a number of research groups worldwide. These strategies mostly focus on a reduction in the 
intestinal uptake of uremic retention solutes, extract UTs directly from the circulation, or 
explore alternative ways of their elimination. The oral sorbent AST-120 was found to decrease 
serum indoxyl sulfate levels in both dialyzed and un-dialyzed patients with CKD, through 
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adsorption of indole, a precursor of indoxyl sulfate [105]. Clinical trials of AST-120 have 
indicated a beneficial effect on time to dialysis and a reduction of symptoms of uremia [106].
Brettschneider et al. recently reported the effective use of hydrophobic and cationic 
adsorbers for the extracorporeal removal of protein-bound, hydrophobic UTs. This system 
proved more effective in the removal of phenylacetic acid, indoxyl sulfate and p-cresyl sulfate 
then conventional hemodialysis techniques [107]. A combination of these absorbers together 
with conventional hemodialysis might provide easily implemented therapeutic options to 
increase the removal rate of these UTs. Another example is the wearable artificial kidney 
(WAK) [108-110]. In pilot studies with ESRD patients this wearable hemodialysis device 
demonstrated solute clearance, including middle molecules, and effective ultrafiltration [111-
113]. Adsorbent-based treatment options are viewed as very promising tools for the removal 
of uremic solutes. As no biological components in the form of cultured cells are involved, 
many complicating factors, like cellular expansion, transport storage and safety concerns, are 
taken out of the equation.
However, in a bioartificial RAD, living ciPTEC membranes would provide additional sup-
port in the removal of accumulating UTs together with the benefits of solute reabsorption, 
and could offer important metabolic, paracrine, endocrine, and immunologic signaling. In 
a recent study by Westover et al. [114], treatment with an extracorporeal device containing 
PTEC seeded porous disks showed to convey a clear survival advantage in a porcine model 
of septic shock. This bioartificial renal epithelial cell system (named BRECS) was perfused 
with ultrafiltered blood or body fluids, but did not provide active transepithelial clearance of 
uremic solutes. The amelioration of the effects of septic shock was ascribed to the immuno-
regulatory role of tubule cells [115,116]. These effects on the deranged inflammatory response 
in acute kidney injury AKI [117,118], were already described in initial (pre-) clinical studies 
by Humes et al. [119]. Although the effects are promising, it is still unclear which paracrine 
factor secreted by renal epithelial cells is responsible for the observed anti-inflammatory 
response.
PersPecTiVes for fUTUre researcH
The results of this thesis show that the development of a bioartificial device such as a RAD 
based on ciPTEC might be possible from a cell-biological point of view. By demonstrating the 
presence of functional (cationic) uremic toxin elimination pathways by 2D ciPTEC monolay-
ers, the groundwork has been laid for the demonstration of active uremic solute removal 
through living membranes. At this time, however, we cannot estimate if the addition of a RAD 
would make renal replacement therapy more efficient. Nevertheless, innovation often leads 
to development of novel insights. Before making the translation to in-vivo testing of a device, 
there are several interesting and also crucial aspects that deserve future attention.
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The translation of the flat PES membrane based set-up to a 3D hollow fiber environment, 
which can be subjected to flow, will involve experiments with regard to membrane coating 
and cell monolayer formation. With cells cultured on the inside of hollow fiber bioreactors, 
it will be challenging to prevent obstruction of both the fiber lumen as well as the pores, as a 
result of coating or cell seeding. Optimization strategies may entail the inclusion of bioactive 
or ECM peptides into the hollow fiber material itself, thereby eliminating the need for coat-
ing. Furthermore, seeding cells under flow conditions could prevent clogging of the system 
during cellular expansion. In this regard, the use of a bioreactor, a closed system in which the 
cells can be cultured under strictly defined conditions, provides good opportunities to control 
pressure, flow, and could provide normoxic (renal) conditions. This latter factor cannot be 
achieved in “open” cell culture where oxygen levels reach up to 21%, which could affect cel-
lular functionality and proliferative capacity [120,121]. Furthermore, investigations towards 
both the short and long term efficiency of uremic solute removal under bovine serum-free 
culture conditions are indispensable in the preparation towards a (pre-) clinical application.
Regarding the cell model, the absence of OAT1 and OAT3 expression limit the eventual 
clearance capacity of a RAD. As indicated before, endogenous expression of these transporters 
has not yet been achieved. In our lab, first steps have been undertaken for the introduction of 
these transporters through overexpression (unpublished data). Artificial introduction implies 
further genetic modification of the cell model, which complicates the use of this model in 
a clinical setting. A one to one comparison between the uremic solute clearance capacities 
of the existing ciPTEC cell line to OAT1/3 (over)expressing ciPTEC can provide important 
insights in the role of these OATs in toxin clearance.
In the evaluation of transmembrane toxin clearance within a bioreactor or a RAD, sophis-
ticated bioanalysis methods that utilize LC-MS/MS provide opportunities to directly measure 
toxin levels [62-64]. This is preferred, as it circumvents the indirect estimation of transport 
processes by using radiolabeled or fluorescent model compounds such as [14C]-labeled cre-
atinine or ASP+. Furthermore, these analysis techniques can be applied in in-vivo settings 
where the detection of UTs in plasma has to take place in complex biological mixtures. In 
this respect, animal investigations will be a necessary step for the investigation of the clinical 
feasibility, proof-of-principle and safety of a RAD. Evaluation will involve testing of the im-
munogenic and oncogenic properties of the living membranes and transport functionality of 
ciPTEC.
The results within this thesis expanded our knowledge on uremic toxin handling by proxi-
mal tubular monolayers, and provide ample ground for further research and development 
towards the in-vivo application of a bioartificial device in the treatment of uremia related 
pathologies.
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In patients suffering from Chronic Kidney Disease (CKD) or End-Stage Renal Disease 
(ESRD), kidney function is severely impaired. As a consequence, waste products are insuf-
ficiently cleared from the circulation. The systemic accumulation of these retention solutes 
contributes to the development of uremic syndrome, which is associated with increased mor-
bidity and mortality. Over the last decade, more than 150 uremic retention solutes have been 
identified that accumulate during renal failure. Many of these solutes have the potential to 
act as uremic toxins, because they exert adverse biological or biochemical activities. Dialysis 
therapy aims to remove as many of these solutes as possible, thereby hoping to alleviate their 
destructive effects. Although current dialysis therapy can prolong many ESRD patients’ lives, 
the treatment is unable to replace renal function completely. Mortality (15-20% per year) and 
morbidity of these patients remain high, whereas their quality of life is generally low. Renal 
replacement therapy removes mainly small, unbound substances from the circulation, while 
leaving large, compartmentalized and protein-bound uremic retention solutes untouched.
The need for improved renal replacement therapy has stimulated research into the de-
velopment of a so-called bioartificial kidney or renal assist devices (RAD). These innovative 
devices aim to complement the hemodialysis treatment, by coupling artificial membranes 
with functional kidney cells. In the scope of this thesis, we examined the handling of cationic 
uremic toxins by proximal tubule epithelial cells (PTEC). In the kidney, PTEC play an active 
role in the clearance of organic solutes and uremic retention solutes. By focusing on the in-
vitro epithelial transport pathways, and regulation involved in the renal removal of cationic 
uremic retention solutes, we aim to elucidate the possibilities to utilize living renal epithelial 
PTEC membranes for the improvement of hemodialysis therapy.
To study the function of renal cells in-vitro, the functionality of cell models has to reflect 
the native situation. It is therefore essential to characterize the nephron-specific properties, 
such as polarized transport, (re)uptake of solutes, and the formation of tight monolayers, in 
both established and novel cell lines. In chapter 2, we compared the functional properties 
of two newly developed conditionally immortalized PTEC cell lines (ciPTEC) originating 
from kidney tissue to ciPTEC previously isolated from urine. The presence and functionality 
of proximal tubule specific transporters, like the influx carrier Organic Cation Transporter 
2 (OCT-2), the efflux pumps P-glycoprotein (P-gp), Multidrug Resistance Protein 4 (MRP4) 
and Breast Cancer Resistance Protein (BCRP), was confirmed with only slight differences 
between the three cell lines. Extracellular matrix (ECM) genes collagen I and -IV α1 were 
highly present in both tissue derived ciPTEC, whereas ciPTEC isolated from urine showed 
a more pronounced fibronectin I and laminin 5 gene expression. Furthermore, functional 
endogenous albumin and phosphate reabsorption was observed in all models. The presence 
of these endogenous and specific proximal tubular features marks these cell lines as promising 
tools to study the uptake and elimination pathways of uremic solutes by PTEC. As a first 
Chapter 8
182
step in examining these clearance processes, chapter 3 focuses on the interaction of cationic 
uremic toxins with organic cation influx carriers (OCTs) in ciPTEC. OCT transporter ac-
tivity was measured and validated in cell suspensions by studying uptake of the fluorescent 
substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium-iodide (ASP+). Subsequently, 
the inhibitory potencies of the cationic uremic toxins, cadaverine, putrescine, spermine and 
spermidine (polyamines), acrolein (polyamine breakdown product), guanidine and methyl-
guanidine (guanidino compounds) were determined. Inhibition of cellular cation uptake was 
demonstrated for all uremic toxins, with acrolein showing the most potent interaction.
The accumulation of most uremic retention solutes is generally considered a result of a 
disturbance in their renal excretion. Next to direct inhibition of transporters, the toxic or 
regulatory effects of these compounds could play important roles in disease progression. 
chapter 4 illustrates that exposure of ciPTEC to various cationic uremic toxins can lead to re-
lease of inflammatory cytokines IL-6 and IL-8, which are correlated with increased mortality 
and poor disease outcome in renal failure. Furthermore, an increase in endothelin-1 (ET-1) 
release was measured, which in renal failure is associated to interstitial fibrosis, proteinuria, 
cardiomyopathy and glomerulosclerosis. Exposure of ciPTEC to ET-1 was found to differ-
entially regulate the functionality of OCT-2, through the ET-1 endothelin-β receptor axis. 
This led to a down-regulation of organic cation uptake after 30 minutes, while long-term 
exposure increased ASP+ uptake significantly. These findings indicate that uremic solutes are 
able to influence transport processes not only by (competitive) inhibition, but also through 
secondary regulatory pathways.
Influx transport of uremic toxins is a crucial first step in the elimination of (uremic) sol-
utes from the circulation. However, for the development of a bioartificial kidney, or RAD, 
the combination of functional in-vitro influx and efflux transport is essential to facilitate 
clearance. Therefore in chapter 5 we focused on the transepithelial transport processes in 
living ciPTEC grown on artificial semi-permeable surfaces. We have shown that ciPTEC can 
grow to a confluent monolayer on commercially available polyester Transwell® membranes. 
However for clinical application the use of hemocompatible materials would be preferred. 
Therefore, we optimized a coating consisting of 3,4-dihydroxy-L-phenylalanine (L-DOPA) 
and collagen IV that enables ciPTEC to be cultured to a confluent monolayer on polyethersul-
fone (PES) dialysis membranes. By optimizing the coating protocol, we were able to maintain 
water permeability of the membrane and promoting cell adhesion, while blocking vital blood 
components. Using immunocytochemistry, tight junctions could be detected. Furthermore, 
as an important step towards the development of a RAD, the functionality of vital clearance 
processes was shown by transepithelial transport of radiolabeled creatinine.
For ciPTEC characterization, static culture conditions were used. However, perfusion plays 
an important role both in the in-vivo situation as well and in a biological RAD. Tissue perfu-
sion allows delivering nutrients and soluble factors to cells, but also the removal of metabolic 
waste relevant for homeostasis. chapter 6 describes the effect of fluid flow on transepithelial 
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cation transport by ciPTEC. We evaluated the effects of flow on monolayer quality as well as 
the transepithelial creatinine transport. The confluent monolayers were either cultured stati-
cally, or on a 2d plate rocker. Fluid movement was found to increase epithelial characteristics 
such as cilia length and monolayer height. Furthermore, the mRNA expression levels of the 
organic cation transporting influx and efflux transporters examined (viz. OATP4C1, OCT1, 
OCT2 and MATE1, MATE2K) increased significantly. This was accompanied by higher tran-
sepithelial flux of radiolabeled creatinine, as well as increased cellular sensitivity to cationic 
uremic toxins.
The increased transport observed under dynamic culture conditions indicates that the 
use of a relatively simple system for modeling fluid flow positively affects cell functionality. 
Enhancing the endogenous cellular features of ciPTECs, could make this cell line even more 
interesting for research towards renal clearance processes in pharmacological and physi-
ological studies. Furthermore, transepithelial solute transport is an important aspect of an 
innovative bioartificial RAD.
In this thesis we aimed to functionally characterize uremic solute handling by ciPTEC, by 
evaluating the in-vitro functional characteristics of cultured ciPTEC monolayers and measur-
ing their organic cation transport properties. In chapter 7, the implications of the results are 
considered and crucial considerations important for future research into the development of 
a RAD are being discussed. Our results showed that the stable ciPTEC model is a promising 
candidate for the development of living membranes to use in a RAD. However, before such a 
concept can be applied in an animal or clinical setting, further research should focus on the 
existing challenges regarding the design, 3D engineering, its functionality, durability, associ-
ated safety concerns and costs.
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Patiënten die lijden aan chronisch of eindstadium nierfalen hebben een ernstig verstoorde 
nierfunctie. Als gevolg hiervan worden afvalstoffen onvoldoende verwijderd uit het bloed. De 
stapeling van deze zogenoemde uremische toxines (UTs), kan bijdragen aan de ontwikkeling 
van het uremisch syndroom, dat geassocieerd is met een verhoogde kans op de ontwikke-
ling van gerelateerde ziekten en op overlijden. In de afgelopen tien jaar zijn er meer dan 
150 uremische afvalstoffen geïdentificeerd die zich ophopen tijdens nierfalen. Veel van deze 
opgeloste stoffen hebben een nadelig effect op biologische en biochemische lichaamsproces-
sen. De behandeling van nierpatiënten met (hemo)dialyse is er dan ook op gericht om zoveel 
mogelijk van deze afvalstoffen te verwijderen. Hoewel de huidige dialysetechnieken het leven 
van veel nierpatiënten verlengt, kan de behandeling de nierfunctie helaas niet voldoende 
overnemen. Onder nierpatiënten die behandeld worden met dialyse blijft de mortaliteit hoog 
(15-20% per jaar), terwijl de kwaliteit van leven relatief laag is. Een van de mogelijke redenen 
hiervoor is dat nierfunctievervangende therapie voornamelijk kleine, niet-eiwitgebonden 
stoffen uit de circulatie verwijdert. De uitscheiding van grote, complexe en eiwitgebonden 
UTs is onvoldoende, waardoor deze afvalstoffen blijven stapelen in het bloed met allerlei 
bijkomende problemen, zoals vaat- en hartlijden.
De behoefte aan betere nierfunctievervangende therapie gaf de aanleiding voor het 
onderzoek naar de ontwikkeling van een biologische kunstnier, of een renal assist device 
(RAD). Door gebruik te maken van “levende membranen”, bestaande uit niercellen gekweekt 
op polymeren, zouden UTs op een efficiëntere manier verwijderd kunnen worden. In dit 
proefschrift onderzochten wij hoe kationische (positief geladen) UTs worden getransporteerd 
door proximale tubulus-epitheelcellen (PTEC). In de nier zijn deze cellen namelijk van groot 
belang voor het transport van organische afvalstoffen. We hebben de processen en mechanis-
men die betrokken zijn bij het transport van kationische organische stoffen onderzocht om zo 
meer inzicht te krijgen in de mogelijkheden om levende PTEC-membranen toe te passen in 
verbeterde nierfunctievervangende therapieën.
Om de functie van niercellen in vitro te kunnen bestuderen, is het van belang dat de 
gebruikte celmodellen functionele eigenschappen bezitten die oorspronkelijk in de nier 
aanwezig zijn. Nieuwe cellijnen worden daarom gecontroleerd op specifieke kenmerken, 
zoals de vorming van dichte celmonolagen, directioneel transport, en (her)opname van 
opgeloste stoffen. In hoofdstuk 2 hebben we de eigenschappen van twee, uit humaan nier-
weefsel ontwikkelde, conditioneel geïmmortaliseerde PTEC cellijnen (ciPTEC) vergeleken 
met een bestaande ciPTEC lijn ontwikkeld uit humane urine. Het grootste verschil tussen de 
cellijnen werd gevonden in het vermogen om biologische weefselstructuren te produceren. In 
de cellijnen ontwikkeld uit nierweefsel, was het RNA coderend voor weefselstructuren zoals 
collageen I en collageen IV duidelijk aanwezig. In de oorspronkelijk uit urine ontwikkelde 
ciPTEC werd juist meer fibronectine I en laminine 5 gevonden. Dit zou kunnen betekenen 
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dat cellen geïsoleerd uit urine het vermogen om hun extracellulaire matrix aan te maken deels 
hebben verloren. Desalniettemin kon de functionele aanwezigheid van meerdere specifieke 
transporteiwitten, zoals de organische-kation transporter 2 (OCT2), P-glycoprotein (P-gp), 
multidrugresistentie-eiwit 4 (MRP4) en breast cancer resistance protein (BCRP), worden 
bevestigd in alle de drie onderzochte cellijnen. Ook waren de cellijnen in staat tot (her)
opname van fosfaat en albumine, belangrijke eigenschappen van de proximale tubulus. De 
aanwezigheid van deze specifieke kenmerken maakt de ciPTEC een veelbelovend celmodel 
om de uitscheidingsprocessen van UTs nader te bestuderen.
Hoofdstuk 3 richtte zich vervolgens op de interactie tussen kationische UTs en organische-
kation transporters (OCTs) in ciPTEC. De geteste UTs, cadaverine, putrescine, spermine en 
spermidine (polyamines), acrolein (polyamine afbraakproduct), guanidine en methylguani-
dine (guanidines), hadden allemaal een remmend effect op de opname van de fluorescente 
stof 4-(4-(dimethylamino)styryl)-N-methylpyridinium-iodide (ASP+). Acrolein was hierin 
het meest potent. Deze bevindingen geven aan dat UTs een competitieve/concurrerende 
interactie aangaan met de transporters. De stapeling van de meeste UTs wordt gezien als het 
gevolg van een verstoorde uitscheiding. Zoals aangetoond in Hoofdstuk 3, kan deze versto-
ring veroorzaakt worden door directe remming. Daarnaast zouden uremische afvalstoffen 
transportprocessen kunnen beïnvloeden door hun toxische of regulerende effecten.
In Hoofdstuk 4 hebben we laten zien dat blootstelling van ciPTEC aan verschillende katio-
nische UTs leidt tot de afgifte van de ontstekingsfactoren IL-6 en IL-8. Deze ontstekingsfacto-
ren worden vaak gezien bij chronische ontstekingsprocessen, en worden in verband gebracht 
met een slechte overleving bij nierfalen. Ook zorgt de blootstelling van ciPTEC aan UTs voor 
een verhoogde afgifte van het bloeddrukregulerende hormoon endotheline-1 (ET-1). Ver-
hoogde ET-1 concentraties in het bloed worden in verband gebracht met de ontwikkeling van 
chronisch nierlijden. De bevindingen beschreven in Hoofdstuk 4 tonen daarnaast ook aan 
dat ET-1 de OCT gemedieerde opname van ASP+ door ciPTEC kan reguleren. Na 30 minuten 
blootstelling was de opname van ASP+ verminderd, terwijl ET-1 op langere termijn (24 uur) 
leidde tot een toename in ASP+-opname. Deze bevindingen wijzen erop dat het transport 
van UTs niet alleen door middel van competitieve remming kan worden beïnvloed, maar dat 
andere regulerende mechanismen, zoals ontstekingsprocessen, ook een rol kunnen spelen.
De opname van uremische toxines in de niercel is een cruciale eerste stap in de uitscheiding 
van (uremische) afvalstoffen. Maar voor de ontwikkeling van een biologische kunstnier of 
RAD is het ook van belang dat uitscheidingsprocessen kunnen plaatsvinden in het gebruikte 
celmodel. In Hoofdstuk 5 hebben we ons daarom gericht op het meten van transportproces-
sen door ciPTEC-cellagen gekweekt op kunstmatige membranen. We hebben aangetoond dat 
ciPTEC mooie dichte cellagen vormen op, commercieel verkrijgbare, polyester Transwell® 
membranen en polyethersulfon (PES) dialysemembranen. Omdat de PES-membranen zijn 
ontworpen om in contact te staan met bloed, zijn ze klinisch beter toepasbaar, maar gaan ze 
celhechting ook grotendeels tegen. Om toch dichte celmonolagen te kunnen kweken, hebben 
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we het membraan gecoat met 3,4-dihydroxy-L-fenylalanine (L-DOPA) en collageen IV. Door 
gebruik te maken van deze geoptimaliseerde coating, bleef de waterdoorlaatbaarheid van 
het membraan behouden terwijl de vorming van een cellaag werd gestimuleerd. Bovendien 
waren de cellen in staat om creatinine over het membraan te transporteren, wat impliceert dat 
belangrijke transportprocessen functioneel behouden blijven.
Tijdens de in vitro kweek en karakterisatie van ciPTEC zijn voornamelijk statische 
kweekomstandigheden gebruikt. Echter, in de gezonde nier worden tubulus cellen continu 
blootgesteld aan de stroming van voorurine of bloedplasma. Ook in een biologische kunstnier 
zal vloeistofstroming een belangrijke rol spelen. In Hoofdstuk 6 is daarom het effect van 
stroming op het organisch-kation-transport en de kwaliteit van de cellaag onderzocht door 
de cellen te kweken op een 2D kantelplaat. De beweging van vloeistof over de cellen zorgde 
voor een toename in het epitheliale karakter van ciPTEC, en ging gepaard met een verhoogd 
transport van creatinine. Daarnaast bleken de cellen gevoeliger voor de toxische effecten van 
kationische UTs. Deze resultaten geven aan dat de simulatie van vloeistofstroming tijdens 
de kweek van celmonolagen de celfunctionaliteit en gevoeligheid van ciPTEC zou kunnen 
verbeteren.
Samenvattend kunnen we stellen dat in dit proefschrift het transport van organische kat-
ionen door ciPTEC is gekarakteriseerd, waarmee inzicht is verkregen in de mogelijkheden 
om dit celmodel toe te passen in toekomstige nierfunctievervangende therapieën. Hoofdstuk 
7 bediscussieerde de implicaties van deze resultaten. Het ciPTEC-model blijkt veelbelovend 
voor de ontwikkeling van een biologische kunstnier of RAD. Toch zal verder onderzoek 
nodig zijn om inzichten te verkrijgen in de toepasbaarheid van het ontwerp, het gebruik van 
holle vezels, de functionaliteit, duurzaamheid, veiligheid en de kosten, voordat de biologische 
kunstnier in een dierexperimentele of klinische setting zal kunnen worden getest.
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Toen ik in 2010 begon aan dit project had ik nooit gedacht dat er zoveel mensen betrokken 
zouden zijn bij het tot stand komen van dit boekje. Wat fijn dat ik jullie nu eindelijk allemaal 
mag bedanken voor de hulp, de inspiratie, de ondersteuning en de gezelligheid, die de afgelopen 
jaren een grote rol hebben gespeeld gedurende mijn promotietraject.
Allereerst wil ik mijn promotoren bedanken voor hun ondersteuning. Bert, vanaf dag 1 heb 
jij je, naast je drukke werkzaamheden binnen LABGK (het huidige TML) en je werkzaamhe-
den in Leuven, ingezet als promotor. Voor overleg of een peptalk kon ik bij je terecht, en voor 
nieuwe onderzoeksresultaten maakte jij graag plaats in je agenda. Bij dezen bedankt voor de 
fijne samenwerking afgelopen jaren. Roos, dat het BioKid project nog op zoek was naar een 
kandidaat kreeg ik via jou te horen. Nu, 5 jaar later kijk ik terug op een hele leerzame periode. 
Jouw enthousiasme en enorme kennis over transporters, toxicologie en de nier heeft me altijd 
geïnspireerd. Als het onderzoek af en toe niet lekker liep, of de lijn wat onduidelijk dreigde te 
worden dan wist jij met een frisse blik de boel weer op de rails te krijgen. Ik ben dan ook erg blij 
dat jij, nu als professor verbonden aan de Universiteit Utrecht, ook een van mijn promotoren kan 
zijn. Joost, jouw gedrevenheid en doelgerichte werkwijze heeft mij de afgelopen jaren geholpen 
om de rode draad in de experimenten te blijven zien. Dankjewel voor je hulp en ondersteuning!
Tijdens talloze werkbesprekingen op de donderdagochtend kwam het ciPTEC team bij elkaar 
om met elkaar te bespreken wat we nu eigenlijk allemaal uitspoken. Zonder het vaste Nijmeegse 
ciPTEC team, was dit boekje er hoogstwaarschijnlijk niet geweest. Jitske, we begonnen op de-
zelfde dag aan hetzelfde project maar in een ander lab. Hoewel dit niet altijd handig was, hebben 
we toch heel wat nieuwe ciPTEC cellijnen in de vriezer weten te krijgen! Ik heb altijd super met 
je samengewerkt en ben blij dat jij mij bij wilt staan als paranimf. Jouw drive en vermogen om 
te multitasken is enorm! Ik kijk uit naar jouw boekje en ik heb er alle vertrouwen in dat het met 
je promotie en wetenschappelijke carrière helemaal goed komt. Martijn, Mr. ciPTEC himself. 
De eerste presentatie die jij gaf met ciPTEC als onderwerp ben ik nooit vergeten. Je vergelijking 
tussen niercellen uit urine als “cobblestoned yellow brick road” op weg naar een biologische 
kunstnier, was vrij legendarisch. Niet alleen heb je me wegwijs gemaakt in het kweken van, 
en experimenteren met ciPTEC, ook jouw vastberadenheid en doorzettingsvermogen in de 
wetenschap vind ik bewonderenswaardig! Dankjewel voor je hulp, de samenwerking en je on-
vermoeibare aanwezigheid bij alle werkbesprekingen. Rick, ook jij bedankt voor de gezelligheid 
tijdens de werkbesprekingen en de congressen, als meester in het delegeren zou ik nog heel wat 
van je kunnen opsteken. Michele and Milos I wish you good luck in your ciPTEC endeavors. 
I am happy you will continue the research on the BioKid, as part of the Bio-Art project. Een 
speciaal woord van dank richt ik aan de studenten die ik heb mogen begeleiden. Pieter, Ioana 
en Nelleke, thank you so much for your help during the different phases of my research. I hope 
that, like me, you can look back on an inspiring time at the lab.
Chapter 9
192
I would like to thank all other colleagues that have collaborated within the BioKid project. 
The support from the University of Twente with regard to the PES membrane and coatings 
was indispensable for this work. Dimitris, I very much admire your especially positive and 
enthusiastic approach to science, and want to thank you for our very enjoyable collaboration. 
Ilaria, molte grazie, thank you for your work on the coating optimization. I had not realized how 
efficient the use of Dropbox could be until we started writing a paper together. Also I would 
like to thank the group of Ruud Bank from the University of Groningen for their help in the 
characterization of the new cell lines. Furthermore, may thanks to all the colleagues from TU 
Eindhoven, de Nierstichting, and Pharmacell.
Natuurlijk was het dagelijks leven op het lab niet hetzelfde geweest zonder alle collega’s en 
medepromovendi! Graag bedank ik jullie allemaal voor de gezellige tijd. Niet alleen uitten we 
ons wel en wee, maar ook voor blunders en roddels was altijd wel even tijd te maken. Graag 
bedank ik speciaal mijn directe mede nefro-promovendi. We deelden naast een promotor, 
een kantoor of een hoekje in de kantoortuin. Dineke, dankjewel dat jij me altijd alles te wist 
vertellen wat ik zelf was vergeten. De juiste route naar een overleg, waar welke subsidie kon 
worden geregeld, wanneer en hoe laat welke afspraak gepland stond, en ga zo maar door. Jouw 
drive voor het onderzoek en enthousiasme voor HUS is voor mij een inspiratiebron geweest. 
Daarnaast was je ook een heel fijn reismaatje. Het ASN congres in San Diego, de lange vliegreis, 
het sneltreinbezoek aan de ZOO, de sushi, de outlet bij Mexico, de zwervers, de manicure, het 
vliegdekschip en de 10.000 posters, ik zal het niet snel vergeten. Het was goed om te horen dat 
jij met goed gevolg jouw promotie hebt kunnen afsluiten, en ik denk dat een functie als klinisch 
laboratorium geneticus je op het lijf geschreven is. Ruud, jij ook bedankt voor de gezellige tijd! 
Je was altijd in voor een goed gesprek of een toxicologische discussie. Ook heb je me haarfijn de 
voor en nadelen weten uit te leggen van qPCRs. Met jouw inzet en doorzettingsvermogen gaat 
het qua promotie vast helemaal goed komen.
Naast de promovendi wil ik absoluut alle analisten bedanken voor hun hulp en ondersteu-
ning op de werkvloer. De analisten vormen het geheugen van het lab, en voor een promovendus 
is het daarom ongelofelijk belangrijk om terug te kunnen vallen op jullie praktische ervaring en 
expertise. Thea, dankjewel voor de fijne tijd op het lab, je nuchtere houding, je kundigheid in het 
uitvoeren Elisa’s, celkweek, SDS-page, Western blots, je gezang, en niet te vergeten alle cellen die 
ik uit jouw doorloopjes heb mogen isoleren. Ik ben benieuwd hoeveel van mijn blunders (groot 
of klein) er in je beruchte boekje terecht zijn gekomen! Lieve Annelies, afgelopen jaren kon ik 
altijd bij jou terecht. Niet alleen voor praktische zaken, celkweek, qPCR of Elisa, maar ook om 
mijn hart te luchten. Bedankt voor alle keren dat je tijd had voor een goed gesprek, en voor de 
gezelligheid op het lab.
Uiteraard wil ik ook al mijn vrienden en vriendinnen bedanken voor hun steun, belangstel-
ling, en ook voor de nodige afleiding. Lieve studievriendinnen, na ons afstuderen zijn we al-
lemaal uitgevlogen. Sommigen wat verder weg en anderen wat dichterbij. Maar gelukkig hebben 
we nog regelmatig samen leuke dingen kunnen doen en contact kunnen houden. Rianne, Mieke, 
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Linda en Mireille, jullie begrijpen als geen ander wat er komt kijken bij een promotieproject, 
maar dan aan de UvA, VU of UCL. Stuk voor stuk bewonder ik jullie doorzettingsvermogen en 
ik ben blij dat we ondanks ons drukke schema nog regelmatig leuke dingen doen. Jacqueline, 
Nicolien en Mariska, bedankt voor de gezelligheid van al die keren dat we afspraken in de 
kantine van het Radboud. Onder het genot van een boterhammetje kwamen we tot “rust” en 
lieten we onze dagelijkse bezigheden de revu passeren. Jullie steun en adviezen hebben me vaak 
genoeg uit een dipje geholpen!
Ook bedank ik heel graag al mijn dierbare koormaatjes, toen ik in mijn eerste promotiejaar 
lid werd van het NSKAD had ik nooit gedacht hoeveel plezier het zingen in een koor me zou 
brengen. Ik weet zeker dat de afgelopen jaren niet zo leuk waren geweest zonder jullie en alle 
repetities, kroegavonden, concerten, koorweekeinden, buitenlandreizen, diner-roulers, schnab-
bels, vergaderingen, commissies en Bianca’s. Ik ben het koor ook ontzettend dankbaar voor het 
indelen van Jeroen, de allerliefste tenor, in het team tegenover mij tijdens het intro-bowlen in 
2011 .
Ten slotte bedank ik natuurlijk mijn familie. Lieve Martine, als mijn oudere zus heb ik altijd 
naar je opgekeken. Ik ben heel erg blij met jouw steun en humor, zowel voor, tijdens als na de 
plechtigheid en ik vind het super dat je me wilt bijstaan als paranimf. Erik, mijn lieve broer, met 
twee oudere zussen maakten we het jou niet altijd makkelijk. Maar ik ben blij dat we samen 
zoveel fi jne momenten hebben meegemaakt, samen koken, een middagje Scheveningen, naar 
een voorstelling of logeren in Utrecht. Nu mijn boekje klaar is, gaan we hopelijk weer wat vaker 
op pad! Opa, jouw talloze vraagstukken over mijn onderzoek deden vaak niet onder voor de 
daadwerkelijke verdediging! Dankjewel voor je interesse, steun en enthousiasme gedurende de 
afgelopen jaren.
Lieve papa en mama, zonder jullie onvoorwaardelijke steun en liefde was het allemaal niet 
gelukt. Al vanaf kleins af aan hebben jullie mij mijn gang laten gaan met experimenten, zeepsop 
projecten, vulkaanuitbarstingen, kopersulfaatkristallen, schimmels en galnoten. Hoewel de 
onderwerpen ondertussen wel wat serieuzer zijn geworden, ben ik nog steeds ontzettend blij 
dat jullie allebei altijd voor me klaar stonden. Ik kan echt van geluk spreken met zulke geweldige 
ouders.
En dat brengt me bij Jeroen, mijn steun en toeverlaat. Wat heb je veel met me te stellen gehad 
tijdens de zware laatste loodjes van het project. Jouw liefde, verwondering, vrolijkheid, positieve 
houding, en je open blik en hebben me er doorheen geholpen. Jij bent mijn rots in de branding.
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lisT of abbreViaTions
ABC ATP-Binding Cassette
AG Aminoguanidine
ASP 4-(4-(dimethylamino)styryl)-N-methylpyridinium-iodide
ATP Adenosine-Tri-phosphate
ATR-FTIR Attenuated Total Reflection-Fourier Transform Infrared Spectra
BCRP Breast Cancer Resistance Protein
BioKid Bioartificial Kidney (Renal Assist Device)
BRECS Bioartificial Renal Epithelial Cell System
BSA Bovine Serum Albumin
cGMP Cyclic Guanosine Monophosphate.
CiPTEC Conditionally Immortalized Proximal Tubule Epithelial Cell
CiPTEC-T1 Conditionally Immortalized Proximal Tubule Epithelial Cell, Tissue Origin 1
CiPTEC-T2 Conditionally Immortalized Proximal Tubule Epithelial Cell, Tissue Origin 2
CKD Chronic Kidney Disease
CN Normal Concentration
Coll IV Collagen IV
CU Uremic Concentration
DAG Diacylglycerol
DOG Sn-1,2-dioctanoyl glycerol
ECM Extra Cellular Matrix
EDS–EDAX Energy Dispersive Spectroscopy analysis
EMT Epithelial to Mesenchymal Transition
ESRD End Stage Renal Disease
ET-1 Endothelin-1
EUtox European Uremic Toxin (Work Group)
FCS Fetal Calf Serum
G418 Geneticin
GFR Glomerular Filtration Rate
HBSS Hanks’ balanced salt solution
HD Hemodialysis
HDF Hemodiafiltration
HEK Human Embryonic Kidney
HF High Flux
hTERT Essential catalytic subunit of human telomerase
IC50 Half maximal Inhibitory Concentration
IgG Immunoglobulin G
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IL Interleukin
iNOS Inducible Nitric Oxide Synthase
J Flux
JTC-12 Monkey Kidney Proximal Tubule cell line
Ki Dissociation Constant
L-DOPA 3,4-dihydroxy-L-phenylalanine
LLC-PK Lilly Laboratories Cell Porcine Kidney proximal tubular cells
L-NMMA N(G)‐monomethyl‐l‐arginine
LPS Lipopolysaccharide
MATE Multi-antimicrobial extrusion protein
MDCK Madin-Darby Canine Kidney Cells
MF Microfiltration
MRP2 Multidrug Resistance Protein
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
NaDC3 Na+-dicarboxylate cotransporter
NO Nitric Oxide
NOS Nitric Oxide Synthase
OA Organic Anion
OAT Organic Anion Transporter
OATP Organic Anion Transport Protein
OC Organic Cation
OCT Organic Cation Transporter
OCTN Carnitine/Organic Cation Transporter
PAN Polyacrylonitrile
PBS Phosphate Buffered Saline
PBS-T Phosphate Buffered Saline - Tween
PDA Adherent Polydopamine
PES Polyethersulfone
PSF Polysulfone
PTEC Proximal Tubule Epithelial Cell
RAD Renal Assist Device
RAP Receptor-associated protein
RO Reverse Osmosis
SC Sieving Coefficient
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
SEM Standard Error of the Mean
SEM image Scanning Electron Microscope Image
SLC Solute Carrier
197
List of abbreviations
ch
ap
te
r 9
SV40-T Simian Virus 40 large T antigen
TEER Trans-Epithelial Electric Resistance
TPA Tetrapentylammoniumchloride
URAT Urate Reuptake Transporter
UT(s) Uremic Toxin(s)
V/V Volume/Volume
W/V Weight/Volume
WAK Wearable Artificial Kidney
ZO-1 Zona Occludens 1
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